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Abstract:
Apoptosis is essential for correct development and tissue homeostasis of multi-cellular 
organisms as well as providing a critical safety mechanism to remove unwanted and damaged 
cells throughout life. Apoptosis is also relevant to human pathologies: many cancers acquire 
lesions in apoptotic pathways whilst inappropriate activation of apoptosis occurs in 
degenerative disease. This thesis studies the regulation and function of a key regulator of 
apoptosis and mitochondrial dysfunction, the Bcl-2 family member, Bax.
Bax is shown to be a cytoplasmic protein that, upon activation, rapidly translocates into 
mitochondrially-associated foci. The timing and possible causes of Bax activation have been 
studied. Live cell video microscopy reveals that this is a rapid and co-ordinated process and is 
accompanied by loss of the mitochondrial membrane potential. Two viral proteins, El B 19k 
from Adenovirus and BHRF1 from Epstein Bar Virus, are shown to block Bax activation at 
different steps. Using these proteins it is shown that changes in mitochondrial ultrastructure 
occur prior to Bax activation.
In the second part of this thesis, a structure / function analysis of the Bax protein leads to the 
identification of a novel mutation that promotes its activation. Subsequently, this mutation is 
used, in combination with El B 19k, in a proteomic strategy to isolate and identify candidate Bax 
interacting proteins at a critical step in the protein’s activation. The results of this, and a similar 
screen with another Bcl-2 family protein, Bcl-XL, are reported. The data set contains known 
interacting proteins and proteins previously implicated in apoptosis control. In addition a range 
of metabolic and transport proteins not previously implicated in the control of Bcl-2 family 
proteins are identified and their relevance discussed.
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Chapter 1 -  Introduction
1.1 The origins of the apoptosis field:
Nineteenth century anatomists, histologists and developmental biologists were the first to 
observe cells dying in a regulated and predictable manner. In the earliest instance these 
observations related to the metamorphosis of tadpoles and insects and the disappearance of 
transient embryonic structures such as the notocord (Clarke and Clarke, 1996).
The term programmed cell death was first coined by Richard Lockshin working with Carroll 
Williams at Harvard in the early 1960s (Lockshin and Williams, 1965). It captured the notion of 
a predictable and controlled series of events occurring in dying cells which could now be 
examined in detail with improving histological and biochemical techniques. Saunders also 
reported similar observations in a chick limb system (Saunders, 1966). By the late 1960s the 
Australian pathologist John Kerr observed that these dying cells were dying by ‘shrinkage 
necrosis’ . Necrotic cells are predicted to undergo swelling and lyse by rupture due to a failure of 
their ability to maintain their internal osmotic environment. Cell shrinkage is the reverse of this 
and implies an active process. Later it was Kerr, together with Andrew Wyllie and A.R. Currie 
who coined the term apoptosis to describe the specific pattern of cell death characterised by 
shrinkage, coalescence of chromatin and fragmentation of the nucleus and cell. The word itself 
is derived from the Greek words apo = from and ptosis = falling, as is reminiscent of the 
dropping o f petals or of leaves from deciduous trees. However, their contribution went further 
than merely another description of the process, in their 1972 paper they argued that cell death or 
apoptosis was as much of a controlled cell process as mitosis, migration or differentiation (Kerr 
et al., 1972). They suggested the process is naturally occurring during development and for 
tissue homeostasis and may also be responsible for therapeutically-induced tumour regression.
1.2 Defining a genetic pathway for programmed cell death:
Ever since these initial descriptions of regulated cell death intensive work has focused on 
unravelling its genetic and biochemical basis. During the 1970s the role of lysosomal death
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pathways in systems such as metamorphosing of tadpole tails and the involution of mammary 
glands were given the most attention. Lysosomes are now recognised to play an important role 
in regulated autophagic and necrotic cell death pathways, an area that is receiving increased 
attention because of its role in cancer therapeutics (Zong and Thompson, 2006).
By 1976 the application of modem genetic techniques had lead to the first breakthrough in 
proving apoptosis was a genetically controlled cell fate. Sydney Brenner envisioned that the 
nematode worm, Caenorhabditis elegans would be an ideal model organism to define the genes 
responsible for cell fate. John Sulston and Robert Horvitz were able to undertake a complete 
cell lineage analysis and discovered that in addition to 959 cells generated during worm 
development a further 131 cells were generated but were not present in the adult (Sulston, 
1976). These cells were absent because they undergo programmed cell death and therefore 
identify programmed cell death as a legitimate cell fate. They reasoned that there should be 
genes controlling both the decision to die and the implementation of the death program and such 
genes should be identifiable by genetic screening. By 1983 the first of these had been identified 
and were named ced-1 and ced-2, for cell death abnormal (Hedgecock et al., 1983). These genes 
turned out not to control the cell autonomous death program but instead to control engulfment, 
or phagocytosis, the process which normally removes dying cells from multicellular organisms. 
The identification of these mutations solved a significant problem in the cell death field; how to 
study cells which may disappear completely in the space of an hour. In a ced-1 mutant 
background dead corpses were not removed and could therefore be detected by Nomarski optics 
in living worms. Over the next decade, a complete genetic pathway was defined:
Egl-1 - I  Ced-9 -I Ced-4 -> Ced-3 Cell death.
Where ced-3 is responsible for the execution of apoptotic cell death, ced-4 is necessary to 
promote the activity of ced-3 and ced-9 is an inhibitor apoptosis, protecting cells by preventing 
ced-4 from activating ced-3. egl-1 is the gene positioned to activate the pathway by relieving the 
inhibition of ced-9 on ced-4. These experiments illustrate the power of a tractable genetic 
system in identifying key molecular players in a molecular pathway. However, the true 
significance of these experiments, which earned Robert Horvitz, John Sulston and Sydney 
Brenner the Nobel Prize in 2002, only became clear as the number of sequences deposited in the 
protein databases began to increase and homologous mammalian genes could be identified, ced- 
3 had homology to interleukin-1-beta converting enzyme (ICE), a protease responsible for 
converting the pro-form of the cytokine interleukin-1-beta into an active molecule (Miura et al., 
1993). ICE and ced-3 became the founding members of the family of cysteine proteases now 
known as the caspases (Degterev et al., 2003). ced-4 had homology to the human APAF1
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protein (Zou et al., 1997), and ced-9 was found to be homologous to the human proto-oncogene 
Bcl-2 (B cell lymphoma) (Hengartner and Horvitz, 1994).
The evasion of apoptosis is now recognised as a key step in oncogenesis. The link between 
deregulated apoptosis and cancer was initially identified by the finding that in human follicular 
lymphoma, the BCL-2 gene becomes translocated to the immunoglobulin locus, t( 14; 18), 
resulting in constitutive over-expression of Bcl-2 (Tsujimoto et al., 1984). Traditionally, the 
activation oncogenes, like Myc (Lutz et al., 2002), through over-expression or mutation, were 
thought to promote oncogenesis by promoting unrestrained cell cycle progression. However, 
unlike all other oncogenes known at the time, Bcl-2 did not promote cell proliferation. Instead, 
it was the founding member of a new category of proteins that could block cell death in 
response to multiple physiological and pathological triggers (Vaux et al., 1988). It is now 
widely accepted that activation of apoptosis, by proliferation-inducing oncogenes (Harrington 
et al., 1994b), functions as a tumour-suppressive mechanism to prevent unrestrained cell 
proliferation (Harrington et al., 1994a), and defects in the apoptotic pathway are considered a 
prerequisite for tumour formation. Recapitulation of the t( 14; 18) translocation seen in human 
follicular lymphoma in transgenic mouse models was the first demonstration that perturbations 
of the apoptotic pathway promotes oncogenesis. These mice contain a BCL-2-immunoglobulin 
minigene and developed polyclonal follicular lymphoma comprised of resting B cells that 
accumulate because of extended survival, not increased proliferation (McDonnell et al., 1989). 
These mice went on to develop spontaneous high-grade monoclonal lymphoma following 
spontaneous activation of c-myc (McDonnell and Korsmeyer, 1991). Bcl-2/myc double 
transgenic mice were also created, and they develop undifferentiated hematopoietic leukaemia 
(Strasser et al., 1990). Thus demonstrating that synergy between two genetic lesions, one 
promoting proliferation and the other suppressing apoptosis, is a central component of tumour 
development (Hanahan and Weinberg, 2000; Johnstone et al., 2002). Bcl-2, became the 
founding member of a family of related apoptotic regulators in mammals. It is the regulation 
and action of these Bcl-2 proteins that forms the main subject for this thesis.
1.3 The Bcl-2 family and their place in cell death pathways:
In the two decades since the discovery of Bcl-2 the family of related genes has continued to 
expand and now includes members that can be both pro- and anti-apoptotic. The family is now 
divided into three groups defined, in part, by four short stretches of relatively conserved 
sequence, or Bcl-2 Homology (BH) domains (Figure 1.1, left panel).
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Bcl-2 has been joined by four others, Bcl-XL (Boise et al., 1993), Bcl-w (Gibson et al., 1996), 
A l (Choi et al., 1995) and Mcl-1 (Kozopas et al., 1993) all of which promote cell survival, 
protecting cells from a wide variety of cytotoxic insults, such as cytokine deprivation, UV- and 
y-irradiation. They share all four of the BH domains (BH1 - BH4) and are therefore referred to 
as the multi-domain pro-survival proteins.
Bax, the founding member of the pro-apoptotic sub-family, was identified by its ability to 
interact with Bcl-2 (Oltvai et al., 1993). Bax, together with two close relatives, Bak (Chittenden 
et al., 1995b; Kiefer et al., 1995), and Bok (Hsu et al., 1997a) share three domains (BH1, BH2 
and BH3). These proteins act, at least in part, by perturbing intracellular membranes.
The remaining family members, the BH3-only proteins, are more diverse, lacking sequence 
homology amongst themselves and to the wider Bcl-2 family, outside of their signature BH3 
interaction domain. There are now at least 13 of these BH3-only proteins, although the function 
of several of these is not yet clear. They are all pro-apoptotic and the BH3 domain is necessary, 
and probably sufficient, to mediate both their killing activity and their interaction with other 
family members (Cory et al., 2003).
Apoptotic signal transduction has traditionally been divided into two pathways, extrinsic or 
intrinsic. Both eventually lead to the same caspase-dependent pathways mediating the 
dismantling of the cell and its eventual engulfment; they differ in the way the signals are 
in itially processed. The extrinsic pathway is initiated by the activation of death receptors on the 
cell’s surface and is summarised Figure 1.2 A. This w ill be considered in more detail in section 
1.4. The intrinsic pathway is initiated in response to a wide variety of cellular metabolic and 
physiological stresses. The pathway is currently thought to be initiated primarily by the 
activation of BH3-only proteins and is summarised in Figure 1.2 B. This is considered in more 
detail in section 1.5. The Bcl-2 family of proteins constitute a critical cellular checkpoint in all 
intrinsic and many extrinsic death pathways, acting at a level proximal to mitochondrial 
dysfunction, which w ill be considered in more detail in section 1.6.
1.4 Extrinsic cell death pathways:
The extrinsic cell death pathway is responsible for the elimination of cells during development, 
in the immune system programming and in immuosurveillance throughout life. The pathway is 
initiated by engagement of a tumour necrosis factor type I superfamily transmembrane death 
receptor, the best-studied member of this family of Fas (CD95/APO-1) (Ashkenazi and Dixit,
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1998). Binding of the Fas ligand to the Fas receptor, which is preassembled as a timer, causes a 
conformational change the receptor’s cytoplasmic tail. This results in recruitment of the adaptor 
molecule FADD (Fas-Associated protein with Death Domain), mediated by death domains 
(DDs) contained in both molecules. FADD then recruits caspase-8 zymogens via Death Effector 
Domains (DEDs), present in both proteins (Kischkel et al., 1995). The resulting complex is 
known as the Death-Inducing Signalling Complex (DISC), and caspase-8 becomes active 
according to an 'induced proximity’ model whereby a low intrinsic degree of caspase-8 activity, 
in the confined space of the DISC, leads to cleavage in trans of caspase-8 dimers. Recent data 
suggests that, unlike for effector caspases, cleavage of caspase-8 is not required for formation of 
the caspase-8 active site, but adds stability to active dimmers created at the DISC; in this case 
’ induced proximity’ becomes the driving force for recruited monomers to dimerise (Boatright 
and Salvesen, 2003). Once active caspase-8 as an initiator caspase can then activate the effector 
caspases-3 and -7, responsible for cleaving key cellular substrates and the execution phases of 
apoptosis (discussed above). Interestingly, following cleavage casapse-8 is released from the 
DISC complex and translocates to mitochondria, where it may have additional roles in 
coordinating apoptotic signalling which have yet to be fu lly investigated (Chandra et al., 2004).
Apoptotic signalling via the extrinsic pathway can be modulated at various levels: antagonistic 
decoy receptors have also evolved which capture death ligands but fail to propagate the signal 
downstream due to non-functional or absent death domains (LeBlanc and Ashkenazi, 2003). 
FLIP (FLICE-like inhibitory protein) is a proteolytically inactive homology of capase-8 
(originally called FLICE), due to the lack of a catalytic cysteine. Interestingly low levels of 
FLIP expression enhance casapse-8 activation at the DISC by helping to drive formation of 
FLIP/caspase-8 heterodimers, which are active. In contrast, high levels of FLIP expression, as 
found in some tumours, inhibit caspase-8 activation, presumably through competing caspase-8 
recruitment to the DISC. FLIP can heterodimerise with capase-8 when it presumably blocks 
caspase-8 recruitment to the DISC (Chang et al., 2002). In addition, there are other death 
receptors including DR4/5 that are responsive to the ligand TRAIL (TNF-related apoptosis 
inducing ligand). In some settings engagement of death receptors has been reported to activate 
cell proliferation, and survival signalling through the NFkB pathway. These significance of 
these observations is not yet not fully understood but is likely to involve different adaptor 
complexes forming downstream of activated receptors (Micheau and Tschopp, 2003).
In response to Fas-induced apoptosis, cells have traditionally been categorised as Type I and 
Type II (Scaffidi et al., 1998). Type I cells, such as thymocytes, are not protected by Bcl-2 
proteins since sufficient caspase-8 activity is generated to cleave and activate caspases-3 and -7. 
Type II cells, such as hepatocytes, are protected by Bcl-2 expression since a mitochondrial
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amplification loop initiated by the cleavage caspase-8 dependent cleavage of the BH3-only 
protein Bid is also required to generate sufficient caspase activity to k ill these cells (Li et al., 
1998; Luo et al., 1998).
1.5 BH3 only proteins -  initiators of intrinsic cell deaths:
The BH3-only proteins members of the Bcl-2 family connect a wide variety of death signals to 
the core apoptotic pathway at mitochondria. There are currently at least 11 recognised members 
of this group, the best known of which are introduced below:
1.5.1 Bid
As mentioned in the previous section, the Bid is a component of the extrinsic cell death- 
signalling pathway. Activation of p22 Bid involves cleavage by caspase-8, followed N- 
myristoylation, resulting in translocation of p7/Myr-pl5 Bid to mitochondria (Li et al., 1998; 
Luo et al., 1998; Zha et al., 2000). In a reconstituted mitochondrial assay p 15 tBid has been 
shown to trigger oligomerisaiton of Bax and rapid Cyt-c release, a process dependent on its 
BH3-domain (Desagher et al., 1999; Eskes et al., 2000; Kluck et al., 1999). tBid also induced 
oligomisation of Bak in mitochondria isolated from hepatocytes (Wei et al., 2000). The role of 
Bid in direct activation of Bax and Bak is discussed in more detail in Section 1.12.
1.5.2 Bim
Bim was found to be a complex with the dynein motor complex on microtubules via an 
interaction with dynein light chain-1 (DL-1 or LC8) (Puthalakath et al., 1999). However, this 
may be cell type specific since in healthy hematopoietic cells it has also been reported to 
associate with the mitochondria and not microtubules (Zhu et al., 2004). Bim responds to a 
diverse range of apoptotic stimuli, for example, the protein is required for the deletion of 
autoreactive thymocytes in vivo and for apoptosis of T-cells in vitro following treatment 
cytokine deprivation, treatment and treatment with taxol (Bouillet et al., 1999; Bouillet et al., 
2002). Bim has also been seen to be transcriptionally up-regulated in haematopoietic and 
neuronal cells in response to cytokine deprivation (Dijkers et al., 2000; Putcha et al., 2001) and 
is thought to be regulated by phosphorylation events which can act to enhance its degradation 
following growth factor stimulation or promote its activation in when growth factors are 
withdrawn (Ley et al., 2005).
1.5.3 Bmf
Bmf is bound to the myosin V motor complex through interaction with dynein light chain-2 
(DLC2) and may play a role in detachment-induced death of epithelial cells, called anoikis
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(Puthalakath et al., 2001). Through their sequestration to the cytoskeleton it is thought both Bim 
and Bmf are able to monitor cytoskeletal integrity. Interestingly, Bim, but not Bmf, is released 
in response to treatment with taxol, which prevents tubulin depolarisation and thereby disrupts 
normal regulation of the microtubule cytoskeleton (Puthalakath et al., 2001). Both proteins have 
been reported to be released in response to UV irradiation through a mechanism that may 
involve their phosphorylation (Lei and Davis, 2003)
1.5.4 Noxa and Puma
Noxa and Puma/bbc3 are transcriptionally induced by p53 following DNA damage (Oda et al., 
2000; Vousden and Lu, 2002; Yu et al., 2001). Both have been genetically demonstrated to be 
important in p53-mediated cell death following drug-induced genotoxic damage (Jeffers et al., 
2003; Villunger et al., 2003) and down-regulation of Puma by an RNA interference strategy has 
been shown to promote transformation in a primary murine fibroblast tumour model (Hemann 
et al., 2004). This mode of regulation has direct parallel with that seen in C. elegans, where 
transcriptional regulation predominates. In this organism the BH3-only homologue EGL-l is 
induced in all somatic cells fated to die (Conradt and Horvitz, 1998), and in response to the 
worm p53 homologue CEP-1, in germline cells which have suffered DNA damage (Hofmann et 
al., 2002).
1.5.5 Bad
Bad is regulated by phosphorylation by kinases such as Akt/PKB and PKA in response to 
growth factors leading to its sequestration by 14-3-3 scaffold proteins (Zha et al., 1996). Bad 
activation is promoted by dephosphorylation, for example by calcineurin (Wang et al., 1999). 
Interestingly Bad has also recently been found in a complex with protein kinase A, protein 
phosphatase l catalytic units, WAVE-1 and glucokinase which may have novel roles in 
coordinating glycolysis and apoptosis in situations of glucose deprivation (Danial et al., 2003).
Currently little is known about the regulation of mechanism of action of the other BH3-only 
proteins, which include: Bik/Nbk, Hrk/DP5, Boo/Dive, Bcl-B, Bcl-G, Bcl-Rambo and Bfk. 
However, further characterisation of these proteins is expected to reveal they also act to 
promote apoptosis in particular cell types or in response to physiological stresses.
The activation of BH3-ony proteins leads, directly or indirectly, to the activation of Bax and 
Bak; their place in the apoptotic pathway is introduced in the next section. Current models and 
remaining uncertainties regarding their regulation and mechanism of activation is discussed in a 
later section (Section 1.9).
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1.6 Bax and Bak:
The multi-domain pro-apoptotic members of the Bcl-2 family consist of Bax, Bak and Bok 
(Figure 1.1). Bax and Bak are widely expressed and have been extensively studied, whist the 
expression pattern of the third member of this sub-family, Bok, is restricted to reproductive 
tissues and it has consequently been studied in much less depth (Hsu et al., 1997a).
Significant insights into the role of these proteins have recently been obtained through the study 
of mice lacking one or both of them. Bax-deficient mice have a range of abnormalities, 
specifically lymphoid hyperplasia, decreased cell death in the central and peripheral nervous 
systems and abnormal gametogenic development (Knudson et al., 1995). Nevertheless, they are 
viable, showing the Bax is not essential for development. Disruption of Bak in mice had no 
discernible effect, with no reported developmental or age-related defects (Lindsten et al., 2000). 
However, when Bax-I-Bak-I- doubly knocked out (DKO) mice were generated fewer than 10% 
of animals survived to adulthood, and those that did displayed multiple phenotypic 
abnormalities including: retained inter-digital and females had imperforate vaginal canals, 
multiple neurological abnormalities including deafness, circling behaviour and persistence of 
many undifferentiated cells, progressive accumulation of mature B and T cells leads to massive 
enlargement of the spleen and lymph nodes and infiltration into parenchymal organs (Lindsten 
et al., 2000). These findings suggested that the Bax and Bak proteins have largely redundant 
roles in regulating apoptosis, but the lack of both proteins causes a widespread failure of cells to 
undergo apoptosis leading to the inappropriate accumulation of cells which should either die 
during development or during the normal regulation of tissue homeostasis. Subsequent 
characterisation of murine embryonic fibroblasts (MEFs) showed them to be resistant to tBid- 
induced Cyt-c release as well as multiple apoptotic stimuli including staurosporine (STS), 
ultraviolet (UV) irradition, etoposide and thapsigargin (Wei et al., 2001). These finding place 
Bax and Bak as essential regulators of mitochondrial dysfunction in response to diverse signals 
and also implicate the mitochondrial dysfunction as a required step in apoptotic cell deaths 
mediated by the intrinsic cell death pathway. Significantly, the defects reported in Bax-I-Bak-I- 
animals are more severe than for either Apafl or Caspase-9 deficient animals, leading to the 
conclusion that whilst there may be redundancy in the execution of apoptotic cell death the Bcl- 
2 proteins are the critical regulators of the program, a characteristic that also makes them of 
potential interest as pharmaceutical targets.
The formation of oligomeric clusters of Bax and Bak is temporally indistinguishable from the 
initiation of mitochondrial dysfunction and the release of mitochondrial inter-membrane space 
proteins (Korsmeyer et al., 2000). It is therefore considered likely that the former is the cause of
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the later, although the molecular mechanism by which this occurs is still unclear and under 
active investigation. Over-expression of Bax in cells, as well as the addition of purified 
recombinant Bax to mitochondria, can trigger the release of Cyt-c (Eskes et al., 2000; 
Jurgensmeier et al., 1998; Rosse et al., 1998). Further investigation showed recombinant Bax 
purified in the presence of detergent to induce oligomerisation is active, whereas monomeric 
Bax purified in the absence of detergent is not (Antonsson et al., 2000; Hsu and Youle, 1997; 
Hsu and Youle, 1998). Bax has been reported to form pores in synthetic lipid membranes and 
liposomes (Antonsson et al., 1997) and a novel channel has been detected by patch-clamping 
experiments in the mitochondrial membrane of apoptotic cells and Bax expressing yeast (Pavlov 
et al., 2001) and can be prevented by Bcl-2 and blocked by Bax antibodies (Dejean et al., 2005). 
Strong supporting evidence that it is the dimerisation of Bax molecules which is the key event 
in Bax activation came from experiments in which enforced dimerisation of Bax molecules 
resulted in cell death and was able to override the protection from Bcl-XL (Gross et al., 1998). 
Other studies have attempted to address the exact nature of the Bax-induced pore. It has been 
claimed this would require at least a tetramer of Bax molecules to form a pore with diameter 
22A, capable of transporting a 12kD Cyt-c molecule with Stokes diameter of 12A (Saito et al., 
2000). There have also been reports of much larger pores requiring lipid components (Epand et 
al., 2002; Terrones et al., 2004). The nature of the lipid composition of the outer membrane 
lipid is also thought to play a role (Kuwana et al., 2002).
1.7 Mitochondrial permeabilisation:
The first reports connecting mitochondria with apoptotic cell death emerged in the mid-1990s 
(Marchetti et al., 19%; Newmeyer et al., 1994; Petit et al., 1995; Zamzami et al., 1995), and 
soon after Cytochrome-c (Cyt-c) was implicated as a necessary component for caspase-3 
activation, being released from mitochondria into the cytosol during apoptosis (Liu et al., 1996). 
A consensus now exists that it is the Bcl-2 proteins Bax and Bak trigger Cyt-c release when 
they become activated and oligomerise and in most cases this is likely to be the pivotal event in 
committing the cell to die by apoptosis. The most studied consequence of Bax and Bak 
activation is the permeabilisation of the MOM and release of in ter-membrane space proteins 
into the cytoplasm including: Cyt-c (Liu et al., 1996), Smac/DIABLO (Du et al., 2000; 
Verhagen et al., 2000), HtrA2/Omi (Suzuki et al., 2001), apoptosis-inducing factor (AIF) (Susin 
et al., 1999) and Endonuclease G (Li et al., 2001).
The Membrane Permeability Transition Pore (MPTP) is a Ca2+-, voltage-, pH- and redox-gated 
channel traversing both the outer and inner mitochondrial membranes. Although the exact
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molecular composition and function of this channel remains unclear it is thought to have three 
main components: (1) the voltage dependent anion transporter (VDAC) in the outer 
mitochondrial membrane, (2) the adenine nucleotide transporter (ANT) which maintains 
ATP/ADP exchange across the inner mitochondrial membrane and (3) Cyclophilin D (CypD), a 
small soluble molecule found in the mitochondrial matrix and identified because it binds to the 
immunosuppressant Cyclosprorin A (CsA).
MPTP has been observed during apoptotic and necrotic cell deaths, where it was presumed to 
not only be responsible for mitochondrial depolarisation but would also allow water and solutes 
less than 1500 Da in mass from the cytosol to enter the matrix and cause swelling and rupture of 
the outer membrane, hence explaining the release of Cyt-c (Lemasters et al., 1998; Vander 
Heiden et al., 1997). The mitochondrial inner membrane (M IM ) is highly folded into cristae and 
so matrix swelling could have the potential to exceed the constrains of the mitochondrial outer 
membrane (MOM) and result in its rupture. Such models have since fallen out of favour as in 
vivo evidence for swelling or rupture of mitochondria in the early stages of apoptotic cell death 
has remained scant and controversial.
1.8 Execution of apoptotic cell deaths:
Cyt-c, together with Apaf-1, procaspase-9 and ATP/dATP, form the apoptosome caspase 
activating complex. Activation of the apoptosome is initiated by the binding of Cyt-c to the 
WD40 domains of Apaf-1, making Apaf-1 competent to recruit pro-caspase-9 in an ATP/dATP- 
dependent manner via caspase recruitment domains (CARD) present in both Apaf-1 and 
caspase-9 (Li et al., 1997).
Caspases are synthesised as inactive zymogens or procaspases. Active caspases are dimers 
consisting of two identical units, each with a single active site. Each unit is composed of one 
large and one small subunit derived from the zymogen precursor by internal cleavage at a linker 
region (Shi, 2002). Procaspases contain N-terminal pro-domains of varying length: upstream or 
initatior capases, such as caspase-9, have long pro-domains which are involved in their 
regulation and autocatalytic activation. The zymogens of initiator caspases exist as inactive 
monomers and it has recently been shown that cleavage of the zymogen is neither required nor 
sufficient for activation of the initiator caspases. Instead they require dimerisation to assume the 
active conformation, which occurs in multi-protein activating complexes to which the zymogens 
are recruited by their N-terminal domains -  the apoptosome in the case of Caspase-9 (Boatright 
and Salvesen, 2003; Rodriguez and Lazebnik, 1999; Stennicke et al., 1999).
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Downstream or executioner caspases, such a caspase-3, -7 and -6, exist within the cytosol as 
inactive dimers (Boatright and Salvesen, 2003). To become active, these caspases require 
processing by an initiator caspase within their linker region, a process which has been 
structurally defined in the most detail for caspase-7 (Chai et al., 2001). The basis for zymogen 
activation is shared amongst all caspases, but the driving forces differ: for effector caspases 
cleavage within the linker segment is necessary for ordering of the active site whilst for initator 
caspases the reordering of their structures requires dimerisation alone and cleavage is a 
secondary event which stabilises the active dimers (Boatright and Salvesen, 2003). This 
distinction is important as explains how a proteolytic pathway can be initiated without 
proteolysis itself, the initiator caspases rely on induced proximity driven by co-factors. Once 
activated the effector caspases are responsible for the proteolytic cleavage of cellular substrates 
which ultimately leads to cell death and the associated characteristic morphological changes.
In Drosophila, direct regulation of caspases seems to be the major strategy by which apoptosis 
is regulated and they are held in check by inhibitors of apoptosis (IAPs). Originally identified in 
baculovirus (Clem et al., 1991), the family now includes many cellular homologs, including 
DIAP1, which bind to and inhibit both initiator and effector caspases through a baculoviral IAP 
repeat (BIR) motif (Salvesen and Duckett, 2002). IAPs also contain RING domains, which 
recruit E2 ubiquitin-conjugating enzymes, which mediates ubiquitylation and destruction of 
IAP interacting proteins, and IAPs themselves, by the 26S proteasome (Vaux and Silke, 2005). 
Although the in vivo targets of IAP ring fingers have not been characterized, IAP may 
potentially play an important role in regulating the abundance of various components of the 
apoptotic machinery. Mammalian IAPs, such as XIAP (Deveraux et al., 1997), are controlled by 
antagonists: Smac/DIABLO (Verhagen et al., 2000) and HtrA2/Omi (Suzuki et al., 2001), two 
proteins which are released from the mitochondrial intermembrane space. In general 
mammalian cells are not as dependent on IAPs and their antagonists for the regulation of 
apoptosis: Smac, HtrA2, XIAP deletion in mice do not show obvious defects in apoptosis 
indicating this role is dispensable (Harlin et al., 2001; Okada et al., 2002), although HtrA2 has 
other roles, potentially relating to mitochondrial functions prior to its release (Deshmukh et al., 
2002).
1.9 Final rites - DNA degradation and cell engulfm ent:
Condensation and fragmentation of nuclei was observed as one of the original defining 
hallmarks of apoptosis. DNA degradation, which occurs downstream of caspase activation, is
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mediated by caspase activated DNase (CAD) (Enari et al., 1998; Liu et al., 1997). CAD 
becomes activated when its inhibitor ICAD is cleaved by the effector caspases. DNasell, held 
within the lysosomes of phagocytes also plays a role after engulfment (Mcllroy et al., 2000). In 
mammalian cells, the other two proteins mentioned as being released from the mitochondria: 
EndoG (Li et al., 2001) and AIF (Susin et al., 1999) translocate to the nucleus upon their release 
and are believed to contribute to caspase-independent DNA degradation. Translocation of AIF 
into the nucleus and activity is believed to involve cooperation with poly(ADP-ribose) 
polymerase-1 (PARP-1) which attaches poly ADP-ribose to nuclear proteins including histones 
(Yu et al., 2002). Exactly how AIF and EndoG function is not fully understood. Genetic studies 
in C. elegans indicate they may work in concert, but in a caspase dependent manner. The C. 
elegans genes nuc-1 (DNasell), wah-1 (AIF) and cps-6 (EndoG) are conserved.
Dying cells produce “ eat me” signals, for mammalian cells, of which the best characterised is 
exposure of phosphatidylserine on the outer leaflet of the plasma membrane (Fadok et al., 
2000). This signal is recognized by engulfment receptors on phagocytosing cells (Savill and 
Fadok, 2000). The engulfment of apoptotic cell corpses is an essential continuum of the 
apoptotic process and ensures the lack of inflammatory response -  a fundamental difference 
between cell death by apoptosis over cell necrosis. C. elegans has again been useful in defining 
the core genetic elements of this pathway, which depends on CED-3 caspase activity (Hoeppner 
et al., 2001). This process consists two overlapping pathways in C. elegans with mammalian 
homologues. The first pathway recognizes apoptotic cells and consists of: ced-1, an engulfment 
receptor (Zhou et al., 2001), ced-6, an adaptor which is homologous to the mammalian GULP 
protein (Liu and Hengartner, 1998), and ced-7, which is homologous to the ABC-2 transporter 
(Wu and Horvitz, 1998b). The other category is involved in cytoskeletal remodelling and is 
composed of: Ced-2 (Crkll) (Reddien and Horvitz, 2000), ced-5 (DOCK180) (Wu and Horvitz, 
1998a), ced-10 (Rac) (Reddien and Horvitz, 2000) and ced-12 (ELMO) (Gumienny et al., 2001. 
Cells from the immune system play an essential role in removal of apoptotic cells {Ekert, 1997 
#2%). Macrophages are important regulators of pro-inflammatory responses releasing 
cytokines, such as TNFa, but macrophages engaged in engulfing apoptotic cell corpses also 
release anti-inflammatory factors, such as TGF-beta and IL-10, to help prevent unwanted 
immune reactions. In addition, phagocytosing dendritic cells present peptides from apoptotic 
corpses to not initiate activation of T cells. Defects in these clearance pathways are a major 
cause of inflammation and also pre-dispose to autoimmune disorders.
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1.10 The structure of Bcl-2 family proteins:
Structural studies of the Bcl-2 proteins have given many important clues as to their functions. 
The first published structure was that of human Bcl-XL solved by both X-ray crystallography 
and NMR spectroscopy (Muchmore et al., 1996) and since then structures of the anti-apoptotic 
family members: Bcl-2 (Haidar et al., 1998), Bcl-w (Denisov et al., 2003) and Mcl-1 (Day et al., 
2005) and pro-apoptotic members Bax (Suzuki et al., 2000) and Bid (Chou et al., 1999) have 
been reported. The structures all show strikingly a striking degree of similarity, despite 
considerable divergence in their primary amino acid sequence and, in some cases, opposing 
biological functions (Figure 1.3).
Bcl-XL and Bcl-2 both consist of eight a-helices connected by loops of varying length. Two 
helices, a5 and a6, form the core of the protein and are predominantly hydrophobic. 
Amphipathic helices a3 and a4 on one side and a l and a2 on the other flank the central pair. In 
general, the alpha helices roughly correspond to the conserved BH domains: a l to BH4 and a2 
to BH3. The BH1 domain is between a4 and a5 so just ahead of the core a5/ a6 hydrophobic 
helices. The BH2 domain maps to. al/ctS. A long loop between a l and a2 is unstructured and 
dispensable for protective function of Bcl-XL (Muchmore et al., 1996). However, the loop may 
be important for regulation: phosphorylation of Ser 70 in the analogous loop in Bcl-2 blocks its 
protective function (Haidar et al., 1998) and caspase-3 cleavage at Asp 34 within the loop 
converts Bcl-2 from anti-apoptotic to pro-apoptotic (Cheng et al., 1997).
The Bcl-XL structure helped to provide the first insights in the function of the BH domains. The 
BH1, BH2 and BH3 come together to form an elongated hydrophobic groove on the protein 
surface and this was postulated to form the binding surface for BH3 domains of a pro-apoptotic 
protein. This explained earlier findings that mutations in all of these regions affected the ability 
of Bcl-XL to interact with pro-apoptotic proteins, where as in the pro-apoptotic proteins only 
the BH3 domain was required (Cheng et al., 1996; Chittenden et al., 1995a). There are only 
minor differences between the Bcl-XL and Bcl-2 structures; the a3 helix, which contributes 
residues to the BH3 binding cleft is slightly differently positioned and this creates a slightly 
wider cleft in Bcl-2 (Petros et al., 2001).
The BH3 binding cleft model was soon confirmed by the NMR structure of the Bcl-XL/Bak 
peptide complex (Sattler et al., 1997) and Bcl-XL/Bad peptide complex (Petros et al., 2000). 
The BH3 domain peptides do indeed sit across the hydrophobic groove with key conserved 
residues of the BH3 domain pointing directly into the binding pocket. This provides a molecular 
basis for the observed dimerisation between BH3 proteins.
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The BH3 only proteins have extremely divergent sequences outside the short 9-16aa BH3 
domain motif, they are therefore not expected to have similar structures to the multi-domain 
proteins. The limited stretch of sequence between the Bim BH3 domain and the predicted C- 
terminal membrane interaction domain is certainly insufficient to form the core helical 
arrangement described above, or to sequester the BH3 region. This raises the possibility that, for 
Bim at least, the BH3 domain would be constitutively exposed.
To date no structure o f a complex between two full length Bcl-2 family proteins has been 
reported, although a recent report of the structure of Bcl-XL with a longer peptide from Bim 
does provide some additional insights (Liu et al., 2003). In this study the Bim fragment formed 
an extended alpha helix of at least 29 amino acids (amino acids 85-115 of BimL, and 
encompassing the BH3 domain). This is consistent with other experiments which have shown 
residues outside the BH3 motif also contribute to BH3-only proteins binding multi-domain 
proteins (Petros et al., 2000). Hydrophobic residues observed to contact Bcl-XL in the extended 
Bim alpha helix are also found in similar positions in other BH3-only proteins. It is therefore 
possible that extended helices encompassing the BH3 motifs may contribute to the binding of 
other BH3-only proteins to their multidomain partners.
Considering the other pro-survival proteins whose structures are solved: Mcl-1 is a larger 
protein with a unique N-terminal domain, however the structure reported lacked this unique 
151aa N-terminal extension. The remaining Bcl-2-Iike core of the protein looked very similar to 
that described for Bcl-2 and Bcl-XL above and a 23aa C-terminal truncation was also necessary 
to increase solubility of the protein (Day et al., 2005). Finally, the Bcl-w structure showed that, 
in contrast to Bcl-2 and Bcl-XL, the C-terminal domain of Bcl-w was found to fold back across 
the protein and bind in the hydrophobic pocket and the BH3-binding pocket is therefore not 
constitutively available (this is also the case for Bax, see below) (Hinds et al., 2003).
Of the multi-domain pro-apoptotic Bcl-2 family members only the Bax structure has so far been 
solved (Suzuki et al., 2000). Bax also has seven amphipathic helices clustered around two 
central predominantly hydrophobic helices (a5 and a6). However, the a9 helix of Bax, which 
corresponds to the TM domain of Bcl-2 and Bcl-XL, binds across the hydrophobic groove. This 
has two important implications: firstly the groove is not constitutively available for binding the 
BH3-domains of other family members and secondly the shielding of the hydrophobic surface 
leads to an increase in the proteins solubility and contributes to it being predominantly located 
in the cytoplasm prior to an apoptotic stimulus.
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Of the BH3-only proteins only Bid has been solved (Chou et al., 1999; McDonnell et al., 1999). 
The overall fold of Bid is very similar to the multi-domain proteins and described above, 
although there is an additional helix in the N-terminus before the unstructured loop and no helix 
corresponding to the Bcl-XL a l.  However, the hydrophobic groove on Bid is much shorter and 
shallower than in Bcl-XL and Bcl-2 since Bid lacks the BH1 and BH2 domains, which, in the 
Bcl-XL structure, contribute key residues to the BH3 binding cleft. This may explain why Bid is 
unable to bind BH3 domain peptides, despite having an overall similar fold (Chou et al., 1999). 
However, as highlighted in Figure 1.1, the primary sequence of Bid is unique amongst the BH3- 
only group with predicted helices in analogous positions to the multi-domain members. It is 
more likely the Bim peptide bound to Bcl-XL is more generally representative of the 
mechanism by which BH3-only proteins engage the pro-survival Bcl-2 family members.
1.11 Bcl-2 proteins show structural sim ilarity to bacterial pore-forming toxins:
A striking observation made in the very first structural study was how the fold of Bcl-XL 
closely resembled that of the colicins and diphtheria toxin (Muchmore et al., 1996) (Figure 1.3). 
Colicins are made by some bacteria to k ill other bacteria strains. They contain three domains for 
(a) receptor binding, (b) translocation of the toxin, (c) the toxin itself that kills by making pores 
in the bacterial membrane (Stroud et al., 1998). The Bcl-XL structure closely resembled the 
toxin domain. The colicins form pores in the membranes leading to the release of essential 
metabolites and in the influx of water, which causes rupture of the cell. This led to early models 
suggesting that Bcl-2 protein might function in an analogous fashion.
It has been shown that Bcl-XL, like the bacterial toxins, can insert into either synthetic lipid 
vesicles or planar lipid bilayers and form an ion-conducting channel. The channel was shown to 
be pH-sensitive and becomes cation-selective at physiological pH. This led to the suggestion 
that Bcl-2 proteins might regulate the permeability of the membranes where they are located 
(Minn et al., 1997). Bax and Bcl-2 have been reported to have similar properties (Schlesinger et 
al., 1997). However, there are significant problems in interpreting the similarities with the 
colicins too literally and extrapolating a similar function for Bcl-2 proteins. The colicins insert 
into bacterial membranes, but this is the evolutionary equivalent of the MIM, not the MOM, 
where the Bcl-2 proteins are thought to act. The MOM is already porous to water and most 
metabolites due to the presence of non-selective ion channels.
Diphtheria toxin (DT) kills mammalian cells by a different mechanism to the way the colicins 
k ill bacteria. DT is a member of the two domain AB family of toxins: the A domain contains
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enzymatic activity that is toxic to the cell. In the case of DT this is an ADP-ribosyl transferase, 
which inactivates an elongation factor required for protein synthesis. The B domain is a receptor 
binding and translocation domain, which can move the A domain across the membrane and into 
the cell (Falnes and Sandvig, 2000). When the B domain of DT binds a receptor it is 
endocytosed and then, in the more acidic environment of the endosomes, a conformational 
change takes place leading to membrane insertion and the translocation of the A domain into the 
cytoplasm. The final step is the reduction in the cytoplasm of a sulfhydril bond which links the 
two domains, freeing the A domain. The translocation domain can also behave as a cation- 
selective channel but it is not clear that this activity is required for translocation of the A 
domain. It seems more likely the B domain acts as a chaperone to unfold the A domain and pass 
it through the channel (Falnes and Sandvig, 2000).
There is some direct evidence to support an analogous role for Bcl-XL. It has been 
demonstrated that a hybrid protein, in which the Diptheria toxin B chain was deleted and the 
translocation domain replaced with Bcl-XL, was able to protect the cells, presumably by 
translocating itself following endocytosis and proving that Bcl-XL could functionally substitute 
for the translocation domain (Liu et al., 1999). However, another AB toxin anthrax the A 
domain is transported without a requirement for covalent linkage to the B domain (Falnes and 
Sandvig, 2000), it is not clear whether Bcl-XL would be able to translocate proteins other than 
itself though the membrane.
A significant problem posed by these structural homology studies is how Bax and Bcl-XL, 
which have very similar structures and in vitro properties as ion channels, have opposing 
biological functions in vivo. However, the structural similarities between multi-domain Bcl-2 
proteins and bacterial toxins are striking and it remains likely that the proteins share at least 
some common functions in relation to their ability to form pores in membranes (Lazebnik, 
2001).
1.12 Models for Bcl-2 family action and questions remaining:
This introduction has summarised current views regarding the place of Bcl-2 family proteins, 
and specifically Bax, in the mammalian apoptotic pathway. At this point it is pertinent to 
consider current models concerning the regulation of Bcl-2 family proteins and highlight 
remaining areas of uncertainty.
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The apoptotic program can be invoked by intrinsic cell signalling indicating cytotoxic damage 
or infection and by extrinsic cell signalling mediated via the engagement of death receptors. In 
addition it can be initiated in response to developmentally regulated cues. The emerging 
consensus from structural and binding studies and from mouse models is that, in almost ever 
case, it is the BH3-proteins appear to provide the upper level of regulation upon apoptotic 
decisions mediated by the Bcl-2 family. Some BH3-only proteins are expressed in a limited 
subset of cell types, whilst other appear to monitor a particular subcellular compartment, stress 
signal or damage response (see section 1.5 and Figure 1.4 A). These diverse mechanisms of 
regulation are thought to provide fine-tuning to the apoptotic response and reflect the diverse 
range of conditions under which apoptosis may be initiated.
Whilst the BH3-only proteins are regulated by diverse mechanisms, some common themes have 
recently emerged concerning their mode of action. Evidence accumulated from structural 
studies (discussed in section 1.10) and binding studies (Cheng et al., 2001) has led to a model 
by which multi-domain anti-apoptotic proteins protect cells by sequestration of active BH3-only 
proteins. Initially, this binding was envisioned to be promiscuous but more recent data suggests 
that some BH3-only proteins, namely Bim, Puma and Bid, have a more prominent role than 
others. An explanation for this became apparent when a systematic study of the binding 
affinities between eight BH3-only peptides and five Bcl-2 pro-survival proteins revealed over 
10,000-fold differences existed between different pairings (Chen et al., 2005). This implies that 
under physiological conditions only certain binding combinations were likely (Figure 1.4 B). Of 
the BH3-containing peptides tested, only those from Bim and Puma showed high affinity for all 
five pro-survival proteins. Bad and Bmf appeared specific for Bcl-2, Bcl-XL and Bcl-w, whilst 
Noxa binds to Mcl-1 and A l. These findings imply that there may, in fact, be two classes of 
Bcl-2 pro-survival proteins, those neutralised by Bad and Bmf (Bcl-2, Bcl-XL and Bcl-w), and 
those neutralised by Noxa (Mcl-1 and A l)  (Chen et al., 2005). Bim and Puma are more potent 
killers since they are able to target both classes (Figure 1.4 B).
Models in which BH3-only proteins target the pro-survival proteins are consistent with the 
genetically established ordering of the apoptotic pathway in C. elegans where the BH3-only 
protein egl-1 is genetically upstream of the multi-domain ced-9 pro-survival molecule (Conradt 
and Horvitz, 1998). However, in the mammalian system, it is Bax and Bak which are required 
for apoptosis (Lindsten et al., 2000; Wei et al., 2001), and in their absence, the binding of BH3- 
only proteins to pro-survival Bcl-2 family members fails to induce apoptosis (Zong et al., 2001). 
This leads directly to the question of how Bax and Bak are regulated, and of the nature of the 
inhibition Bcl-2 pro-survival proteins impose upon them.
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Despite their sequence homology, Bax and Bak exist in different subcellular locations prior to 
the receipt of an apoptotic stimulus; Bax is largely cytosol and Bak localises to the 
mitochondria. This suggests their regulation is likely to differ. Bak has recently been shown to 
be complexed with both Mcl-1 and Bcl-XL in healthy cells, but not with Bcl-2, Bcl-w or A l 
(W illis et al., 2005). It was determined that whilst Noxa alone could release Bak from Mcl-1, 
Bak killing required the addition of a second BH3-only protein such as Bad (Figure 1.4 C) 
(W illis et al., 2005). This data also supports the model shown in Figure 1.4 B, defined based on 
BH3-only protein binding affinities (Chen et al., 2005), that inhibition of both classes of pro­
survival proteins is necessary before Bak becomes active.
Whether Bax is regulated in a similar manner is less certain, since in healthy cells Bax is 
predominantly a cytosolic monomer (Antonsson et al., 2000; Hsu et al., 1997b). One possibility 
is that a small, but crucial pool of Bax molecules exist at the mitochondria and is sequestered in 
an analogous manner to Bak. However, this has not yet been demonstrated in the absence of 
non-ionic detergents.
An alternative explanation for Bax activation has been suggested based on structural similarities 
with pro-survival Bcl-2 family proteins complexed with BH3-peptides (Liu et al., 2003; Suzuki 
et al., 2000). The model suggests that some BH3-only proteins, namely tBid and Bim, are able 
directly engage Bax and Bak and function as ‘activators’ , whilst others are ‘sensitiser’ which 
bind to the pro-survival proteins and displace tBid and Bim, allowing them to engage Bax and 
Bak (Figure 1.4 D) (Letai et al., 2002). These observations were based on the ability of Bim and 
Bid BH3 peptides to initiate Cyt-c release from isolated mitochondria, whilst those from other 
BH3-only proteins, the sensitisers, also required the presence of limiting amounts of Bim or Bid 
BH3 peptide. In this study the effect of the BH3 peptides Bcl-2 pro-survival proteins was not 
investigated. However, more recently it has been reported that Bid and Bim BH3 peptides co­
operate with Bax to permeabilise artificial liposomes, and in this situation a role on pro-survival 
proteins can be excluded (Kuwana et al., 2005). However, interpretation of such data has been 
complicated by the lack of a detectable interaction between Bid and Bax. This has often been 
explained in terms of a ‘hit-and-run’ mechanism whereby the activating interaction between Bid 
would be transient and unstable, and therefore not detectable (Sundararajan and White, 2001; 
Wei et al., 2000). More recently, an interaction between the BH3 peptides from Bid and Puma 
and the N-terminal helix (ha l) of Bax as been reported (Cartron et al., 2004). However, this 
data is difficult to reconcile based on the BH3-binding cleft model developed for the other 
family members (see Section 1.10). Finally, reports placing Bid as an important Bax activator 
must be reconciled with the minimal phenotype observed in Bid deficient animals (Yin et al., 
1999).
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There leads to the conclusion that, as yet, there is no comprehensive mechanistic description of 
how Bax is regulated and becomes activated in vivo (Figure 1.4 E). Direct inhibition of Bax by 
Bcl-2 pro-survival proteins to block oligomerisation of Bax has suggested based on the ability 
of the proteins to heterodimerise (Oltvai et al., 1993) (Figure 1.4 E). However, this interaction 
has only been seen following the addition of non-ionic detergents (Hsu and Youle, 1997; Hsu 
and Youle, 1998) and has yet to be validated in vivo. An alternative mechanism is that Bcl-2 
pro-survival proteins may have an as yet undefined role in inhibiting Bax activation through an 
unknown intermediary, this could encompass modification of the mitochondrial 
microenvironment (Figure 1.4 E). Finally, there have been suggestions that the pro-survival 
proteins may be able to compete with Bax for an as yet unidentified shared target. In such a 
model the pro-survival proteins would protect by sequestering a protein required to drive Bax 
activation (Hsu et al., 1997b; Polcic and Forte, 2003; Wilson-Annan et al., 2003) (Figure 1.4 E). 
The experimental work reported in this thesis was designed to further investigate these issues by 
taking unbiased microscopic and proteomic approaches to the study of Bax regulation.
1.13 Outline of subsequent chapters:
In this chapter I have tried to place the Bcl-2 family, and in particular Bax, into the complex and 
ever-growing field of apoptosis research. At this time many of issues in this field remain 
controversial. I have tried to present the consensus views of the currently available data. In late 
2000, when this work was begun, much less was known about the regulation of Bcl2 family 
proteins. At that time it was decided to take two unbiased approach to address the problem of 
Bax regulation and the subsequent chapters outline how these studies progressed.
The first approach perused was a detailed microscopy-based analysis of Bax activation. The 
premise behind this work was that by observing Bax activation in high spatial and temporal 
resolution might reveal clues as to how Bax was regulated. The data collected is presented in 
Chapter 3 and resulted in evidence that, whilst Bax activation was a rapid event, it may be 
locally initiated within the cell. The data suggest that once the first Bax molecules become 
active the process rapidly propagated across the cell to ensure complete and co-ordinated 
recruitment of all mitochondria into the apoptotic program.
Viral proteins have often proved to be useful in identifying and perturbing key cellular 
processes; they can also be used to gain insights into cellular apoptotic mechanisms. The data 
presented in Chapter 4 characterises the impact of two viral proteins, BHRF1 from Epstein Bar 
Virus and E lB 19k from Adenovirus, on Bax and Bak activation. The data demonstrates that
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whilst both proteins are able to potently block full Bax and Bak activation, they do so by acting 
at different steps. Furthermore, even both viral proteins are able to prevent Bax/Bak 
oligomerisation and irreversible mitochondria dysfunction, analysis of mitochondrial 
ultrastructure reveals that changes still occur. Thereby demonstrating that mitochondrial 
changes in response to the receipt of an apoptotic stimulus are not solely the result of Bax and 
Bak activation.
The mitochondrial distribution in which El B 19k is able to stabilise N-terminally active Bax and 
prevent full activation may be directly comparable to a state that, in wild type cells, exists only 
transiently. This property El B 19k, together with a novel Bax mutation identified in Chapter 5 
as promoting activation, was subsequently used as the basis for an unbiased proteomic approach 
in an attempt to identify proteins interacting with Bax at a critical step in the molecule’s 
activation. In Chapter 6 the results of this screen, together with that for a similar screen 
conducted to identify proteins interacting with Bcl-XL, are presented. The data set contains 
known Bcl-2 interacting proteins and proteins previously implicated in apoptosis. In addition, a 
range of major metabolic and transport proteins not previously implicated in the control of 
apoptosis were also identified. This data suggests that Bax regulation, and that of the Bcl-2 
family more widely, may be more closely integrated into the control of cell metabolism and 
physiology than previously anticipated.
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Figure 1.1 The sub-families of the Bcl-2 family and related viral pro-survival proteins.
The Bcl-2 family are divided into three major groups, the Bcl-2 group promote cell survival, the 
Bax and BH3-only groups promote apoptosis. BH homology domains (BH1-BH4) are shown 
and helical regions are indicated where known. Hydrophobic C-terminal transmembrane (TM) 
domains are also shown (TM). Viral Bcl-2 homologues are grouped into those with sequence 
homology to the cellular proteins (sequence homologues) and those which target Bax/Bak but 
lack significant sequence homology to the cellular proteins (function homologues) Figure 
adapted from Cory et. al, 2003 to show viral proteins with sequence and functional homology.
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Figure 1.2 Extrinsic and intrinsic apoptotic pathways.
Apoptosis can be initiated through either extrinsic or intrinsic apoptotic signalling pathways. (A) 
Activation of the extrinsic pathway is triggered by ligation of death receptors and results in 
formation of the DISC complex and activation of caspase-8 and then effector caspases leading 
to apoptosis. Bid cleavage by caspase-8 provides cross-talk with the mitochondrial pathway. (B) 
Activation of the intrinsic pathway is triggered by BH3 only proteins and results in Bax / Bak 
mediated mitochondrial dysfunction, leading to the release Cyt-c and activation of the 
apoptosome caspase-9 complex and then effector caspases leading to apoptosis. Figure from 
Igney et. al., 2002.
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Figure 1.3 Protein structures of Bcl-2 family members and related proteins.
Bcl-2 cellular proteins have structure which closely resemble viral Bcl-2 sequence homologues 
bacterial pore-forming toxins. Cartoon structures of cellular Bcl-2 (1G5H), Bax (1F16), Bcl- 
XL+Bak peptide (1BXL), Bcl-w (1MK3) and Bid (2BID), the viral Bcl-2 homolgoue BHRF1 
(1Q59) and the Collicin toxin (1COL) are shown. For clarity N-terminal helices are in yellow, C- 
terminal helices are in red and the central helical hairpin (a5/a6 in Bax) is shown in cyan. The 
Bak peptide is shown in purple. Cartoons generated using RasMol software and the Protein 
Data Bank (PDB) record numbers indicated (www.rcsb.org/pdb).
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Figure 1.4 Models for the action of Bcl-2 family proteins.
(A) BH3-only proteins are regulated by diverse mechanisms; (B) Bcl-2 pro-survival proteins 
show specificity for subsets of BH3-only proteins; (C) Bak can be held in check Mcl-1 and Bcl- 
XL prior to release due to a BH3-only protein; (D) tBid, along with Bim (not shown) has been 
suggested to directly activate Bax, whilst other BH3-only proteins target the pro-survival family 
members; (E) Suggest models and current uncertainties regarding Bax activation -  see main 
text for details. Figure from Willis et. al., 2005 (parts A to C) and Cory et. al., 2003 (parts D and 
E).
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Chapter 2 -  Materials and Methods
2.1 General buffers and solutions:
All laboratory chemicals were of analytical grade and purchased from Sigma-Aldrich unless 
stated otherwise. Buffers and solutions were prepared with Millipore purified, autoclaved 
distilled water (ddH20). * indicates solutions supplied centrally by Cancer Research UK central 
research services.
• Luria-Bertani (LB) bacterial liquid growth media*: 10 g/l bactotryptone, 5 g/1 yeast 
extract, 170 mM (10g/l) NaCl. Made up to 1 litre in ddHzO and adjusted to pH 7.0. For solid 
media plates: 1.5% w/v agar was added to above solution. Molten L-agar was poured into
plastic culture dishes (20 ml per 10 cm dish).
• Tris solution: 1 M Tris stock solution was 121.1 g Trizma base per litre, pH 7.5 with HC1.
• NaCl stock solution: 5 M NaCl stock solution was prepared as 292.2 g/l.
• Phosphate buffered saline (PBS)*: 137 mM NaCl (8 g/l), 3 mM KC1 (0.25 g/l), 10 mM 
Na2HP04 (1.43 g/l), KH2P04 (0.25 g/l), pH 7.2.
• Tris buffered saline (TBS)*: 137 mM NaCl (8 g/l), 25 mM Trizma Base (3 g/l), pH 7.4.
• Tris-acetate-EDTA buffer (TAE): A 50X stock solution was prepared as 242 g/l Trizma 
base (2 M), 57.2 ml/1 glacial acetic acid and 100 ml/1 0.5 M EDTA, pH8.0*.
• 20X MES SDS PAGE running buffer (NuPAGE buffer): 97.6 g MES (2 (N-morpholino) 
ethane sulphonic acid, 1.0 M), 60.6 g Tris Base (1.0 M), 10.0 g SDS (69.3 mM), 3.0 g EDTA 
(20.5 mM) and then ddH20 to 500ml. pH 7.3.
• 10X SDS PAGE wet transfer buffer: 250 mM Trizma base (30.3 g/l), 1.92M glycine 
(144.2 g/l), 1% SDS (10 g/l).
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• 1% CHAPS mammalian cell lysis buffer: 50 mM Tris HC1, 150 mM NaCl, 1% CHAPS, 
2 mM EDTA, 5% glycerol. pH 8.0. Complete protease inhibitors (Roche, Lewes, East Sussex) 
were added to IX  final concentration immediately before use. This buffer was used for all 
immunoprecipitation and mammalian cell lysis, including the initial lysis step during TAP 
purifications (section 2.5.5). For gel filtration experiments the glycerol was omitted.
• TEV cleavage buffer (for TAP purifications): 10 mM Tris HC1, 150 mM NaCl, 0.1% 
CHAPS, 0.5 mM EDTA, 1 mM dithiothreitol (DTT), pH 8.0.
• Calmodulin binding buffer (for TAP purifications): 10 mM Tris HCI, 150 mM NaCl, 0.1% 
CHAPS, 1 mM magnesium acetate, 1 mM imidazole, 2 mM CaCl2, lOmM beta- 
mercaptoethanol (BME), pH 8.0.
• Calmodulin elution buffer (for TAP purifications): 10 mM Tris HCI, 150 mM NaCl, 0.1% 
CHAPS, 1 mM magnesium acetate, 1 mM imidazole, 2 mM EGTA, lOmM BME, pH 8.0.
• 10X DNA loading buffer: 2.5 g Ficoll type 400, 0.001 g bromophenol blue, 0.001 g xylene 
cyanol FF made up to 10ml in ddH20.
• 4X SDS sample buffer: 200mM Tris pH 6.8,8% SDS, 40% glycerol and 0.01 g bromophenol 
blue. DTT added to a final concentration of 100 mM immediately before use.
2.2 Reagents and drug treatm ents:
2.2.1 Drugs and reagents used to induce apoptosis:
• Anti-Fas IgM / Cyclohexamide (CHX): Anti-Fas IgM (human, activating), clone CHI l 
(Upstate, Lake Placid, NY) was purchased at 0.5 mg/ml and stored at -20°C. CHX (Sigma) was 
prepared as a 2 mg/ml stock in 100% ethanol and stored at -20°C. To induce apoptosis a final 
concentration of 250 ng/ml (1:2000 dilution) anti-Fas IgM and 2 /<g/ml CHX (1:1000 dilution) 
was added to cells. Unless stated otherwise the abbreviation Fas/CHX is used throughout the 
test to indicate these conditions. For MCF10A cells Fas/CHX was prepared in minimal media 
supplemented only with 5% horse serum and lacking other supplements. For all other cell lines 
complete media was used.
- 4 5 -
• Ultra violet irradiation (UV): Media was removed and cells were briefly rinsed with PBS to 
remove traces of phenol red. PBS was removed by tipping the dish and cells were then rapidly 
exposed to 30 J/m2 UVC irradiation in a UV crosslinker (Hoefer, San Francisco). Media was 
then replaced: for MCF10A cells minimal media supplemented only with 5% horse serum and 
lacking other supplements, for other cell lines this was serum free media.
• Staurosporine (STS): STS (Calbiochem, San Diego, CA) was prepared as ImM stock in 
DMSO and stored at -20°C. A final concentration of 250nM diluted in complete media was 
routinely used to induce apoptosis.
• Hydrogen peroxide (H20 2): 30% stock solution (BDH chemicals, Poole, UK) was diluted to 
a final concentration of ImM diluted in complete media to induce apoptosis.
2.2.2 Antibiotics used for cell selection:
Drug selections were performed using the antibiotics shown in Table 2.1.
Table 2.1 Selective antibiotics used in this study.
Antibiotic Manufacturer Stock
concentration
Working
concentration
Cells selected
Ampicillin Sigma 50 mg/ml 50-100 f4g/m\ Bacterial cells
Kanamycin Sigma 10 mg/ml 25 - 50 /<g/ml Bacterial cells
Blasticidin S HCI Invitrogen 5 mg/ml 2 - 10  f4g/m\ 293 T-REx cells
Zeocin Invitrogen 100 mg/ml 500 - 1000 f4g/m\ 293 T-REx cells
Neomycin
(G418)
Gibco (Invitrogen) 100 mg/ml 0.5 - 1 mg/ml MCF10A cells 
Jurkat cells
Puromycin Calbiochem 10 mg/ml 1 - 2 f4g/ml MCF10A cells 
Jurkat cells
Hygromycin B Calbiochem 385 mg/ml 300 f4 g/ml MCF10A cells
2.2.3 Antibodies:
Primary antibodies used in this work are catalogued in Table 2.2 and secondary antibodies in 
Table 2.3. For western blotting primary antibodies were used at dilutions of l: 1000 unless stated 
otherwise. For immunofluorescence primary antibodies were used at dilutions of 1:200 unless 
stated otherwise. Working dilutions for secondary antibodies are indicated in Table 2.2.
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Table 2.2 Details of primary antibodies appearing in this study.
Name appearing Distributor or Product code Species and Epitope
in this study source & other details quantity information
(A) Bax antibodies:
Bax 6A7 Trevigen 2281-MC-100 Mouse 12-24 hBax
Also: BD, Merck Y2H-6A7 100 pig in 100 j41 N-terminus
Bax N20 Santa Cruz sc-493 Rabbit 11-30 hBax
200 /ig in 1 ml N-terminus
Bax N20 AC Santa Cruz sc-493AC Rabbit 500 pig / 11-30 hBax
250 f<1 agarose N-terminus
Bax NT Upstate 06-499 Rabbit 1-21 hBax
200 pig in 200 pi\ N-terminus
Bax 2D2 Oncogene (Merck) AM32 Mouse 3-16 hBax
(Ab3) 100 pig in 1 ml N-terminus
Bax N19 Santa Cruz sc-526 Rabbit 1-19 mBax
200 f4g in 1 ml N-terminus
Bax AF820 R&D Systems AF820 Rabbit 12-33 hBax
30 pig in 100 pi1 N-terminus
Bax Loop BD PharMingen 554101 Rabbit 43-61 hBax
(Neomarkers) 100 pt\ serum a 1 to a2 loop
Bax Mid BD Transduction 610983 Mouse 55-178 hBax
Labs 250 pig in 600 pi1 a2 to a9
Bax TL41 Gift from Evan Serum Rabbit 57-72 hBax
Lab, ICRF, UK. (not purified) 100 pi\ serum BH3 domain
Bax Ab4 Oncogene PC103 Rabbit 98-117 hBax
(Merck) (Ab4) 100 f4g in 1ml BH1 domain
Bax a7/a8 Oncogene PC66 Rabbit 150-165 hBax
(Merck) (A b l) 100 pig in 1ml BH2 domain
Bax FL-TM Santa Cruz sc-6236 Rabbit 1-171 mBax
(A21) 200 f4g in 1ml Full length - TM
(B) Bak antibodies:
Bak A b l Oncogene AM03 Mouse 1-52 hBak
♦discontinued* ♦discontinued* ♦discontinued* N-terminus
Bak N-term Calbiochem 196150 Rabbit 2-14 hBak
100 }4g N-terminus
Bak NT Upstate 06-536 Rabbit 23-37 hBak
200 pig in 200 pi\ N-terminus
Bak BD BD PharMingen 556396 Rabbit 14-36 hBak
100 pi\ serum N-terminus, 1:500
Bak sc-832 Santa Cruz sc-832 Rabbit
200 {4g in 1 ml
Unspecified 
internal epitope
Bak B0055 US Biological B0055-02 Mouse 41-54 hBak
0.5 mg/ml, 100 /d N-terminal
Bak AF816 R&D Systems AF816 Rabbit 53-72 hBak
100 /ag in 100 f4\ N-terminal
Bak Ab3 Calbiochem AM15 Mouse 82-135 hBak
♦discontinued* ♦discontinued* ♦discontinued* BH1 domain
Bak N20 Santa Cruz sc-1035 Goat Unspecified N-
200 f4g in 1 ml terminal epitope
Bak FL Santa Cruz sc-7873 Rabbit 1-211 hBak
200 /*g in 1 ml full length
Bak T C I00 Calbiochem AM03 Mouse Full length hBak
♦replaces A b l* ♦replaces A b l * 100/^g minus TM.
(C) ATP synthase components:
ATP synthase Molecular Porbes A-21350 Mouse, 100 }4% Clone: 7H10
alpha subunit
ATP synthase Molecular Porbes A-21351 Mouse, 100 pi% Clone: 3D5
beta subunit
ATP synthase Molecular Porbes A-21353 Mouse, 100//g Clone: 7F9
d subunit 1:500
ATP synthase Molecular Porbes A-21354 Mouse, 100 (4% Clone: 4C11
OSCP subunit 1:500
ATP synthase R.Capaldi (gift) MS501 (Aggeler Mouse, 250 pi% Clone:
IPing Ab &  Mitosciences et. al., 2002) agarose coupled 12F4AD8AF8
(D) Endoplasmic reticulum (ER) proteins:
R ibol Santa Cruz sc-12164 Goat, 200 (4% C-terminal
R iboII Santa Cruz sc-12165 Goat, 200 f4% N-terminal
Ost48 Santa Cruz sc-12171 Goat, 200 j4% C-terminal
Calnexin Transduction Labs 610524 Mouse, 150 /4% 116-301 hCanx
(E) Caspases:
Caspase 8 Cell Signaling 9746 Mouse C-terminal peptide
(1C 12) NEB 18,43, 57kDa 200/d purified from hCasp8
Caspase 9 Cell Signaling 9502 Rabbit Peptide around
NEB 17,35,37,47kDa 100 /d purified Asp315 hCasp9
Caspase 3 Cell Signaling 9668 Mouse Residues 28-44
(3G2) NEB 17,19,35kDa 100 f4\ purified of hCasp3
Cleaved Caspase 3 Cell Signaling 9661 Rabbit N-terminal,
(Aspl75) NEB 17, 19kDa 100 /d purified around Aspl75
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(F) Pro-survival proteins:
ElB19k Oncogene DP07L Rat, 100 pi g Clone: 1G11, 1:500
BHRF1 Chemicon MAB8188 Mouse, 100 pig Clone: 5B11
Bcl-2 Santa Cruz sc-509 Mouse, 200 pig 41-54 hBcl-2
Bcl-XL Transduction Labs B61220 (610746) Mouse, 50 pig 18-233 rBcl-XL
Bid (FL-195) Santa Cruz sc-11423 Rabbit, 200pig 1-195 hBid, 1:500
(G) Other miscellaneous antibodies:
Cyt-c (native) BD Pharmingen 556432 Mouse, 100 pig Clone: 6H2.B4
PARP BD Pharmingen 556362 Mouse, 0.1ml Clone: C2-10
Actin Santa Cruz sc-1615 Goat, 200pig C-terminus hActin
Table 2.3 Details of secondary antibodies appearing in this study.
Name appearing Distributor or Product code Species Regular working
in this study source Pack size dilutions
HRP-linked Amersham NA931V Donkey 1:3000
anti-mouse IgG 1.0 ml
HRP-linked Amersham NA934V Donkey 1:3000
anti-rabbit IgG 1.0 ml
HRP-linked Pierce 31433 Rabbit 1:1000
anti-goat IgG 1.5 ml
HRP-linked Amersham NA935V Goat 1:1000
anti-rat IgG 1.0 ml
HRP-linked Jackson Labs 315-035-008 Rabbit 1:75,000
anti-rabbit FcY (Stratech UK) 1.5 ml Fey fragment specific
HRP-linked Jackson Labs 111-035-008 Goat 1:75,000
anti-rabbit FcY (Stratech UK) 1.5 ml Fey fragment specific
FITC anti-mouse Jackson Labs 715-095-150 Donkey 1:200 range
IgG (H+L) (Stratech UK) 0.5 mg, 0.6 ptglpi\ 1:50-1:200
FITC anti-rabbit Jackson Labs 711-095-152 Donkey 1:200 range
IgG (H+L) (Stratech UK) 0.5 mg, 0.6 pig/pi\ 1:50-1:200
Cy3 anti-mouse Jackson Labs 715-165-150 Donkey 1:200 range
IgG (H+L) (Stratech UK) 0.5 mg, 0.6 pig/pi\ 1:100-1:800
Cy3 anti-rabbbit Jackson Labs 711-165-152 Donkey 1:200 range
IgG (H+L) (Stratech UK) 0.5 mg, 0.6 pig/pi\ 1:100-1:800
Cy5 anti-mouse Jackson Labs 715-175-150 Donkey 1:200 range
IgG (H+L)(Cylc) (Stratech UK) 0.5 mg, 0.6 pig/pt\ 1:100-1:800
FITC anti-rat Jackson Labs 712-095-153 Donkey 1:200 range
IgG (H+L)(E1B) (Stratech UK) 0.5 mg, 0.6 pig/pi\ 1:100-1:800
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2.2.4 Oligonucleotide primers:
All primers were synthesised by the CR-UK oligonucleotide facility, resuspended in ddH20  and 
stored as 5/<M stocks at -20°C. A ll primer sequences are written in the 5’ to 3’ direction.
(A) Sequencing primers:
pcDNA4/TO fo rw a rd  primer: c g c a a a tg g g c g g ta g g c g tg  
pcDNA4/TO reverse primer: ta g a a g g c a c a g tc g a g g  
pBABE fo rw a rd  primer: c g t c t c t c c c c c t t g a a c c t c c t c t t t c g  
pBABE reverse primer: c c a c a c c c ta a c tg a c a c a c a t tc c a c a g g  
pEGFPN3 fo rw a rd  primer: g g c g tg ta c g g tg g g a g g tc ta ta ta a g c a  
pEGFPN3 reverse primer: tc g c c g tc c a g c tc g a c c a g g a tg  
pEGFPC3 fo rw a rd  primer: c a t g g t c c t g c t g g a g t t c g t g a c c g  
pEGFPC3 reverse primer: c a g g ttc a g g g g g a g g tg tg g g a g g
(B) Primers for PCR amplification of Bax:
pEGFPN3 forward primer: g a g c c g a g a tc ta tg g a c g g g tc c g g g g a g c a  
pEGFPN3 reverse primer: g a g c t a c t c g a g t c a g c c c a t c t t c t t c c a g a t g g t g a  
pECFPCl forward primer: g a tg c g a a g c tta tg g a c g g g tc c g g g g a g c a g c c c a g  
pECFPCl reverse primer: c t a c g c g a a t t c t t a g c c c a t c t t c t t c c a g a t g g t g a g c g a  
pcDNA RFP(N) forward primer: g a tg c g a a g c tta tg g a c g g g tc c g g g g a g c a g c c c a g  
pcDNA RFP(N) reverse primer: c t a c g c c t c g a g t t a g c c c a t c t t c t t c c a g a t g g tg a g c g a  
pcDNA4TO/NTAP forward primer: g a g c c g g g a tc c g c c a c c a tg g a c g g g tc c g g g g a g c a  
pcDNA4TO/NTAP reverse primer: g a g c t a t c t a g a t c a g c c c a t c t t c t t c c a g a t g g t g a  
pcDNA4TO/CTAP forward primer: g a g c c g g a a ttc a tg g a c g g g tc c g g g g a g c a  
pcDNA4TO/CTAP reverse primer: g a g c t a t c t a g a t c a g c c c a t c t t c t t c c a g a t g g t g a
(C) Bax mutagenesis primers (positions of mutant codons are marked in bold):
Bax SI84V Forward: g c g g g a g tg c tc a c c g c c g tg c tc a c c a tc tg g a a g a a g
Bax SI84V Reverse: c t t c t t c c a g a t g g t g a g c a c g g c g g tg a g c a c tc c c g c  
Bax L25P Forward: a tc a tg a a g a c a g g g g c c c c t t t g c t t c a g g g t t t c a t c  
Bax L25P Reverse: g a tg a a a c c c tg a a g c a a a g g g g c c c c tg tc t tc a tg a t  
Bax K119A, K123A, K128A (AAA) Forward:
CCCTTTTCTACTTTGCCAGCQCACTGGTGCTCOCGGCCCTGTGCACCGCQGTGCCGGAACTGATCAG
Bax K119A, K123A, K128A (AAA) Reverse:
CTGATCAGTTCCGGCACCGCGGTGCACAGGGCCGCGAGCACCAGTGCGCTGGCAAAGTAGAAAAGGG
Bax K119A, K123E, K128E (AEE) Forward:
CCCTTTTCTACTTTGCCAGCGCACTGGTGCTCGAGGCCCTGTGCACCGAGGTGCCGGAACTGATCAG
Bax K119A, K123E, K128E (AEE) Reverse:
CTGATCAGTTCCGGCACCTCGGTGCACAGGGCCTCGAGCACCAGTGCGCTGGCAAAGTAGAAAAGGG
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2.3 DNA methods:
2.3.1 Basic DNA manipulations:
DNA amplification by polymerase chain reaction (PCR) was performed in a 50/d reaction 
according to the general scheme: 400 ng DNA template, 5 f tM forward and reverse primers 
(section 2.2.4), 5 /d I OX Pfu buffer, l /d dNTP mix and l /d Pfu polymerase (Stratagene) made 
up to 50 /d with ddH20. Thermocycling parameters were: 95°C for l min; (95°C for 30 sec, 
54°C for l min, 68°C for 3 min) repeated for 30 cycles; 68°C for 10 min, then held at 4°C. PCR 
grade deoxynucleoside triphosphates (dNTPs, Roche) were combined and diluted to a 50X 
stock solution containing dATP, dCTP, dGTP and dTTP at 10 mM each.
Restriction enzyme digests were performed according to the manufacturer’s protocol (New 
England Biolabs (NEB), Hitchin, Herts) in a total volume of 20 /d and then analysed by DNA 
gel electrophoresis (section 2.3.2). DNA fragments were excised form agarose gels and 
recovered using QIAquick Gel Extraction kit (Qiagen). DNA ligation reactions were performed 
in 10 /d total volume as DNA vector (0.5 /d), DNA insert (0.5 /d), T4 DNA ligase (1 /d) 
(NEB), 10X T4 ligase buffer (1 /d) and 7 /d ddHzO, for 1-2 hrs at RT and then 2 /d of the 
ligation reaction was use to transform competent E.coli as described in section 2.3.4.
2.3.2 DNA gel electrophoresis:
Agarose gels were prepared by dissolving 1% agarose in IX  TAE buffer and heating until 
boiling. Ethidium bromide was added to a final concentration of 0.5 p g/ml before the gel was 
cast. PCR reactions and DNA digests were supplemented with DNA loading buffer to a final IX  
concentration and loaded. DNA molecular weight markers ( lkb  ladder, Invitrogen) were 
included on all gels. Electrophoresis was at 5-10 V/cm in TAE buffer and bands were visualised 
on a UV transilluminator.
2.3.3 Plasmid mutagenesis:
Plasmid DNA mutagenesis was performed by an adapted QuickChange method (Stratagene, La 
Jolla, CA) as a 50 /d reaction: 50 ng parental DNA template, 3.2 pmol of the appropriate 
forward and reverse primers (section 2.2.4), 5 //I 10X Pfu buffer, 1 /d 50X dNTP mix and 1 /d 
Pfu polymerase made up to 50 /d with ddHzO. Thermocycling parameters were: 95°C for 30 
sec; (95°C for 30 sec, 55°C for 1 min, 68°C for 16 min) repeated for 16 cycles; then held at 4°C. 
1 pi 1 Dpnl restriction enzyme (NEB) was then added to the PCR reaction and incubated for 1 hr 
at 37°C to digest methylated parental DNA strands. 1 /d of the resulting reaction was used to
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transform competent E.coli as Section 2.3.4. A control reaction with no Pfu polyermerase was 
performed in parallel and colonies only picked for analysis i f  the control plate was clear of 
colonies.
2.3.4 Transformation of DNA into competent E.coli by heat shock:
20 ng of plasmid DNA, 2 fi\ of ligation reactions or 1 /d of mutagenesis reactions was incubated 
with 30 (a 1 competent XL10 gold E.coli bacteria (Stratagene) on ice for 30 mins. The bacteria 
were then heat shocked by transfer to a 42°C hot-block for 45 seconds and then returned to ice 
for a further 2 mins. 1 ml fresh LB medium was added and bacteria were allowed to recover by 
Ihr incubation at 37°C with gentle shaking. Bacteria were then pelleted in a microcentrifuge, 
resuspended in 100 //I LB medium and spread onto LB agar plates containing the appropriate 
selective antibiotic. Plates were incubated overnight at 37°C and then stored at 4°C.
2.3.5 Purification of plasmid DNA:
Single bacterial colonies picked from LB agar plates containing the appropriate selection 
antibiotic, were used to inoculate 5 ml cultures of LB medium also containing antibiotic and 
incubated overnight at 37°C with shaking. For small scale (mini prep) plasmid purification the 
5 ml overnight culture was pelleted by centrifugation and plasmid DNA isolated using 
DirectPrep 96 MiniPrep automated plasmid purification system (Qiagen) according to the 
manufacturer’s instructions. For large scale (maxi prep) plasmid DNA purification 1ml of the 
overnight culture was used to inoculate 400 ml of LB / antibiotic and incubated at 37°C 
overnight with shaking. Cells were harvested by centrifugation and used for Maxi-prep plasmid 
purification kit (Qiagen) according to the manufacture’s instructions. Purified plasmid DNA 
was resuspended in ddH20  and the concentration and purity assessed using an Eppendorf 
spectrophotometer (Hamburg, Germany) by measuring optical density at 260nm (OD26onm) 
according to the equation: Concentration (mg/ml) = OD260nm x 50 x dilution factor x pathlength.
2.3.6 DNA sequencing:
Sequencing PCR reactions were performed according to the general scheme: 8.0//I of Big Dye 
Terminator reaction mix, 3.2 pmol of primer, 150-200 ng of double stranded primer template in 
a total reaction volume of 20 /ri. Thermocycling parameters were: 2.5°C/sec to 96°C, 96°C for 1 
min; (96°C for 10 sec, l°C/sec to 48°C, 48°C for 5 sec, l°C/sec to 60°C, 60°C for 4 mins) 
repeated for 24 cycles; then held at 12°C. Dye-terminator removal was achieved either with 
DyeEx2.0 spin columns (Qiagen), according to the manufacturer’s instructions or manually by 
ethanol/EDTA/sodium acetate precipitation, briefly: 2 pi\ 125 mM EDTA, 2 /ri 3 M sodium
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acetate and 50 /d 100% ethanol were added to each 20 /d reaction, vortexed, and spun in a 
microcentrifuge at 14,000 rpm for 15 mins at RT. Supernatant was removed by tube inversion 
and precipitant washed with 200 /d 70% ethanol. Samples were then spun again in a 
microcentrifuge at 14,000 rpm for 15 mins at 4°C and supernatant again removed by tube 
inversion. Finally samples was dried in a Speed Vac microcentrifuge and stored at -20°C until 
run. Sequences were read by capillary sequencing using an ABI Prism 3730 DNA analyser 
(Applied Biosystems, Foster City, CA). DNA sequence reads were aligned and manipulated 
using the DNA strider (http://www.cellbiol.com/soft.htnrO.
2.3.7 DNA constructs:
• Fluorescent protein Bax constructs: The N-terminally tagged green fluorescent protein 
(GFP) vector, pEGFPC3 GFP-Bax, was a gift from R.Youle, NIH, Bethesda, USA. The human 
Bax insert was amplified by PCR and inserted (Bglll / EcoRI) into pECFPCl (Clontech) to 
produce the N-terminally tagged cyan fluorescent protein (CFP) variant CFP-Bax. The Bax 
insert was amplified by PCR and inserted (H ind lll / Xhol) into pcDNA RFP-N (a gift from 
R.Tsien, Stanford, USA) to create the red fluoresent protein (RFP) variant RFP-Bax. The Bax 
insert was also amplified by PCR and inserted (Bg lll / Xhol) into pEGFPN3 (Clontech) to 
create the C-terminally tagged variant Bax-GFP. A ll vectors contain Kanamycin/Neomycin 
resistance cassettes except pcDNA RFP-Bax which has Ampicillin/Neomycin resistance 
cassettes.
• TAP tag Bax constructs: pcDNA4/TO TAP-Bax and pcDNA4/TO Bax-TAP were 
constructed based on pcDNA4/TO tetracycline inducible vector (T-REx system, Invitrogen). 
This vector has Ampicillin/Zeocin resistance cassettes. The C-TAP tag template sequence was 
obtained from B.Seraphin, EMBL, Heidelberg, Germany and sub-cloned into pcDNA4/TO 
(EcoRI / Xbal). The human Bax coding sequence was amplified by PCR and inserted 
immediately upstream (5’) of the TAP tag (H indlll / EcoRI) to create Bax-TAP. The N-TAP tag 
template sequence was obtained from Euroscarf (the EUROpean Saccharomyces Cerevisiae 
ARchive for Functional analysis, Frankfurt, Germany) and sub-cloned into pcDNA4/TO 
(H ind lll / EcoRI). The human Bax coding sequence was amplified by PCR and inserted 
immediately downstream (3’ ) of the TAP tag (EcoRI / Xbal) to create TAP-Bax.
• Retroviral constructs containing pro-survival proteins: pBABE puro Bcl-2, pBABE hygro 
Bcl-XL, pBABE puro El B 19k and pBABE puro BHRF1 were all obtained from D.Hancock, 
CR-UK.
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• Other constructs: A retroviral expression vector containing the Ecotropic receptor, pBABE 
neo EcoR, was obtained from P.Wame, CR-UK. The pEGFPC3 GFP-Bax, pEGFPN3 Bax-GFP, 
pcDNA4/TO TAP-Bax and pcDNA4/TO Bax-TAP constructs listed above were used as 
templates in mutagenesis reactions, as described in section 2.3.3 and using primers listed in 
section 2.2.4, to generate the series of four mutants: SI84V, L25P, AAA and AEE which are 
characterised in Chapters 5 and 6. A ll constructs were sequence verified.
2.4 Mammalian cell culture:
2.4.1 Sources of cell lines used in this study:
• 293 T-REx cells: Human embryonic kidney cells expressing pcDNA6/TR. Invitrogen.
• HeLa cells: Human cervical cells. CR-UK central cell services.
• Jurkat cells: Human T lymphocytes. CR-UK central cell services.
• MCF10A cells: Human mammary epithelial cells. P.Wame, CR-UK.
• MCF10A AktER: MCF10A cell line stably expressing an oestrogen receptor (ER) fusion of 
activated (myristoylated) human A ktl (Kohn et al., 1998). This construct can be activated by 
the addition of 4-hydroxytamoxifen (OHT). P.Wame, CR-UK.
• Phoenix A/E cells: 293 based retrovial packaging cells. A gift from G.Nolan, Stanford. 
(Phoenix A indicates amphotropic and Phoenix E indicates ecotropic host selectivity).
• U20S cells: Human osteosarcoma cells (HTB96). CR-UK central cell services.
2.4.2 Cell growth conditions:
Adherent epithelial cells (293 T-REx, HeLa, Phoenix and U20S) were in Dulbecco's MEM 
(E4) media supplemented with 10% foetal bovine serum (FBS). Suspension cells (Jurkat) were 
grown in RPMI 1640 2% (RPMI) media also supplemented with 10% foetal bovine serum 
(FBS). MCF10A cells were grown in Ham's nutrient mixture F-12 / DMEM (1:1) media 
supplemented with 5% horse serum, 10 pig/ml insulin, 20 ng/ml EGF, 5 /^g/ml hydrocortisone, 
and 100 ng/ml cholera toxin (full medium). Minimal medium consisted of Ham's nutrient 
mixture F-12 / DMEM (1:1) containing 5% horse serum only. A ll media formulations were 
prepared by CR-UK central cell services.
Cell lines were grown in environmentally controlled humidified incubators at 37°C and 10% 
COz. Adherent cells passaged when 80-90% confluent by removing the old growth media, 
rinsing cells in warm PBS and then covering the monolayer with 0.25% trypsin / versene 
solution (CR-UK central cell services). Cells were returned to the incubator until they detached
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and the resuspended in fresh complete growth media and distributed into fresh culture dishes at 
1:5 to 1:10 dilutions. In preparation for microscopy experiments cells were re-plated at higher 
dilutions (1:30) to allow time for them to re-adherence onto glass coverslips and transfection 
and still be < 75% confluent at the time of analysis. Suspension cells maintained at 0.5 - 2.0xl06 
cells/ml by diluting the culture with fresh complete media.
Expression of pcDNA4/TO tetracycline inducible constructs in 293 T-REx was achieved by the 
addition doxycycline (dox, Clontech, Mountain View, CA) to a final concentration of 100 ng/ml 
for 12 hrs. Dox was prepared as a 1 mg/ml stock solution in 70% ethanol and stored at -20°C. 
Doxycycline is approximately 100 times more active than tetracycline in this system and these 
conditions 293 T-REx cells were induced at maximal levels. Activation of the 4- 
hydroxytamoxifen dependent AktER fustion in MCF10A AktER cells was achieved by addition 
of 4-hydroxytamoxifen (OHT, Sigma Aldrich) to a final concentration of 250 nM. OHT was 
prepared as a 1 mM stock solution in 100% ethanol and stored at -20°C.
2.4.3 Transfection methods:
A ll transfections for biochemistry and microscopy experiments were preformed with Effectene 
(Qiagen) unless stated otherwise. Transfections were performed according to the manufacturer’s 
instructions, briefly: cells were seeded into 6-well plates 1 day before, or onto flame sterilised 
glass coverslips in 6-well plates 2 days prior to transfection. The transfection mix was prepared 
as: 0.4 p g DNA, 3.2 p\ Enhancer, 100 /d EC buffer and incubated at room temperature (RT) for 
5mins. 10 /d Effectene reagent was then added and incubated for a further 10 mins at RT, 
during this period old media was removed from cells and replaced with 1.6 ml fresh media. 
Finally the transfection mix was then diluted in a further 600 /d fresh media and added to the 
cells.
To obtain higher transfection efficiencies in Phoenix retroviral packaging cell lines (section
2.4.4) either a Calcium Phosphate based method (Invitrogen) or Lipofectamine 2000 reagent 
(Invitrogen) were used according to the manufacturer’ s instructions. In both cases this yielded 
> 80% transfection efficiency as assessed by transfection of a GFP marker plasmid.
2.4.4 Retroviral infections:
MCF10A Bcl-2, Bcl-XL El B 19k and BHRF1 cell lines and Jurkat Bcl-2 cells were produced 
by retroviral transduction. Briefly, the pBabe constructs described in section 2.3.7 were used to 
transfect Phoenix packaging cells as described in section 2.4.3. At 24 and 48 hrs post­
transfection virus-containing supernatant was collect from the Phoenix cells, filtered though a
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0.45 pm syringe unit (Millipore) and diluted 1:1 with fresh growth media appropriate for the 
target cells. Viruses were then added to the cells for a total of 48hrs. After a further 24hrs (72hrs 
after the initial infection) cells were passaged into fresh growth media containing the 
appropriate selective antibiotic (Table 2.1). Selective media was replaced every 3-4 days until 
no more cell death was observed (~3 days for puromycin, ~6 days for hygromycin and ~14 days 
for G418). Stable integration of pBabe-encoded protein in the resulting cell population was 
confirmed by western blotting. In the interests of safety all stable cell lines were constructed 
using a two-step infection regime. In the first round, naive MCF10A and Jurkat cells were first 
infected with the pBabe Neo EcoR virus produced from Phoenix A cells to have amphotropic 
receptor selectivity. This conferred expression of the murine ecotropic receptor on the target cell 
lines. In the second round, pBabe constructs encoding the indicated pro-survival proteins were 
packaged using Phoenix E cells. The viruses produced therefore had more limited ecotropic host 
selectivity and could be safely used to infect cells produced during the initial round.
2.4.5 Production of stable inducible 293 T-REx cell lines:
293 clonal cell lines inducibly expressing TAP-tagged Bax and Bax mutants were produced 
using the T-REx system (Invitrogen). 293 T-Rex cells stably express the tetracycline repressor 
(TetR) encoded by pcDNA6/TR (selection marker: blasticidin). TAP-tagged Bax constructs 
were created in pcDNA4/TO as described in section 2.3.7. pcDNA4/TO is a cytomegalovirus 
(CMV) driven expression vector containing two copies of the tetracycline operator (Tet02) 
sequence. In cells expressing pcDNA6/TR, TetR binds to these sequences and prevents 
transcription from the CMV promoter. Upon the addition of tetracycline or doxycycline (Dox) 
this repression is relieved resulting in transcriptional induction of the gene of interest (Figure 
2.1). Prior to transfection the pcDNA4/TO TAP Bax constructs, and TAP alone control, were 
linearised by digestion with the single-cutting enzyme SspI (NEB) in an attempt to increase the 
efficiency of stable integration. Plasmid DNA was then purified on QIAquick columns (Qiagen) 
and transfected into 293 T-Rex cells plated in 6 cm dishes at 70-80% confluency. 24 hrs after 
transfection the cells were split at dilutions of 1:100, 1:500 and 1:1000 into three 15 cm plates. 
Cells were allowed a further 24hrs to adhere to these plates before the growth media was 
supplemented with Zeocin to a final concentration of 100 /<g/ml. Zeocin-containing selective 
media was gently aspirated and replaced with fresh every 4 days until surviving clones were 
clearly visible to the naked eye (usually 14-16 days for discrete, well-spaced clones to become 
visible on the 1:500 and 1:1000 dilutions). To isolate surviving clones the media was gently 
aspirated from the cells and the clones covered with small circles of Whatman filter paper, 
autoclaved and pre-soaked in trypsin / versene solution. After returning the plates to the 
incubator for 5 mins the filter paper discs were recovered using sterile forceps and placed into
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individual wells of a 24-well plate. Selection was maintained while cells transferred from the 
filter paper and expanded in the wells. Once confluent, clones were each passaged into two 
wells of a 6-well plate and single 6 cm dishe. When nearing confluency one well from the 6- 
well plate was induced with Dox (100 ng/ml for 18 hrs) and then both were lysed and analysed 
by western blotting for induction of the Bax TAP fusion protein. Clones exhibiting tight and 
high-level induction of the Bax TAP fusion were recovered from the remaining 6 cm dishes and 
expanded to prepare frozen stocks and for use in tandem affinity purifications. Representative 
western blots showing induction levels in Bax TAP expressing clones generated by this 
procedure are shown in Figure 2.2.
Repressed  State
Transcription  — ►  |
TATA 2XT*tOj g e n t  at
T-REx™ expression vector pcDNA4/TO
♦ Tetracycline
D erepressed  State
Transcription  -
full CMV promotorj TATA 2XT«tO, 9 0 no of mtoro.t
T-REx™ expression vector pcDNA4/T0
Figure 2.1 T-REx system (Invitrogen) inducible protein expression.
In cells expressing the pcDNA6/TR encoded Tetracycline repressor protein (TetR) a gene of 
interest encoded by pcDNA4/TO is constitutively repressed as transcription from the CMV 
promoter is blocked by the binding of TetR to tetracycline operator sequences (Tet02) 
positioned immediately 3’ of the promoter. The addition of tetracycline (or doxycycline) causes a 
conformational change in TetR and release from the operator sequences, thereby allowing 
transcription of the gene of interest.
N-TAP tag set C-TAP tag set
^  f  &  £
- ♦ - + - + - + - + - +
TAP tagged Bax  
Endogenous Bax
Figure 2.2 Representative clonal cell lines used for Tandem Affinity Purifications.
293 T-REx clonal cell lines containing the indicated pcDNA4/TO TAP Bax variants were treated 
+/- 100 ng/ml doxycycline for 18hrs. Cells were then lysed in 1% CHAPS lysis buffer and 20 /jg 
of total protein analysed by western blotting with an anti-Bax antibody (2D2).
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2.5 Protein methods:
2.5.1 Determination of protein concentrations:
Protein concentrations were measured using a modified Lowry method (Bio-Rad DC Assay, 
Bio-Rad, Hercules, CA). Briefly: 5 pi\ of 1:5 dilutions of protein lysates or of protein standards 
were aliquotted into a 96-well plate in triplicate. Standard samples covering the linear range of 
the assay (0-2.0 mg/ml) were prepared from bovine serum albumin (10 mg/ml, NEB). 25 pi\ 
Reagent A and 200 /d Reagent B were added to each well and the plate was then incubated at 
RT for 20 mins. Protein concentrations were then determined in relation to the standard curve 
by measuring OD750nin on a plate reader.
2.5.2 SDS PAGE and western blotting:
In most cases 20 of 1% CHAPS total protein lysate or one third of the final eluate from 
immunoprecipitations in a total volume of 15 /d was prepared. SDS sample buffer was added to 
a final concentration of IX. Full range pre-stained molecular weight markers (Amersham) were 
included on all gels. Samples were loaded onto 4-12% gradient Bis-Tris NuPAGE gels 
(Invitrogen) for electrophoresis in MES buffer at 200 volts for 35 mins. Following separation 
proteins were transferred to PVDF membranes (Millipore) using mini-gel wet transfer apparatus 
(BioRad) at 85V for 1.5 hrs at 4°C. Membranes were blocked in 5% milk in PBS for 1 hr at RT 
and then incubated with primary antibodies diluted in 5% milk in PBS at 4°C O/N with gentle 
shaking. Membranes were then washed 3 times for 10 mins in PBS with 0.1% Tween-20 and 
incubated with the appropriate secondary antibody diluted in 5% milk in PBS for 1 hr at RT. 
Finally membranes were washed 4 more times for 10 mins in PBS with 0.1% Tween-20. 
Immunoreactive proteins were visualised by enhanced chemiluminescence according to the 
manufacturer’s protocol (Amersham) and exposed to x-ray film  (FujiFilm).
2.5.3 Co-immunoprecipitation:
MCF10A cells were lysed in 1% CHAPS lysis buffer and clarified by spinning at 6000 x g for 
12 mins at 4°C and added to 20 pi\ of pre-washed Ultralink protein A/G bead matrix (Pierce) 
and the indicated antibody (3 pig of purified monoclonal antibody or 5 pi 1 of purified polyclonal 
sera, unless stated otherwise). Samples were incubated O/N at 4°C with rotation. Beads were 
recovered by centrifugation at 1000 x g for 3 mins at 4°C and washed 3 times with 1 ml of 1% 
CHAPS lysis buffer. Following the final wash immunoprecipitated proteins were eluted by the 
addition of 30 pi\ 1.5X SDS sample buffer and the eluate stored at -80°C.
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2.5.4 Gel filtration:
MCF10A cells (2 x 80% confluent 10 cm dishes) were harvested by scraping into PBS and 
pelleted at 2000 rpm in a benchtop centrifuge. Cells were lysed in an equal volume of 2% 
CHAPS lysis buffer (without glycerol). Following rotation at 4°C for 20 mins, samples were 
clarified by spinning at 21,000 x g for 20 min and 40 /d loaded onto a pre-equilibrated Superdex 
200 Precision Column PC 3.2/30 (2.4 ml) gel filtration column (Pharmacia). The column was 
calibrated using thyroglobulin (667 kDa), ferritin (440 kDa), aldolase (158 kDa), BSA (67 
kDa), ovalbumin (43 kDa), chymotrypsinogen A (25 kDa) and ribonuclease A (14 kDa). The 
entire column volume was collected in 40 jA fractions and 10 /d analysed by SDS PAGE.
2.5.5 Tandem affinity purifications:
Each 293 T-REx TAP Bax expressing clone was expanded to 15 x 15 cm culture dishes, except 
for the TAP purification shown in Figure 6.6 where a total of 60 x 15 cm plates were used. 
When cells reached confluency the Bax TAP fusion was induced with the addition Dox to a 
final concentration of 100 ng/ml for 12 hrs. The growth media was then removed and cells 
detached by the addition of 2 ml of 2 mM EDTA in PBS for 10 mins. Cells were then collected 
in PBS and pelleted at 1300 rpm in a benchtop centrifuge. Cell pellets were lysed on ice in 10ml 
of 1% CHAPS lysis buffer with 10 strokes in a dounce homogeniser. The lysate was then 
cleared of nuclei and large fragments by centrifugation at 4300 x g for 20 mins at 4°C and then 
added to 15 ml tube containing 500 /d of a 50% slurry of pre-washed IgG-linked agarose 
(Sigma) and incubated for 2 hrs at 4°C with rotation. Beads were then recovered by 
centrifugation for 5 mins at 1600 rpm in a benchtop centrifuge and washed 3 x 10 ml 1% 
CHAPS lysis buffer and then 1 x 10ml TEV cleavage buffer. The bead matrix, resuspended in 
the second of these washes, was transferred to a 15 ml Poly-prep chromatography column 
(BioRad) to simply further handling. After TEV cleavage buffer wash the base of the column 
was capped and 950 jA TEV cleavage buffer and 100 /d recombinant tobacco etch virus (TEV) 
protease (manufactured by the CR-UK protein isolation laboratory) added. The column was 
then capped at the top and incubated for 2hrs at RT followed by O/N at 4°C with rotation. 
Following TEV cleavage the sample was eluted directly into a second column containing 
capped at the base and containing 500 /d of a 50% suspension of Calmodulin-linked affinity 
resin (Stratagene). 3.5 ml calmodulin binding buffer and 3.5 /d 1 M CaCl2 were then added, the 
column capped at the top and incubated for 2-4 hrs at 4°C with rotation. Finally, the calmodulin 
resin was washed 3 x 10 ml calmodulin binding buffer and bound proteins eluted in 5 x 200 /d 
fractions of calmodulin elution buffer. At each step aliquots were saved for diagnostic western 
blotting. For TAP purifications shown in Figure 6.4 CHAPS was exchanged for Triton-XlOO 
throughout. A summary of the TAP method is shown in Figure 2.3.
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Figure 2.3 Summary of the Tandem Affinity Purification (TAP) method.
Stable cell lines expressing TAP fusion proteins were lysed (A) and the tagged protein bound to 
an IgG-linked bead matrix via the Protein A epitope of the tag (B) The column was washed and 
the tagged protein eluted with TEV protease (C) and then bound to a calmodulin-linked bead 
matrix via the Calmodulin binding peptide (CBP) of the tag (D). Following more washes (E), the 
tagged protein was eluted by chelation of Ca2* and collected for concentration and analysis (F).
2.5.6 Concentration and visualisation of TAP purified proteins:
Final TAP eluates were concentrated using Microcon YM-10 columns (Millipore) operating at 
5000 x g and 4°C from an initial volume of -  1 ml to a final volume of ~ 30 p\. SDS sample 
buffer was added to IX  final concentration and the sample run on 10-well 4-12% NuPAGE gels 
(Invitrogen) and fixed in 40% ethanol, 10% acetic acid, made with ddH20  for 1 hr at RT. Gels 
were then stained using either SilverQuest mass spectrometry compatible silver stain 
(Invitrogen) or colloidal coomassie (Sigma).
2.5.7 Addition of cross-linkers to TAP purifications:
A modified TAP purification is outlined in Figure 6.9. Essential changes were that the TEV 
cleavage was performed in a modified buffer in which the Tris buffer was substituted for Hepes. 
Following the TEV cleavage the crosslinker disuccinimidyl suberate (DSS, Pierce) was added 
to a final concentration of 0.1 mM from a 100 mM stock prepared in DMSO. The cross-linking 
reaction was allowed to proceed for 30 mins at RT with rotation and then neutralised by the 
addition of 1 M Tris pH 7.5 to a final concentration of 50 mM. Following a further incubation 
for 15 mins at RT, SDS was added to a final concentration of 1% and the sample to promote 
dissociation of unlinked proteins and the sample was rotated for a further 15 mins at RT. 
Finally, the SDS was diluted to 0.1% by the addition of 1% CHAPS lysis buffer and entire 
sample added to 50 1 compact pre-washed Bax N20-linked agarose beads (Santa Cruz) and
incubated at 4°C O/N. After this immunoprecipitation step the Bax N20 agarose was washed 3 
times with 10ml of 1% CHAPS lysis buffer and the immunoprecipitated proteins eluted in 1.5X 
SDS sample buffer for analysis by SDS PAGE.
2.6 Mass spectrometry:
Bands of interest were excised, destained using 50:50 25 mM ammonium bicarbonate / 
acetonitrile (ACN), then washed with HzO (20 min) and dried in a SpeedVac (45 min). Porcine 
trypsin (Promega) was prepared in 200 /ri ice-cold resuspension buffer (supplied with the 
enzyme; 0.1 mg/ml trypsin at 16 000 U/mg) and made up to 500 pi\ with 25 mM ammonium 
bicarbonate to give a working solution. Gel pieces were rehydrated in 5 /ri of this working 
solution for 5 min on ice. 30 f41 of 25 mM ammonium bicarbonate was then added and samples 
incubated for 2 hrs at 37°C. Digestion was stopped by placing the samples on dry ice. Samples 
were later defrosted and the supernatant transferred to a 0.2 ml siliconized thin walled tube 
(Bioquote, York, UK). Two further extractions were performed with 30 /ri of 5% v/v formic 
acid, incubating in a sonicating water bath for 15 min. Peptides from the three extractions were 
pooled then dried in a SpeedVac. Prior to MS the peptides were desalted twice by re-suspending 
and washing in 50 jA HzO and then taken to dryness in a SpeedVac to remove all volatile salts.
Immediately prior to analysis peptides were resuspended in 7 //I 1% formic acid and 5 pA 
injected onto a nano HPLC (high pressure liquid chromatorgraphy) system (LC Packings, 
Sunnyvale, CA). Separation is achieved on a nano LC column (75 pim I.D. x 150 mm) packed 
with Vydac C18 (5 ptm particles) at a flow rate of 250 nl/min with a gradient from 0% to 95% 
of 0.1% acetic acid in acetonitrile and anlysed directly by tandem electrospray mass 
spectrometry using either a qTOF (Micromass) or API 4000 QTRAP MS/MS System (Applied 
Biosystems). The resulting spectra were initially collected using proprietary software supplied 
with the instruments. Subsequently peptide masses were searched against the National Center 
for Biotechnology Information (NCBI) non-redundant database using the Mascot software 
(Matrix Science, London). One missed cleavage per peptide and an initial mass tolerance of 
10 ppm were used in all searches.
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2.7 Fluorescence activated cell sorting (FACS) methods:
2.7.1 Bax and Bak activation staining:
At specific times after drug treatments cells (minimum 106) were harvested from suspension 
cultures by centrifugation or 6-well dishes by scraping into PBS. Cells were then fixed in ice 
cold 70% ethanol for at least 30 mins at 4°C and stored at 4°C. Prior to analysis cells were 
immunostained with the indicated anti-Bax and -Bak antibodies at 1:200 dilutions in 500 /ig/ml 
digitonin in PBS, either overnight at 4°C or for 1 hr at room temperature (RT). Cells were then 
washed in PBS and incubated with the appropriate FITC-linked secondary antibody at 1:200 
dilution in PBS for lh r at room temperature (RT) in the dark and then washed for a final time in 
PBS (Griffiths et al., 1999).
Cells were then analysed by FACS using a FACSCalibur instrument fitted with an argon-ion 
488 nm laser and red HeNe 633 nm red diode laser (Becton Dickinson, San Jose, CA). The 
instrument was configured to record 10000 events per sample in the FITC (FL-1) channel. Data 
handling was performed using CellQuest software (Becton Dickinson, San Jose, CA) to display 
histograms of the staining intensity for each sample.
2.7.2 Analysis of DNA content -  SubGl apoptosis assay:
Cells were grown in 6 cm dishes and treated with Fas/CHX as indicated to induce apoptosis. At 
each time point samples were harvested in triplicate by scraping into PBS and fixed with ice 
cold 70% ethanol for at least 30 mins and accumulated at 4°C for analysis. Cells were then 
washed twice in phosphate-citrate buffer (0.2 M disodium phosphate (Na2HP04), 4 mM citric 
acid (pH 7.8)), between washes cells were collected by spinning at 2000 rpm in a benchtop 
centrifuge. Each sample was then treated with 50 pi of 100 /*g/ml RNase followed by 200 pi\ of 
50 f ig/ml propidium iodide (PI).
Cells were then analysed by FACS using a FACSCalibur instrument fitted with an argon-ion 
488 nm laser and red HeNe 633 nm red diode laser (Becton Dickinson, San Jose, CA). The 
instrument was configured to exclude debris and cell doublets and then record PI staining 
intensity (FL-3) as a measure of DNA content as shown in Figure 2.4. For each sample 10,000 
events were acquired and data analysis was preformed using FlowJo software (TreeStar Inc, 
CA).
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Figure 2.4 FACS analysis for dead cells with sub-G1 DNA content.
Representative FACS profiles to demonstrate how the proportion of dead cells with sub-Gl DNA 
content was measured. MCF10A cells were harvested and stained as described in section 
2.7.2. (A) Untreated, (B) 14hrs after exposure to Fas/CHX. In both parts 3 analysis steps were 
performed sequentially: (i) gating of forward scatter against side scatter to discriminate whole 
cells; (ii) doublet discrimination was achieved by adjusting area and width parameters; (iii) finally 
fluorescence intensity of PI (FL-3) was measured on a linear scale and the proportion of cells 
with a sub-G1 DNA content was then calculated using FlowJo sowtware.
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2.7.3 Annexin V staining  -  measuring apoptosis in GFP transfected cells:
MCF10A cells were grown in 6-well dishes and transfected with the GFP constructs indicated 
using Effectene reagent (Qiagen). 24 hrs after transfection, cells were harvested by scraping into 
PBS, collected by centrifugation and washed in PBS. Cells were then resuspended in calcium- 
rich buffer (Becton Dickinson, San Jose, CA) containing 2 pi Alexa 647 linked anti-Annexin V 
IgG (Molecular Probes, Oregon, USA) and 5 pg/ml propidium iodide (PI, Sigma Chemicals, 
Poole, UK) for 15 min at RT.
Cells were analysed by FACS using a FACSCalibur instrument Fitted with an argon-ion 488 nm 
laser and red HeNe 633 nm red diode laser (Becton Dickinson, San Jose, CA). The instrument 
was configured to measure GFP (FL-1) fluorescence intensity on a logarithmic scale and gate 
5000 GFP positive cells. This subset was then analysed for PI (FL-2/3) and Annexin V Alexa 
647 (FL-4) positivity. The percentage of GFP-positive cells displaying characteristic features of
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apoptotic cell death (ie. Annexin V positive and PI negative) was calculated as a proportion of 
the total GFP-positive cells using CellQuest software (Becton Dickinson, San Jose, CA). For 
each sample the median GFP (FL-1) intensity was also recorded as a measure of the GFP-fusion 
protein expression level.
2.8 Im m unofluorescence and confocal m icroscopy:
Cells were plated onto glass coverslips (22mm diameter, Thickness No 1.5, Raymond A Lamb 
Ltd., East Sussex, UK). Where possible MCF10A cells were plated 2 days prior to transfection 
and 3 days prior to analysis as these cells take longer to adhere and spread on a glass surface. 
Transfections were carried out as outlined in section 2.4.3. At least 24 hrs was allowed for 
expression of the transfected plasmids prior to cell fixation or induction of apoptosis by 
treatments outlined in section 2.2.1. Where indicated Mitotracker Orange (Molecular probes, 
Carlsbad, CA) was added to the medium to a final concentration of 200 nM for 20 mins prior to 
fixation. Cells were then rinsed briefly with warm PBS and fixed by flooding coverslips with 
warm 3% paraformaldehyde solution in PBS. After 20 mins fixation at RT were washed 3 times 
in PBS and stored at 4°C until before immunostaining. Note: for the GFP/Mitotracker/DAPI 
combination used to characterise Bax mutants in Chapter 5 no additional staining was necessary 
and coverslips were mounted directly onto glass slides and imaged directly.
For immunostaining fixed cells were permeabilised by incubation in 0.1% Triton X -100 in PBS 
for 5 mins on ice and then washed 3 times in PBS. Cells were then blocked to reduce unspecific 
binding using 0.2% fish skin gelatine (FSG) in PBS for at least 20 mins at RT. Primary 
antibodies were diluted to 1:200 (unless stated otherwise) in 0.2% FSG / PBS and incubated on 
the cells for 1 hr at RT or overnight at 4°C. Where co-staining with more than one primary 
antibody was used they were added simultaneously. Coverslips were placed on pedestals made 
from inverted 1.5 ml tube caps mounted in a Petri dish and then kept inside a damp chamber. 
This arrangement meant 200 /ri antibody solution was sufficient to cover the cells on each 
coverslip and be held in place by surface tension. Following incubation with the primary 
antibody coverslips picked up with forceps and drained by tilting and touching their edges onto 
absorbent paper. They were then rinsed by moving sequentially through a series of four baths of 
0.2% FSG / PBS (50 ml each) and placed back onto pedestals. 200 of the appropriate 
secondary antibody dilutions were then added for 1 hr at RT in the dark (see table 2.2). 
Coverslips were then rinsed through another 4 washes of 0.2% FSG / PBS, 1 wash of PBS and 
1 wash of water (to prevent PBS derived salt crystals forming between coverslip and glass slide 
after mounting). Finally, coverslips were mounted onto glass slides using 8 y\ of ProLong Gold
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anti-fade reagent containing DAPI (Molecular Probes) and left to set at 4°C overnight. Cells 
were visualised on an LSM510 confocal microscopy (Carl Zeiss, Thomwood, NY) equipped 
Argon 288 nm, HeNe 543 nm, HeHe 633 nm and blue diode 405 nm laser lines. Image 
acquisition was achieved using a 63X plan-apochromat Phase 3 oil immersion objective, 
numerical aperture 1.4 (Carl Zeiss), operating and operating at 1 airy unit (optical slice size 
~0.8 /*m) and image manipulation was using the LSM510 propriety software and Photoshop 
CS2 (Adobe, San Jose, CA).
2.9 Live cell video microscopy:
Cells were grown in 35 mm glass bottomed dishes (MatTek Corporation, Ashland, MA) for 1 
day prior to transfection. Transfections were with Effectene (Qiagen) as described in section 
2.4.3. 24 hrs after transfection cells were loaded with tetramethylrhodamine methyl ester 
(TMRE, Molecular Probes) by adding a 1 f4M stock to a final concentration of 2 nM in the 
growth media for 20 mins. Cells were then washed and placed in fresh media and indicated 
treatment to induce apoptosis applied (either Fas/CHX or UV irradiation, see section 2.2.1).
2.9.1 Basic live cell recording experimental setup:
Digital time-lapse microscopy was used to record cell behaviour following the induction of 
apoptosis. A ll time-lapse experiments were conducted on the same Zeiss Axiovert 135 TV (Carl 
Zeiss) inverted microscope. The microscope was optimised for multi-channel digital time-lapse 
microscopy and to accommodate the long-term imaging of mammalian cells in culture. The 
microscope was fitted with tungsten and mercury lamps to enable both bright field and 
fluorescence imaging, and was equipped with separate bright field and fluorescence shutters 
(Uniblitz), a shutter controller (Sutter Instruments), and a sensitive CCD camera (Orca ER, 
Hamamatsu). A ll peripheral devices were under the control of image acquisition software 
(Acquisition Manager, Kinetic Imaging). The CCD camera was mounted directly under the 
sample on the lower camera port of the microscope in order to minimise the number of optical 
elements in the path from the objective to the camera, therefore maximising the fluorescence 
signal. Blocks containing excitation and emission filters and compatible dichromatic mirrors 
enabled a range of fluorophore species to be imaged and were constructed as shown in figure 
2.5. In addition, motorised excitation and emission filter wheels containing a selection of 
different fluorescence filters enabled the rapid sequential imaging of multiple fluorophores 
during a single time-lapse experiment when used in conjunction with appropriate multiple 
dichromatic mirrors.
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Figure 2.5 Basic design of filter system used for low light live cell microscopy.
Basic design of filter blocks containing excitation and emission filters and compatible 
dichromatic mirrors. During automated image acquisition a block position containing only the 
appropriate dichroic was used, the excitation and emission filters being contained in motorised 
filter wheels for automated switching.
Filters and dichromatic mirrors were purchased from Omega Optical Inc. and permitted the 
imaging of EGFP (FX100-2 Alpha Vivid: Ex 475 AF40, DRLP 505, Em 535 AF45) and Alexa 
568/Cy3/Cy3.5 (FX108-2 Alpha Vivid: Ex 525 AF45, DRLP 560, Em 695 AF55) fluorescence, 
the latter being suitable for visualising TMRE. The microscope was housed in a purpose built 
Perspex environmental chamber accurately maintained at 37°C using a heater unit constructed 
in-house (CR-UK Research Services). The main body of the microscope rested on an optical 
table isolator (Melles Griot) in order to minimize the effects of ambient vibrations on image 
acquisition. The glass-bottomed culture dish was positioned on the stage of the microscope in a 
glass-topped, steel humidity chamber (also constructed in-house) and efficiently prevented 
evaporation during the course of time-lapse recording. A 63X plan-apochromat Phase 3 oil- 
immersion objective, numerical aperture 1.4 (Carl Zeiss) was used for all recordings.
The time-lapse interval, total duration of the recording, and filter configurations varied 
according to the experimental assay and are therefore described for each assay. Most commonly 
EGFP fluorescence, TMRE fluorescence and phase frame acquisitions were made at 1 min 
intervals for a total of 1000 cycles. Exposure times for each channel were set individually to
avoid saturation of the detector, this usually invoked a delay of around 20 mins between the 
addition of treatments to start of automated image acquisition,
2.9.2 Specific modifications for caspase 3/7 activity reporter experiments:
To monitor the first evidence significant caspase3/7 activity MCF10A cells were co-transfected 
with a caspase 3/7 reporter construct (BD Clontech) and cyan flouresence protein tagged Bax 
(CFP-Bax). Details of the construction and function of the caspase 3/7 reporter are shown in 
Figure 2.6. Live cell recording was as described in section 2.9.1 with the only modification 
being the use of a specially optimised excitation/emission filter set for CFP (Bax) and YFP 
(caspase 3/7 reporter) acquisition (Omega Optical Inc). Full details of the recordings are 
included in the appropriate figure legends.
Figure 2.6 Schematic outline of the Caspase 3 reporter construct (Clontech).
The Caspase 3 sensor vector consists of a yellow fluorescent protein (YFP) fused at the N- 
terminus there to a Nuclear Export Signal (NES) and caspase consensus cleavage site 
(DEVD)*. A Nuclear Localisation Signal (NLS) is fused at the C-terminus. (A) In healthy cells the 
NES is dominant over the NLS and the fusion protein is excluded from the nucleus. (B) Upon 
activation of effector caspases cleavage at the DEVD motif releases the NLS-targeted YFP from 
the NES and the fluorescent protein is rapidly sequestered into the nucleus. By transiently co­
transfecting this construct with an N-terminally CFP-tagged Bax it is possible address the 
temporal relationship between the appearance of Bax clusters and significant effector caspase 
enzymatic activity.
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2.9.3 Specific modifications for Pericam Ca2* imaging experiments:
The dual-excitation ratiometric pericam fluorescent Ca2+ indicator construct has been described 
in detail elsewhere (Nagai et al., 2001; Zhang et al., 2002). The basic principle of the construct 
is shown in Figure 2.7. A mitochondrially targeted version of the ratiometric pericam was a gift 
from M.Martins, University of Leicester and used in co-transfection experiments together with 
red fluorescent protein fusion of Bax (RFP-Bax). Three excitation/emission filter combinations 
were used to image these constructs: RFP-Bax: 560±20nm/625±25nm, pericam 410nm: 
380±25nm/535±15nm and pericam 510nm: 480±20nm/535±15nm, together with a
DAPI/FITC/TexasRed optimised dichromatic mirror (all from Omega Optical Inc). This 
enabled the live cell system described in section 2.9.1 to be adapted for the sequential 
acquisition of: (i) RFP-Bax, (ii) pericam excited at ~410nm, (iii) pericam excited at ~510nm, 
(iv) phase contrast. The ratio the pericam 510nm excitation / 410nm excitation was then 
calculated using the Kinetic Imaging software and as a qualitative readout of changes in 
mitochondria |Ca2+|.
Peptide Y
Peptide X
Figure 2.7 The mitochondrial pericam -  a conformation sensitive permuted AFP protein.
The pericam protein is based on Aequorea fluorescent protein (AFP) engineered to be directly 
sensitive to calcium ions (red circle). In this case Ca2+ sensitive proteins X and Y (Calmodulin 
and M13 peptide) have been fused to the amino- and carboxy-termini of the circularly permuted 
AFP. Upon binding of Ca2+ the pericam protein exhibits changes in excitation spectra as well as 
increased fluorescence emission intensity. This is detected by monitoring changes in the ratio of 
emissions following excitation at two different wavelengths: ~510nm excitation and ~410nm 
excitation and allows these proteins to report on changes in intracellular Ca2+. Since such 
proteins can be targeted to specific subcellular locations such as organelles they enable 
organelle-specific Ca2* measurements to be made. (Figure from Zhang et. al., 2002).
2.10 Electron microscopy:
For standard morphological analysis MCF10A were grown on 13 mm diameter Thermanox 
plastic coverslips (Agar scientific). 293-T-REx cells were grown in 10 cm plastic culture dishes. 
Following induction of apoptosis (MCF10A) or induction of Bax TAP fusions (293 T-REx) 
cells growth media was removed and cells were fixed for 1 hr in a modified Kamovsky’s 
fixative: 4% paraformaldehyde, 2.5% glutaraldehyde, 2mM CaCl2 in 0.1M Na Cacodylate 
(Na(CH3)2As02.3H20), pH7.4. 293 T-REx cells were scraped in the fixative and pelleted using 
a benchtop centrifuge and processed as a loose pellet. MCF10A cells were fixed and processed 
on the plastic coverslips. Cells were then washed in cacodylate buffer twice for 10 mins at room 
temperature. Samples were then post-fixed using 1% osmium tetroxide (0s04) and 1% 
potassium ferricyanide (K3Fe(CN)6) in 0.1M Na Cacodylate pH7.4 at room temperature for 30 
mins. Samples were then washed 2 x 20 mins in cacodylate buffer, 2 x 5  mins in ddHzO. Finally 
2% aqueous uranyl acetate solution was added for contrast enhancement and samples were 
stored at 4°C overnight.
In preparation for sectioning samples were again washed 3 x 5  mins in ddH20  and then 
dehydrated by processing through a graded series of ethanol: 70% 1 x 20 mins, 80% 1 x 20 
mins, 90% 1 x 20 mins, 100% 3 x 20mins. Samples were then washed in intermediate solvent 
(propylene oxide) 1 x 20mins before resin infiltration using a 50/50 mixture of 
araldite/propylene oxide overnight at room temperature. The next day infiltration was continued 
with 3 x lh r changes of araldite alone (the samples were warmed to 60°C for about lOmins 
before each change). Samples were then left to polymerise at 60°C overnight.
Sections of approximately 90nm thickness were then cut on Leica Ultracut S Ultratome (Leica, 
Wetzlar, Germany) and collected on 200 mesh copper grids. Sections were further stained with 
a saturated solution of uranyl acetate in methanol for approximately 6 mins at RT, rinsed x 4 in 
methanol and then with Reynold's lead citrate stain for 4 mins RT and rinsed x 4 in ddH20. 
Samples were then viewed in a JEOL 1200 TEM (JEOL, Tokyo, Japan). Each micrograph 
collected represented a different cell selected at random from the grid and at least 30 cells were 
examined in each sample. For MCF10A samples all mitochondria in the micrograph were 
scored for morphology and included in the analysis.
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Chapter 3 -  Behaviour of the Bax protein
3.1 Introduction:
In late 2000, when this work was begun, the central role of Bcl-2 family proteins in the cellular 
decision to initiate apoptosis was already becoming clear. Earlier in 2000, the first reports of 
Bax-I-Bak-I- doubly deficient animals provided genetic proof that the presence of at least Bax or 
Bak was required to initiate cell death by apoptosis (Lindsten et al., 2000; Wei et al., 2001), 
Yet, despite a significant body of work in this area, both the mechanism of action of these 
proteins, and the process by which they become active, remained a matter of debate, and does 
so to this day. The work described here was initiated to gain further insights into the process of 
Bax regulation and activation.
Several publications in the preceding years have revealed the Bcl-2 proteins, and particularly 
the pro-apoptotic Bax and Bak molecules, were artificially activated by commonly used non­
ionic detergents such as Triton X-100 and NP-40 (Hsu and Youle, 1997; Hsu and Youle, 1998). 
In 2000, this was confirmed when the NMR structure showed dramatic shifts in the spectra 
upon the addition of detergent (Suzuki et al., 2000). Early explanations for Bcl-2 protein 
function were largely based around a so-called rheostat model, in which the life or death 
decision was a consequence of whether pro-survival or pro-apoptotic members predominated 
after taking into account intra-family binding by which pro-survival and pro-apoptotic members 
were able to neutralise each others function. As it became clear that detergent-induced 
activation promoted promiscuous binding between the different Bcl-2 family proteins, the 
physiological relevance of the earliest incarnations of the rheostat models had to be re­
evaluated. Further studies have since led to revisions and modifications, but certain aspects of 
the rheostat model have stood the test of time. Here it is only mentioned in order to reiterate two 
key points: one is that it now seems most likely the BH3-only proteins are primarily ligands to 
neutralise pro-survival proteins, and thereby relieve inhibition on Bax and Bak. Only a minority 
of BH3-only proteins can directly activate Bax and Bak, and even these are not essential. The 
second is that although direct binding of pro-survival Bcl-2 proteins to Bak has been validated 
(W illis et al., 2005), it is unlikely a similar mechanism can be invoked to explain how Bax is 
held in check since the Bax protein is predominantly a cytoplasmic monomer and is not found
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complexed with pro-survival proteins in healthy cells. Therefore, although an essential step in 
the initiation of apoptosis, the mechanisms by which Bax becomes activated and by which Bcl- 
2 pro-survival proteins prevent Bax activation remain largely unknown.
There are many possible models which can, and have, been invoked to explain Bax activation, 
including release from a cytoplasmic anchor (Sawada et al., 2003), hit-and-run activation by 
another protein (Eskes et al., 2000), recruitment to the mitochondria (Marzo et al., 1998), 
binding of a small molecule such as a metabolite or change in the physiological conditions of 
the cell such as pH (Tafani et al., 2002). However, none of these models has yet been widely 
accepted. Most of the previous studies of Bax activation have been carried out in cell 
populations. Spatial and temporal organisation of apoptotic signalling in general, and of Bax 
activation in particular, remains a largely uninvestigated area. With such a diverse range of 
possible mechanisms involved, a reasonable starting point therefore seemed to be to take an 
unbiased approach and see if  further insights could be gained by observing the Bax protein in 
action, in order to characterise when and where in the cell activation takes place. This was 
achieved initially by using antibodies raised against the endogenous protein and later by 
expressing GFP-Bax to monitor changes in Bax localisation in live cells. Although some of the 
data presented in this chapter has been superseded by more recent publications, the results 
shown have not previously been reported in MCF10A cells or followed at such high resolution 
following the activation of apoptosis by Fas/CHX. These observations formed the basis for 
further attempts to interrogate and manipulate the Bax activation process, the results of which 
are presented in the subsequent chapter.
3.2 Characterisation of conform ationally sensitive Bax and Bak antibodies:
Early reports had demonstrated that antibodies raised against the N-terminus of Bax were 
conformationally sensitive, meaning that they only recognised Bax subsequently to its 
activation (Nechushtan et al., 1999). Antibodies raised against the N-terminus of Bak behave in 
a similar conformationally sensitive manner and have been used to quantify the early stages of 
apoptosis (Griffiths et al., 1999; Makin et al., 2001; Postigo et al., 2006). The ability of these 
antibodies to identify individual cells undergoing apoptosis could therefore be used in assays to 
quantitate apoptosis. In this section an example is shown for both Bax and Bak.
To demonstrate the conformational sensitivity of the Bax 6A7 antibody, U20S cells were 
treated 1 mM H20 2 to induce apoptosis. 4 hrs later the cells were loaded with Mitotracker to 
reveal the location of energised mitochondria, fixed and immunostained with the Bax 6A7
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antibody. Apoptotic cells are clearly identified as being recognised by the 6A7 (12-24) anti-Bax 
antibody (Figure 3.1 A). A reciprocal staining pattern, whereby “ Bax-positive cells” have failed 
to stain with Mitotracker, indicates that the mitochondria have already lost the A\pm, suggesting 
that these cells are undergoing the early stages of apoptosis. The binary nature of this staining 
pattern, whereby cells are either strongly positive for 6A7 staining or remain completely 
unstained, makes it a useful assay with which to quantify apoptosis at a stage much earlier than 
other commonly used readouts, for example DNA fragmentation. This can be visualised in 
MCF10A mAkt-ER cells, which are protected from apoptosis by the tamoxifen-dependent 
activation of the pro-survival kinase Akt l.  By counting the percentage of cells staining 
positively with the 6A7 antibody, the level of apoptosis induced by etoposide, Fas alone or 
Fas/CHX was clearly reduced by a 4 hr prior activation of Akt l  (Figure 3.1 B, panel i). Lysates 
prepared from parallel cultures were used in a western blot with a phospho-specific antibody to 
detect phosphorylation of residue serine 473, which indicates that the protein kinase is active.
Bak has an analogous function to Bax and was shown to be genetically redundant (Wei et al., 
2001). Jurkat cells are a useful system in which to study Bak activation since they fail to express 
Bax, due a frame-shift mutation within a polyguanine tract in the Bax open reading frame 
(Brimmell et al., 1998), and are therefore reliant on Bak to mediate mitochondria dysfunction. 
To demonstrate the use of Bak conformationally sensitive antibodies Jurkat cells were treated 
with H20 2 to induce apoptosis and then stained using an antibody against the N-terminus of 
Bak, Ab l (1-52). When staining intensity was analysed by FACS a clear shift in the Bak 
staining intensity could be seen in cells induced to undergo apoptosis (Figure 3.2 A, blue trace), 
compared to untreated cells (red trace). As with Bax 6A7 staining, the clear increase in staining 
intensity that accompanies Bak activation makes the A b l antibody ideally suitable for use as the 
basis for assays to monitor protection from apoptosis. This is shown for Bak Abl staining of 
Jurkat cells with and without stable over-expression of Bcl-2. The experiment reveals that Bcl-2 
efficiently protected the cells against staurosporine (STS) induced Bak conformational change 
(Figure 3.2 B, upper row). STS is a broad specificity kinase inhibitor and therefore triggers 
apoptosis by ‘cell intrinsic’ pathways. This contrasts with Fas/CHX, which is considered an 
activator of ‘cell extrinsic’ pathways since it directly activates Fas death receptor signalling. In 
response to Fas/CHX the Bcl-2 expressing Jurkat cells are not protected and show the same 
degree of Bak conformational activation as the wild type cells (Figure 3.2 B, lower row). Jurkat 
cells are a human T-cell leukaemia cell line, which generate large amounts of caspase-8 and 
caspase-3 activity directly following death receptor activation (Strasser et al., 1995). Such cells, 
primarily restricted to those of lymphatic origin, are classically referred to as Type I cells, being 
able to activate effector caspases independently of mitochondrial involvement (Scaffidi et al., 
1998). The majority of cells from other tissues, including the MCF10A cells used extensively in
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this work, are defined as Type II cells which show an absolute dependence on mitochondrial 
dysfunction to initiate apoptosis downstream of death receptor ligation.
There are, of course, many commercially available antibodies raised against various epitopes 
within the human Bax and Bak proteins (Figure 3.3 A). To test the conformational sensitivity of 
a range of these antibodies, immunoprecipitations were performed from lysates prepared from 
MCF10A cells treated with Fas/CHX to induce apoptosis. It was, however, somewhat surprising 
to find that the conformationally sensitive behaviour of the Bax and Bak antibodies, described 
above, was not limited to those raised against N-terminal epitopes of the proteins. This suggests 
that, for Bax, at least, activation is associated with a more dramatic conformational change than 
just rearrangement of the N-terminus (Suzuki et al., 2000). The majority of anti-Bax and -Bak 
antibodies tested were in fact conformationally sensitive, only able to immunoprecipitate their 
respective proteins following a treatment to induce apoptosis (Figure 3.3 B-D). A notable 
exception to this was an antibody raised against residues 43-61 of human Bax. This was able to 
efficiently immunoprecipitate Bax from both healthy and apoptotic cells (Figure 3.2 C, labelled 
43-61). A possible explanation for this difference is the location of the epitope; it is located in a 
flexible loop between helix a l and a2 and is therefore more likely to be constitutively exposed. 
The Bak antibodies tested also displayed a high degree of conformational sensitivity, although 
there was a higher level of Bak recognition prior to the induction of apoptosis. This is an 
interesting result since it indicates that a pool of Bak protein exists with a constitutively exposed 
N-terminus, even in healthy cells, although this is substantially increased by the induction of 
apoptosis. This pool could be analogous to the fraction reported to be interacting with Bcl-2 
pro-survival proteins (W illis et al., 2005), although this point was not investigated further.
3.3 Characterisation of Bax antibodies by immuofluorescence:
To examine the location of active Bax in cells undergoing apoptosis, the Bax antibodies 
characterised biochemically in Figure 3.3 were also tested in immunofluorescence experiments 
and examined by high-resolution confocal microscopy. U20S cells, treated with Fas/CHX, were 
loaded with Mitotracker to reveal the mitochondria and immunostained with the two of the N- 
terminal Bax antibodies: NT (1-21) and N20 (11-30). Apoptotic cells could be clearly identified 
by bright mitochondrially-associated foci (Figure 3.4). This pattern was analogous to the 
staining pattern seen at lower resolution with the Bax 6A7 antibody (Figure 3.1). During the 
early stages of cell death these clusters appeared to be small (< 0.5 pivci) and positioned at the 
tips of mitochondria and at restriction points along the mitochondrial network (Figure 3.4 A-C). 
Cells in the later stages of apoptosis appeared to contain larger clusters, and whilst these were
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still closely associated with the mitochondrial network, they were mainly adjacent to, rather 
than co-localised with, mitochondria. In addition, in cells with larger Bax clusters, the 
mitochondria showed evidence of fragmentation, forming a more punctate and less reticular 
network (Figure 3.4 D).
Although these antibodies are useful in revealing the post-activation distribution of Bax, they do 
not report of the location of Bax immediately prior to the activating conformational change. For 
this reason further immunoflouresence experiments were conducted with the Bax 43-61 
antibody, which was uniquely able to immunoprecipitate Bax from healthy cells (Figure 3.3 C). 
When U20S osteosarcoma cells were exposed to a low dose of UV irradiation (30 J/m2) the 
majority of cells were still alive 18 hrs later. Whilst this mild stress trigger was insufficient to 
induce widespread apoptosis, immunofluorescence using the Bax 43-61 antibody under these 
conditions revealed a re-distribution of Bax onto the mitochondrial network, co-localising with 
Mitotracker Orange (Figure 3.5 A). This redistribution of Bax to mitochondria following UV 
irradiation was striking in that it occurred in every cell in the culture and was evenly distributed 
along the mitochondrial network. Both features distinguish it from full Bax activation, which 
involved entry into bright foci and initiated stochastically throughout the population (Figure
3.4). At longer times after UV irradiation, or following the addition of more acutely acting death 
stimuli, such as Fas/CHX, the Bax 43-61 was also able to recognise the bright foci associated 
with full activation (data not shown). In addition, it was confirmed that Cyt-c retained an 
exclusively mitochondrial distribution in cells exhibiting this UV-induced Bax redistribution. It 
was only in cells where Bax had formed bright foci where Cyt-c had been released from the 
mitochondria and become diffusely distributed in the cytoplasm (Figure 3.5 B and data not 
shown). This result demonstrates that translocation of, at least a portion of, the Bax protein to 
mitochondria does not result in full activation of the protein and therefore is not sufficient to 
initiate apoptosis.
3.4 GFP-Bax can be used to monitor Bax activation in live cells:
When considering the Bax 43-61 immunostaining shown in Figure 3.5 A, it is not possible to be 
certain whether the cytoplasmic staining truly represents the cytoplasmic pool of Bax or is 
simply unspecific background staining. It is also possible that Bax co-localisation with 
mitochondria following UV irradiation is the result of conformational change in the protein 
rather than redistribution. In an attempt to address these questions the experiments were 
repeated using a transiently transfected N-terminal green fluorescent protein (GFP) fusion of
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Bax (GFP-Bax). This has the advantage that the total cellular pool of GFP-Bax is always 
visible, regardless of its activation state.
Examination of the cells 24 hrs after transfection revealed that moderate levels of GFP-Bax 
over-expression were well tolerated by both U20S and MCF10A cells. In healthy MCF10A 
cells, GFP-Bax was predominantly cyctoplasmic (Figure 3.6 A, upper row). Following the 
induction of apoptosis with Fas/CHX, transfected cells underwent apoptosis in response to 
Fas/CHX or UV irradiation within a similar time period to surrounding untransfected cells. 
GFP-Bax could be seen to enter small mitochondrial-associated foci (Figure 3.6 A, middle row). 
At later stages of cell death, when fragmentation of the nuclei was clearly visible from the 
DAPI co-staining, these foci appeared considerably larger and Mitotracker staining was absent 
or disrupted (Figure 3.6 A, bottom row). Similar distributions were observed in U20S cells 
(data not shown). In U20S cells transfected with GFP-Bax and treated with low-dose UV 
irradiation, enrichment of GFP-Bax evenly along the mitochondrial network, could also be 
clearly observed 18 hrs later (Figure 3.6 B). This latter result also confirms that mitochondrially 
localised Bax appearing after low doses of UV irradiation was indeed the result of partial 
translocation of the cytoplasmic pool to the mitochondria. Together, the data presented in 
Figure 3.6 also demonstrates that GFP-Bax can recapitulate the distributions observed using 
antibodies to the endogenous protein, thereby validating its use as a Bax reporter.
An additional advantage of GFP-Bax is that translocation and activation of the protein can be 
followed in live cells. To this end a low light imaging system was established with which to 
monitor changes in GFP-Bax distribution in transiently transfected cells following the induction 
of apoptosis. The position of energised mitochondria was also recorded by pre-loading the cells 
with the mitochondrial specific fluorescent probe tetramethylrhodamine methyl ester (TMRE). 
Representative recordings of U20S and MCF10A cells undergoing apoptosis in response to UV 
irradiation are included as Supplementary Movie Figures M3.1 and M3.2, with static frames 
from M3.2 shown in Figure 3.7 C. From these initial results it was clear that the initiation of 
GFP-Bax clustering was a rapid event and was temporally closely linked to the loss of Atpm, as 
detected by dissipation of TMRE sequestered in mitochondria (Figure 3.7 C, compare frames at 
28 -  36 mins).
It was also possible to see enrichment of GFP-Bax onto the mitochondrial network in U20S 
cells following a low dose of UV irradiation. The partial translocation itself occurred extremely 
slowly and was difficult to document. However, once formed, the distribution was observed to 
persist for several hours and was therefore not predictive that full GFP-Bax activation was 
imminent. An example is shown in Figure 3.8 and Supplementary Movie Figure M3.3. In this
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recording, which began approximately 18 hrs after the UV dose was administered, there is no 
detectable further increase in GFP-Bax at the mitochondria during the first hour of recording 
(Movie M3.3). Strikingly, just 1 min before the onset of GFP-Bax clustering, there is no 
evidence of mitochondrial fragmentation or any other visible evidence of the cell’s impending 
death (Figure 3.8 B, frame 59 mins). However, when Bax activation does occur it is rapid and 
associated with complete loss of Atpm within 5 mins (Figure 3.8 B, frames 60 - 64 mins). An 
enlargement of a small peri-nuclear region from the sequence shown in Figure 3.8 B is included 
as Figure 3.8 C. From these frames it is clear that there is a degree of heterogeneity in the 
behaviour of individual mitochondria in the same cell undergoing these events. For example, in 
the frames recorded at 60 mins, exactly as the first GFP-Bax become visible, the first detectable 
loss of A\l)m occurs in just a few mitochondria. Interestingly, there is an associated increase in 
the TMRE staining intensity of some of the remaining mitochondria. Over the next 5 mins, as 
the GFP-Bax clusters increase in size, the Aopm is lost from these remaining mitochondria as 
well. The GFP-Bax foci then continue to increase in size throughout the next 30 mins, during 
which time the cell begins to change shape and round up showing the typical morphological 
features of apoptotic cell death (Figure 3.8 B and C, frames up 90 mins). These initial 
recordings indicate that when GFP-Bax activation begins, as detected by the formation of small 
bright foci of GFP-Bax, there is a heterogeneous response of mitochondria within the first 5 
mins, with some losing their A\pm before others in the same cell. This heterogeneity was clearer 
in more polarised cells; two recordings from such cells are described in the next section.
3.5 Rapid and synchronised Bax activation appears to be locally initiated:
Occasionally cells were observed in which activation of GFP-Bax, and loss of Aipm, appeared to 
initiate in one discrete sub-cellular region. This occurred in more polarised cells, where GFP- 
Bax activation initiated in the cell’s periphery, and then spread rapidly across the rest of the cell. 
An example is shown in Figure 3.9 and Supplementary Movie Figure M3.4. This record shows 
a U20S cell treated with UV irradiation 18 hrs previously. The cell demonstrates the partial 
enrichment of GFP-Bax at mitochondria described previously (Figure 3.9 C, blue arrows). GFP- 
Bax activation initiats in a protrusion in the lower part of the cell and there is a corresponding 
loss of A4>m from mitochondria in this localised region. GFP-Bax activation spreads across the 
whole cell, with an associated loss of Aipm, within the next 3 minutes (Figure 3.9 C, yellow 
arrows). A few mitochondria retain their A4>m, briefly gaining a higher TMRE staining intensity, 
before they too become depolarised (Figure 3.9 B, frames at +3 mins and +4 mins). The rapid 
and progressive nature of both GFP-Bax activation and loss of Axpm suggests the existence of a
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feed-forward activation mechanism whereby Bax activation at one mitochondrion can rapidly 
trigger activation in the neighbouring cellular region.
This hypothesis is further supported by a second example which shows a particularly polarised 
MCF10A cell (Figure 3.10 and Supplementary Movie Figures M3.5). During the course of the 
experiment, and as surrounding untransfected cells die, the central GFP-Bax transfected cell 
undergoes morphological changes that result in the formation of a cytoplasmic projection (more 
clearly documented in an extended and accelerated version of the recording M3.6). GFP-Bax 
first becomes active, as detected by the formation of bright foci, in this projection (Figure 3.10 
C, yellow arrows). This region is initially appears isolated from the rest of the cell body by the 
narrow neck of connecting cytoplasm. However, over the course of filming, the projection 
retracts towards the cell body. Exactly as the connecting neck is breached, there is a rapid and 
synchronous activation of GFP-Bax, and corresponding loss of A\pm, throughout the rest of the 
cell body (Figure 3.10 C, red arrows). This is followed by a period during which the GFP-Bax 
clusters increase in size and the cell then dies with the distinctive morphological features of 
apoptosis. This recording therefore shows that Bax can be activated in one region of the cell and 
which then leads to the rapid activation of Bax in adjacent regions. In this case the narrow 
bridge of connecting cytoplasm, separating the main cell body from the region with active GFP- 
Bax is likely to act as a diffusion barrier, preventing communication between the two regions. It 
is only when the narrow neck of the projection is breached by its full retraction into the cell 
body that communication is restored and then the active GFP-Bax efficiently triggers activation 
of the remaining cellular pool.
Together the data presented in this section indicates that Bax activation may not be a globally 
initiated cell-wide process, whereby Bax becomes active in the cell and synchronously targets 
all mitochondria. Instead, Bax activation may begin in a discrete subcellular location which then 
initiates a feed-forward mechanism to ensure that this activation is rapidly spread across the 
whole cell. I f  correct, this interpretation has important implications for understanding Bax 
activation, since it would suggest that the decision to initiate apoptosis can be made at a local 
level, maybe at a single mitochondrion. This would connect the decision to commit to apoptosis 
with the local environment and mitochondrial physiology a particular subcellular region. These 
conclusions are reliant on the ability to detect the very first Bax molecules to become active in 
the cell. For this reason additional experiments were conducted to assess the sensitivity of the 
imaging system and these will be discussed in the next section.
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3.6 Further consideration of the timing of GFP-Bax activation:
The data presented in section 3.5 and 3.6 suggests that in UV-treated U20S and MCF10A cells 
the cell-wide loss of begins coincidentally with GFP-Bax activation and is complete within 
5 minutes. However, some reports have suggested that loss o f Aipm precedes Bax activation, for 
example, in Cos7 cells treated with STS, it was observed that dissipation of A\jjm by at least 50% 
occurred before GFP-Bax was detectable at the mitochondria (Smaili et al., 2001). Occasionally 
in the present study recordings were made which appear to confirm that this order of events was 
also possible (Figure 3.11 and Supplementary Movie Figure M3.7). However, the reasons for 
these rare results were likely to be technical. In this example the cell expressed very low levels 
of GFP-Bax. For comparison, the adjacent cell, appearing in Figure 3.10, is shown in the final 
panel. It is likely that in such low-expressing cells there was insufficient GFP-Bax recruited into 
the early clusters for them to be detectable. In this record, loss of A\pm was detectable at least 
2 mins before the first sign of GFP-Bax foci and it was a further 5 mins before they were 
prominent. (Figure 3.11, compare frames at t = 705, 707 and 714 mins). Nevertheless, it is also 
a long-standing observation that high levels of Bax expression will sensitise cells to more rapid 
apoptosis (Rosse et al., 1998; Xiang et al., 1996) and in live cell systems such cells died well in 
advance of surrounding untransfected cells (Smaili et al., 2001). Therefore, both these extremes 
were avoided in the present study and all recordings shown feature moderately expressing cells. 
Under these conditions, surrounding untransfected cells died in approximately the same 
timeframe as those transfected with GFP-Bax, indicating that significant sensitisation by Bax 
over-expression was not the case.
Given the controversial nature of the temporal relationship between GFP-Bax activation and the 
loss of A\|>m it was preferable to validate the system further by correlating the appearance of the 
first clusters of GFP-Bax to an additional event known to be an immediate downstream 
consequence of Bax activation. If the system is truly detecting the first GFP-Bax to become 
active the bright foci should be detectable immediately before or coincidentally with such an 
event. The use of GFP-tagged Cyt-c has been previously reported and should fu lfil these criteria 
(Goldstein et al., 2005; Goldstein et al., 2000). However, attempts using both N- and C-terminal 
GFP fusions of Cyt-c were confounded by a lack of mitochondrial import of the over-expressed 
protein. In fact, the previously described experiments were performed using clonal cell lines 
specifically selected to have mitochondrial localisation of the over-expressed tagged Cyt-c 
(Goldstein et al., 2000). Following transient transfection this proved to be a surprisingly rare 
event. The details of mitochondrial import of Cyt-c are not currently known but it is likely that 
either over-expression or the addition of the florescent protein tag prevented efficient 
mitochondrial import in the majority of cells. Cyt-c instead accumulated to high levels in the
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cytoplasm. This was not yet toxic, since the active conformation is only attained following the 
addition of haem-groups in the mitochondrial intermembrane space (Kranz et al., 1998), 
nevertheless, this marker was unsuitable for use in live cell imaging.
An alternative approach was therefore employed using a fluorescent caspase reporter construct. 
This consisted of a YFP variant protein engineered to contain a caspase cleavage site, nuclear 
export signal (NES) and nuclear localisation signal (NLS). In healthy cells the protein is 
cytoplasmic due to the dominance of the NES over NLS. Upon activation of effector caspases-3 
and -7, cleavage of the protein results in the removal of the NES, it is subsequently imported 
into the nucleus (for further information see section 2.9.2). This construct was transfected into 
MCF10A cells, together with a CFP-Bax and the cells were imaged following treatment with 
Fas/CHX. A representative recording is shown in Figure 3.12 and Supplementary Movie Figure 
3.8. From this recording it is clear that bright foci of CFP-Bax are detectable at least 1-2 mins 
prior to detectable translocation of the caspase reporter into the nucleus. Recordings from two 
further cells are included Appendix 1 (Supplementary parts 3.12 B and 3.12 C, with 
accompanying movies M3.9 and M3.10). Both show the same 1 - 2 min delay between the Bax 
activation and the first sign of effector caspase activity. Although this experiment measures the 
enzymatic consequence of caspase activation, rather than activation of the caspase itself, it is 
still highly indicative that the first active Bax detectable does represent the first pool becoming 
active in the cell, before the downstream consequences of mitochondrial dysfunction become 
apparent.
Finally, in a few recordings spontaneous transient depolarisations of A\pm, or mitochondrial 
flickers, were occasionally observed. Figure 3.13 A shows a flicker of 2 - 3 mins duration 
recorded in a UV treated MCF10A cell, and Figure 3.13 B shows a major flicker at 10 mins and 
minor flicker at 12 mins, both of 1 - 2 mins duration in UV treated U20S cells. In the former 
example the depolarising mitochondria are still visible in the phase image showing that this is 
not an artefact due to the mitochondria moving out of the focal plane. Flickers were usually 
localised and resulted in a brief increase in the TMRE staining intensity of nearby mitochondria, 
followed by complete recovery of the depolarising mitochondria. Flickers of Aipm were first 
described in healthy neuronal cells (Loew et al., 1993) and have more recently been quantified 
in smooth muscle cells where they are reported to occur with an average frequency of 0.02 
flickers per second (O'Reilly et al., 2003). In the system described in the present work such 
flickers were rarely observed, but this could be because they were too rapid to detect at the 1 
frame/minute acquisition rate used. The flickers w ill be discussed in more detail in Chapter 4. 
However, they did not appear to be predictive of the onset of apoptosis. For example the cell 
shown in Figure 3.12 A was recorded for a further 2 hrs during which time no further flickering
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or complete depolarisation was observed. Flickering of individual mitochondria was also clearly 
distinct from the cell-wide depolarisation that accompanied the onset of apoptosis (Figure
3.13 C).
The results presented in this chapter demonstrate that, in cells over-expressing moderate levels 
of GFP-Bax, the appearance of detectable foci of GFP-Bax occurs prior to detectable effector 
caspase activity and synchronously with loss. It is, therefore, likely that the first foci of 
active GFP-Bax detected using this imaging system accurately correlate with the first Bax 
molecules becoming active in the cell. This means that observations suggesting the existence of 
a feed-forward mechanism of Bax activation, namely the spreading of Bax activation (Figure 
3.9) and the ability of active GFP-Bax in the cellular projection to rapidly activate Bax in 
another location (Figure 3.10), are also likely to be valid.
3.7 Increased mitochondrial calcium is detectable prior to Bax activation:
There are multiple examples of cellular signals that initiate in discrete cellular spatial domains 
and give rise to travelling signalling waves to ensure a signal is propagated at full strength to a 
remote location within the cell. The best known examples are cAMP and calcium (cAMP, Ca2+). 
Of these, Ca2+ ions represent one of the most ubiquitous signalling pathways in all cells, 
regulating many short-term changes in cell function (Berridge et al., 2000). Mechanisms have 
been characterised for feed-forward expansion and propagation of the Ca24 signal, such as the 
Ca2+-induced-Ca2+-release (CICR) from the inositol 1,4,5-trisphosphate receptors (IP3R) at the 
endoplasmic reticulum (ER), and the Ryanodine receptors (RyR) present at the sarcoplasmic 
reticulum (SR) of muscle cells (Berridge et al., 2000). During IP3R-driven Ca2+ signalling 
mitochondrial Ca2+ uptake can modulate propagation of the wave (Simpson and Russell, 1996; 
Tinel et al., 1999). In addition, isolated mitochondria immobilized in agarose gel have been 
shown to drive Ca2+ waves by CICR in their own right (Ichas et al., 1997). Ca2+ waves have also 
been reported in permeabilised myocardial myotubes following apoptosis induced by exposure 
to C2 ceramide (Pacher and Hajnoczky, 2001). It is therefore possible that the feed-forward 
mechanism causing sequential Bax activation is a result of a CICR wave. Direct measurement 
of mitochondrial Ca2+ uptake in situ is now possible due to the advent of selectively targetable 
Ca2+-sensitive fluorescent proteins (Zhang et al., 2002). One of these, the mitochondrial 
pericam, is targeted to the mitochondrial matrix (Nagai et al., 2001) and could therefore be used 
in an attempt to address this hypothesis.
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Ratiometric imaging of the pericam protein (ie. the ratio of emission intensities following 
excitation at two wavelengths) can be used to give a qualitative indication of changes in matrix 
Ca2+ levels. MCF10A cells were co-transfected with the pericam protein together with a red 
fluorescent protein fusion of Bax (RFP-Bax), to provide a marker for when Bax activation 
initiated. The cells were then treated with Fas/CHX to induce apoptosis and imaged sequentially 
to visualise RFP-Bax and mitochondrial pericam at 410 nm and 510 nm, allowing the ratio 
image to be calculated (Figure 3.14 A). In the representative recording shown, the first sign of 
RFP-Bax activation occurs in frame 585, 195.2 mins (Figure 3.14 B). Two small regions of 
interest were then defined to encompass pericam containing mitochondria and the mean 
integrated intensity of the RFP-Bax and pericam emissions were plotted against time (Figure
3.14 C). From this recording it is apparent that the monomeric RFP used here is prone to 
bleaching and this resulted in the steadily declining RFP emission signal seen throughout the 
recording. Nevertheless, the point when RFP-Bax begins to concentrate into mitochondrially- 
associated foci is shown by a rapid increase in RFP-Bax intensity at ~195 mins. An apparent 
increase in the level of mitochondrial Ca2+ is detectable from ~73 mins after the addition of 
Fas/CHX until the initiation of Bax activation at ~ 195 mins, based upon pericam Ca2+ recording. 
At around the time of RFP-Bax activation there is acceleration in the rate of Ca2+ uptake by the 
mitochondria, however this was not detectable in all experiments. Pericam measurements in the 
period after Bax activation must be considered unreliable due to the rapid onset of apoptosis, 
resulting in cell shrinkage and movement of the cell such that the static regions of interest, from 
which the measurements were made, no longer covered the same subcellular region. Recordings 
from two further cells, both showing an increase in mitochondrial Ca2+ in the period 
immediately prior to Bax activation, are included Appendix 1 (Supplementary parts 3.14 D and 
E).
Unfortunately, due to the technical problems encountered during these experiments, it became 
clear that for accurate and reproducible measurements mitochondrial Ca2+ a more rapid rate of 
image acquisition was required than the 20 sec/frame used in the examples shown. In addition, 
the rapid movement of both mitochondria within healthy cells and the cell as a whole, 
particularly in the period immediately after the onset of Bax activation, meant that it was 
extremely difficult to define regions of interest which remained stable for the period required to 
obtain useful data. Nevertheless, the data presented indicates a steady and reproducible increase 
in the pericam signal, following the induction of apoptosis and before Bax becomes active, 
suggesting that mitochondrial calcium levels are increasing. These results are included because 
they are considered supportive of additional data presented in the next chapter.
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Discussion:
The activation of Bcl-2 proteins Bax and Bak, and resulting mitochondrial dysfunction, 
including the release of Cyt-c, is widely accepted to represent the point-of-no-retum in the 
mammalian apoptotic cell death pathway. However, despite a large body of literature on both of 
these proteins, their mechanism of activation remains largely uncertain. The premise of this 
chapter was to follow Bax activation at high temporal and spatial resolution and to see if  such 
an unbiased approach could provide further insights into the protein’s activation.
Antibodies directed against the N-termini of both Bax and Bak provide robust and useful tools 
with which to assay the activation of these proteins (Figure 3.1 and 3.2). However, they are 
limited to use on fixed material and, critically for this study, they fail to report on the location of 
Bax immediately before it becomes active. The finding that most anti-Bax antibodies are in fact 
conformationally sensitive (Figure 3.3), only recognising the protein subsequent to its 
activation, reinforces the dramatic nature of the conformational change Bax is thought to 
undergo (Suzuki et al., 2000). From this analysis, only one antibody, Bax 43-61, was able to 
detect the inactive conformation of the protein, perhaps because this epitope maps to a flexible 
loop in the Bax structure between ha l and ha2. Immunostaining with this antibody following a 
low dose of UV irradiation revealed an enrichment of Bax evenly distributed over the 
mitochondrial network (Figure 3.5 A), not seen by the antibodies which only recognise the full 
active conformation of Bax. In the recent literature, it is often assumed that Bax translocation to 
the mitochondria is synonymous with its activation, oligomerisation and permeabilisation of the 
MOM. However, the finding that, following a mild cellular insult, Bax can become partially 
localised to mitochondria prior to full activation (Figure 3.5 A), suggests that translocation 
alone does not explain Bax activation and that subsequent steps are likely to be required. This 
finding also supports early fractionation data, in which a proportion of Bax was detected at 
mitochondria (Desagher et al., 1999; Goping et al., 1998; Hsu et al., 1997b), and some more 
recent studies in which Bax was characterised at the mitochondrial membrane but not yet fully 
active (Annis et al., 2005; Valentijn et al., 2003).
It is possible that the partial accumulation of Bax (Figure 3.5 A) and GFP-Bax (Figure 3.6 B) at 
mitochondria following UV irradiation represents a snapshot of an ongoing accumulation. If 
mitochondria have a limited, but saturable, capacity to accommodate Bax, a threshold could be 
envisioned beyond which their binding capacity is saturated, or the local concentration of Bax 
becomes high enough, such that oligomerisation of the protein ensues. In support of such an 
accumulation model, it has been reported that translocation of ~20% of the cellular Bax to the 
MOM is sufficient to induce apoptosis (Hsu et al., 1997b) and Bax over-expression has been
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widely reported to promote apoptosis (Rosse et al., 1998; Xiang et al., 1996), indicating that 
over-expression may shift the cellular equilibrium towards greater and faster accumulation of 
Bax at mitochondria. However, several lines of evidence run contrary to this model. Firstly, 
accumulation of GFP-Bax at mitochondria prior to full Bax activation does not occur following 
administration of an acutely acting death stimulus, such as Fas/CHX (see Figure 3.7 for 
example). Additionally, it has been reported that in H015.19 rat fibroblasts, around 40% of Bax 
can translocate to mitochondria without initiating apoptosis (Soucie et al., 2001), although this 
may be related to the fact that these cells are Myc null and, therefore, may not be more 
generally applicable. Finally, live cell recordings from UV treated U20S cells presented in this 
study showed no additional enrichment of GFP-Bax at mitochondria in the period immediately 
before full Bax activation occurred (Movie M3.3). It is therefore likely that Bax is regulated at 
multiple steps and that whilst the protein can become enriched at mitochondria, it is not 
necessarily fully active if  it does so, nor is mitochondrial localisation a prerequisite step to full 
activation and entry into foci. Bax activation at mitochondria can also take place directly, 
without detectable prelocalisation or enrichment.
From observing GFP-Bax activation in live cells, a striking feature was the sudden nature of its 
onset. Just 1 min before full GFP-Bax activation occurred there were no visible signs of 
mitochondrial disruption or the cell’s impending death (see Figure 3.9 for example). This is 
significant because a recent body of literature has accumulated on the role of mitochondrial 
fission and fusion proteins, which are thought to accelerate a ‘ thread-like’ to ‘grain-like’ 
transition of the mitochondrial network, at around the time of Bax activation (Youle and 
Karbowski, 2005). Two of these proteins, D rpl, a large dynamin family GTPase, and 
Endophilin B l, a fatty acyl transferase, have been shown to translocate from the cytosol into 
foci on mitochondria early during apoptosis (Frank et al., 2001; Karbowski et al., 2004). Drpl 
has also been shown to co-localise with Bax (Karbowski et al., 2002), in the foci that appear at 
tips and restriction points in the mitochondrial network (Figure 3.4). Interestingly, Endophilin 
B l was originally identified in a yeast two hybrid screen as Bax Interacting Factor 1, B ifl 
(Cuddeback et al., 2001). It has been suggested mitochondrial fission is a necessary 
physiological step to enhance mitochondrial dysfunction and accelerate apoptosis (Youle and 
Karbowski, 2005). However, this view has recently been challenged by a number of findings. 
Firstly, an inter-membrane space protein, DDP/TIMM8a has been shown to enhance Drpl- 
mediated mitochondrial fission, thereby placing maximal rates of mitochondrial fission 
downstream of the initial mitochondrial dysfunction (Amoult et al., 2005). Secondly, expression 
of dominant negative DRP-1 in C. elegans has been reported to increase long-term survival of 
some cells in the organism, but the phenotype was extremely weak, indicating it may not 
contribute significantly to apoptotic cell deaths in this organism in vivo (Jagasia et al., 2005).
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No evidence of mitochondrial fragmentation was observed in MCF10A and U20S cell lines, in 
response to both UV- and Fas/CHX induced apoptosis prior to Bax activation. This would 
support the view that mitochondrial fragmentation is not required for efficient initiation of 
apoptosis but may play a role in the subsequent dismantling of the cell.
Finally, data presented in this chapter is consistent with the existence of a feed-forward 
mechanism whereby Bax activation first initiates locally and then propagates rapidly throughout 
the cell (Figure 3.9 and 3.10). Such a mechanism would have advantages, particularly in large 
cells, in co-ordinating efficient recruitment of all mitochondria into the apoptotic program. 
However, the propagation of Bax activation, and a corresponding loss of Ail>m, was only 
observed in particularly highly polarised wild type cells. It may be that this is a generally 
applicable phenomenon but occurs too rapidly to be reproducibly captured at the 1 frame/min 
image acquisition rate used, except in more polarised cells where it propagates over larger 
distances and therefore persists for longer. A candidate mechanism for the feed forward 
propagation of Bax activation would be a Ca2+ signal, since mitochondria are known to 
participate in Ca2+ signalling (Ichas et al., 1997), and apoptotic Ca2+ waves have been reported 
previously (Pacher and Hajnoczky, 2001). Whilst it was not technically possible to test this 
hypothesis directly, preliminary evidence of mitochondrial Ca2+ accumulation during the period 
before Bax activation was obtained. This at least indicates mitochondria may contain higher 
than normal levels of Ca2+ following prolonged exposure to an apoptotic stimulus that could be 
available for release when their permeabilisation occurs. The existence of such a mechanism 
would mean that the key signalling events resulting in Bax activation may not take place 
globally throughout the cell but may instead initially occur in a particular subcellular region, or 
maybe at a single mitochondrion.
In this chapter an initial characterisation of Bax activation has been described in relation to 
other characteristic features of the apoptotic program. Insights gained from examining GFP-Bax 
activation in live cells have included its rapid nature, that it is accompanied by a coincident loss 
of A\pm, and the possible existence of a feed-forward mechanism to coordinate cell-wide Bax 
activation. The next chapter describes attempts to perturb this process by co-expressing Bel-2 
pro-survival homologues.
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Figure 3.1 Bax activation can be monitored using conformationally sensitive antibodies.
Antibodies raised against the N-terminus of Bax display conformational specific staining by 
immunofluorescence. (A) U20S cells grown on glass coverslips were treated with 1 mM H20 2 for 
4 hrs to induce apoptosis and then loaded with 200 nM Mitotracker Orange for 20 mins to reveal 
the location of mitochondria with intact membrane potential (red). Cells were then fixed and 
immunostained using anti-Bax 6A7 (12-24) antibody and FITC-linked anti-mouse IgG (green) 
and imaged by confocal microscopy. Scale bars represents 20 /vm; (B) The anti-Bax 6A7 
antibody can be used to assay Akt-mediated protection in response to apoptotic stimuli. (I) 
MCF10A Akt-ER cells were grown on coverslips and treated +/- 250 nM 4-hydroxytamoxifen 
(OHT) for 18 hrs prior to incubation with either: 10 /;M etoposide, 100 ng/ml anti-Fas, 100 ng/ml 
anti-Fas + 1 /;g/ml CHX or DMSO vehicle control, all for a further 4 hrs. Cells were then fixed 
and stained with 6A7 anti-Bax (12-24) antibody and Cy3-linked anti-mouse IgG (red). At least 5 
randomly selected fields were counted, in excess of 400 cells per treatment, were analysed and 
the proportion of positively staining cells expressed as a percentage of total (insets show 
samples of negative and positive staining). Results from a typical experiment are presented with 
inset depicting the typical staining pattern, (il) Whole cell lystes prepared from parallel cultures 
were analysed by western blotting with anti-phospho-Akt (Ser 473) (P.Warne, CR-UK) to 
confirm Akt activation following OHT treatment; D=DMSO, E=etoposide, F=ant-Fas antibody. 
The blots were re-probed using anti-Bax 2D2 as controls. Data produced in collaboration with 
David Hancock, CR-UK.
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Figure 3.2 Bak activation can be monitored using conformationally sensitive antibodies.
Antibodies raised against the N-terminus of Bak display conformation specific staining by FACS. 
(A) Jurkat cells were treated with +/- 1 mM H20 2 for 4 hrs to induce apoptosis. Cells were then 
fixed and immunostained using anti-Bak Ab1 (1-52) antibody and FITC-linked anti-mouse IgG 
before analysis by FACS. Untreated cells: red trace; treated cells: blue trace; (B) Jurkat cells 
with and without stable over-expression of Bcl-2 were treated with the 250 nM STS (upper 
panels), a broad specificity kinase inhibitor to induce apoptosis via intrinsic pathways, or 
Fas/CHX (100 ng/ml anti-Fas and 1 pg/ml CHX, lower panels), to activate the Fas death 
receptor and thereby induce apoptosis via extrinsic pathways. 4 hrs later cells were fixed and 
immunostained using anti-Bak Ab1 (1-52) antibody and FITC-linked anti-mouse IgG before 
analysis by FACS. At least 10,000 events were counted for each condition and fluorescent 
intensities are plotted as percentage of maximum. Untreated cells: red trace; treated cells: blue 
trace.
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Figure 3.3 Characterisation of commercially available anti-Bax and -Bak antibodies.
The majority of commercially available anti-Bax and -Bak antibodies only recognise the proteins 
following a treatment to induce apoptosis. (A) Cartoon schematic showing the epitope locations 
for commercially available anti-Bax and anti-Bak antibodies. Antibodies shown in red text have 
been tested in this study; full details of all antibodies are listed in Table 2.2. Bax and Bak 
domain boundaries were taken from their respective GeneCards entries (www.aenecards.oraV 
Bax helical boundaries were taken from Suzuki M. et. al., 2000; (B) Phase contrast images of 
MCF10A cells were treated +/- Fas/CHX for 8 hrs to induce substantial apoptosis. Whole cell 
lysates were prepared from these cells in 1 % CHAPS buffer to preserve Bax/Bak conformation 
and used in subsequent immunoprecipitations (both adherent and floating cells were collected 
and lysed); (C) Bax was immunoprecipitated from the lysates generated in part (B) using the 
indicated antibodies; (D) Bax was immunoprecipitated from the lysates generated in part (B) 
using the indicated antibodies.
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A Bax (1-192), 21.2kD:
202:3-16
N 20 :11-30
Mid: 55-178
NT: 1-21
al:16-35
TL 41:57-72
a2:54-71 a3:74-81
Ab4:98-117 o7: a8:
-------------------- 149- 158-
a4:89-99 o5:108-126 o6:130-14€ 154 164 a9:170-188
BH3 BH1 BH2 TM
59-73 98-118 151-165 170-188
AF820: 12-33 Loop: 43-61
P19: 1-19
6A7: 12-24
Bak (1-211), ~28kD:
FL-TM: 1-171
TC100 (replaces Ab1) and FL (sc-7873)
o7/o8: 150-165
Ab1:1 -52 (discontinued) AF816: 53-72 Ab3: 82-135 (discontinued)
BH3 BH1 BH2 TM
74-88 117-136 169-184 188-205
N-term: 2-14 NT: 23-37 B0055: 41-54
BD: 14-36
N20: unspecified N-term
sc-832: unspecified internal epitope
(within Ab3 epitope but outside BH1) lOaa
Cont.
B
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a7/aS
Figure 3.4 N-terminally directed anti-Bax antibodies reveal post-activation distributions.
Two N-terminal Bax antibodies reveal bright mitochondrially-associated foci of Bax. (A) U20S 
cells grown on glass coverslips were treated with Fas/CHX for 6 hrs to induce apoptosis and 
then loaded with 200 nM Mitotracker Orange for 20 mins to reveal the location of mitochondria 
(red). Cells were then fixed and immunostained using anti-Bax NT (1-21) antibody and FITC- 
linked anti-rabbit IgG (green) and imaged by confocal microscopy; (B) 2.5X enlargement of the 
area indicated in the merged panel of part (A). Bax clusters form at the tips and restriction 
points of the mitochondrial network; (C) HeLa cells prepared in an identical manner and stained 
with anti-Bax N20 (11-30) antibody also show bright Bax foci forming along the mitochondrial 
network during the early stages of apoptosis; (D) At later stages these clusters increase in size 
and appear adjacent to, but not coincident with, mitochondria. Inset is a 2X enlargement of the 
area indicated in the merged panel. In all images scale bars represent 20 ym.
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Figure 3.5 The Bax 43-61 antibody reveals mitochondrially localised Bax in a distribution 
distinct from the bright Bax foci correlating with Cyt-c release.
The Bax 43-61 antibody reveals Bax evenly distributed on the mitochondrial network in every 
cell following a gentle stress trigger. (A) U20S cells grown on glass coverslips were treated +/- 
UV 30 J/m2 UV irradiation and then re-incubated for a further 18 hrs. Cells were then loaded 
with 200 nM Mitotracker Orange for 20 mins to reveal the location of mitochondria (red), fixed 
and immunostained stained using the anti-Bax 43-61 antibody and FITC-linked anti-rabbit IgG 
(green). Cells were then imaged by confocal microscopy; (B) MCF10A cells prepared in an 
identical manner but treated +/- Fas/CHX for 8 hrs prior to fixation. Cells were then co- 
immunostained stained using anti-Bax N20 (11-30) antibody and FITC-linked anti-rabbit IgG 
(green) together with an anti-Cyt-c antibody and Cy3-linked anti-mouse IgG (red). Formation of 
bright Bax foci correlates with the release of Cyt-c. In all images scale bars represent 20 /ym.
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Figure 3.6 GFP-Bax recapitulates the distributions observed for endogenous Bax.
N-terminally tagged GFP-Bax can be cytoplasmic in healthy cells, enter mitochondrially 
associated clusters in apoptotic cells or become enriched at mitochondria following a low-dose 
UV irradiation. (A) MCF10A cells were grown on glass coverslips and transfected with GFP-Bax 
(green). 24 hrs after transfection cells were loaded with 200 nM Mitotracker Orange for 20 mins 
to reveal the location of mitochondria (red). Cells were then fixed, mounted and imaged by 
confocal microscopy; (B) U20S cells were prepared identically but treated with 30 J/m2 UV 
irradiation 18 hrs prior to fixation in place of Fas/CHX. In all images scale bars represent 20 /;m.
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Figure 3.7 Initial characterisation of GFP-Bax activation in live cells.
In U20S and MCF10A cells GFP-Bax rapidly enters bright foci as Atpm is lost, shortly after the 
morphological characteristics of apoptosis are apparent. (A) Supplementary movie figure 
M3.1: Live cell recording of GFP-Bax transfected U20S cells undergoing apoptosis. U20S cells 
were grown in glass-bottomed dishes and transfected with GFP-Bax. 24 hrs later cells were 
loaded with TMRE to reveal the location of energised mitochondria, then treated with 30 J/m2 
UV irradiation to induce apoptosis and mounted for live cell imaging -  for full details of the 
recording see movie figure legend; (B) Supplementary movie figure M3.2: Live cell recording 
of GFP-Bax transfected MCF10A cells undergoing apoptosis. Cells were treated exactly as 
described in part (A) -  for full details of the recording see movie figure legend; (C) Still frames 
extracted from movie M3.2 showing that the formation of GFP-Bax clusters (green) correlates 
with loss of mitochondrial membrane potential (Atpm, orange). Times shown relate to the 
beginning of this recording and not the time when the UV treatment was administered, which 
was approximately 15 hrs previously. Scale bars represent 10 pm.
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Figure 3.8 Translocation of GFP-Bax into clusters occurs synchronously with Atpm loss. 
Bright foci of GFP-Bax appear exactly as is lost and then increase in size as apoptosis 
proceeds. (A) Supplementary movie figure M3.3: U20S cells were grown in glass-bottomed 
dishes and transfected with GFP-Bax. 24hrs later cells were loaded with TMRE to reveal the 
location of energised mitochondria, then treated with 30 J/m2 UV irradiation and mounted for live 
cell imaging -  for full details of the recording see movie figure legend; (B) Representative still 
frames taken from the upper cell in movie figure M3.3. Times shown relate to the beginning of 
this recording and not the time when the UV treatment was administered, which was 
approximately 18 hrs previously. Scale bars represent 20 pm; (C) 3X enlargement of a central 
portion of the cell shown in part (B). At this magnification some mitochondria clearly show loss 
of A\pm (orange) before others in the same cell. Complete loss of A\pm occurs during a window of 
approximately 5 mins duration. GFP-Bax foci (green) increase in size during this time and 
continue to enlarge throughout the time course shown.
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Figure 3.9 Local initiation of GFP-Bax activation is followed by spreading loss of Atpm.
In a more polarised cell the initiation of bright GFP-Bax foci can be seen to initiate in the cell 
periphery and spread rapidly across the cell body. (A) Supplementary movie figure M3.4: The 
same U20S cell recording shown in movie figure M3.3 but now played at a slower frame rate to 
reveal spreading of GFP-Bax activation and corresponding loss of Atj>m in the lower -  for full 
details of the recording see movie figure legend; (B) Representative still frames taken from 
movie figure M3.4, experimental details therefore as in Figure 3.8. Prior enrichment of GFP-Bax 
onto the mitochondrial network due to the UV stress trigger can be seen in the first frame (blue 
arrows). GFP-Bax activation and loss of Aipm initiates from the base of the cell and spreads 
upwards ( ). Complete loss of A^m occurs within approximately 5 min window,
t = 0 mins is the first image in the sequence presented and does not relate to the time when the 
UV dose was administered, which was approximately 18 hrs previously. Scale bars represent 
20 /vm.
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Figure 3.10 Local Bax activation appears to rapidly trigger Bax activation in a 
neighbouring region.
GFP-Bax becomes active and clustered in the polarised projection of an MCF10A cell and is 
able to rapidly trigger GFP-Bax activation in the remaining cell body when a narrow cytoplasmic 
neck is breached. (A) Supplementary movie figure M3.5: MCF10A cells were grown in glass- 
bottomed dishes and transfected with GFP-Bax. 24 hrs after transfection cells were and loaded 
with TMRE to reveal the location of energised mitochondria, then treated with 30 J/m2 UV 
irradiation to induce apoptosis and mounted for live cell imaging -  for full details of recording 
see movie figure legend; (B) Supplementary movie figure M3.6: An extended and accelerated 
version of the recording shown in movie figure M3.5. The phase overlay shows how early 
changes in the cell shape result in formation of the cytoplasmic projection prior to its retraction 
towards the cell body; (C) Representative still frames taken from movie figure M3.5. GFP-Bax 
activation, detected as bright foci of GFP-Bax, is first visible in a projection to the right of the cell 
body (t = 381mins, ), which retracts inwards over time. GFP-Bax activation and
loss within the main cell body correlates precisely with the breaching of the narrow neck 
separating this region from the active Bax in the projection (t = 528mins, red arrows). Cell 
shrinkage and the morphological features of apoptosis rapidly follow from t = 530mins onwards. 
Times shown indicate relate to the addition of Fas/CHX and start of recording. Scale bars 
represent 20 //m.
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Figure 3.11 In low GFP-Bax expressing cells loss of Atj>m occurs before GFP-Bax foci are 
detectable.
In cells expressing very low levels of GFP-Bax loss of A\pm occurred well before GFP-Bax foci 
were easily detectable. (A) MCF10A cells grown in glass-bottomed dishes and transfected with 
GFP-Bax. 24 hrs after transfection cells were loaded with TMRE to reveal the location of 
energised mitochondria, then treated with 30 J/m2 UV irradiation to induce apoptosis and 
mounted for live cell imaging. Representative still frames extracted from the resulting recording 
are shown. Cell A (final panel) expresses very low levels of GFP-Bax, compared to the 
moderate over-expression in Cell B, (which is the cell recorded in Figure 3.10). The first 
disruption of the membrane potential is at t = 705mins after administration of the Fas/CHX 
treatment (orange arrows). GFP-Bax clustering is not detectable for at least a further 2 mins 
(t = 707 mins, green arrows), and not obvious for a further 5mins (t = 710 mins). Scale bars 
represent 10 ^m; (B) Supplementary movie M3.7: The complete image sequence from which 
still fames shown in part (A) were compiled -  for full details of the recording see movie figure 
legend.
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Figure 3.12 Bax activation precedes significant caspase 3/7 activity.
The formation of bright Bax foci precedes significant caspase 3/7 enzymatic activity by 1-2mins. 
(A) MCF10A cells were grown in glass-bottomed dishes and co-transfected the CFP-Bax 
(green) and YFP based Caspase 3/7 reporter construct (red). 24 hrs after transfection cells 
were treated with Fas/CHX to induce apoptosis and mounted for live cell imaging. Times 
indicated relate to the start of this recording and do not relate to the time when the Fas/CHX 
treatment was administered, which was approximately 4hrs previously. Scale bars represent 
10pM; (B) Supplementary movie figure M3.10: The complete image sequence from which 
the stills shown in part (A) were compiled -  for full details of the recording see movie figure 
legend.
Supplementary material added In support: Additional parts 3.13 C and 3.13 D can be found 
in Appendix 1 and represent two further cells recorded in replicate experiments. Experimental 
details are therefore as part (A) and in both cases CFP-Bax foci formation precedes significant 
caspase 3/7 enzymatic activity by the same 1-2min interval. The complete image sequence 
from which these stills were compiled is shown in movie figures M3.11 and M3.12. See movie 
figure legends for further details of recording.
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Figure 3.13 Flickering of At|>m is occasionally observed but does not correlate with the 
onset of complete Ai|>m loss.
Partial, transient depolarisation of the mitochondrial network was a rare event, and was followed 
by a rapid and complete recovery of Atpm, unlike the cell wide depolarisation that accompanied 
apoptosis. (A) Live cell recording from untransfected MCF10A cells grown in glass-bottomed 
dishes, loaded with TMRE to reveal energised mitochondria and treated with 30 J/m2 UV 
irradiation to induce apoptosis. t=0min is the first image in the sequence presented and does 
not relate to the time when the UV dose was administered, which was approximately 10 hrs 
previously. The position of a transient depolarisation is marked ( ); (B) Live cell
recording from U20S cells showing transient flickers of Cells were prepared as described 
in part (A). Times indicate duration from the start of recording and do not relate to the time when 
the UV dose was administered, which was approximately 18 hrs previously. The positions of 
flickers at t=10mins and t=12mins are marked ( ); (C) Two further examples of
recordings made from MCF10A cells showing complete loss of Atpm during apoptosis. These 
records are included in quantitation shown in Figure 4.16. In all images scale bars represent 
10 /ym. (D) Supplementary movie figure M3.8: The complete image sequence from which still 
fames in part (C) were compiled -  for full details of the recording see movie figure legend.
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Figure 3.14 An increase in mitochondrial calcium is detectable prior to Bax activation.
The mitochondrial pericam reporter construct detects increasing levels of Ca2+ in the 
mitochondria of MCF10A cells treated with Fas/CHX, prior to the activation of RFP-Bax. (A) 
MCF10A cells were grown in glass bottom-dishes and co-transfected with RFP-Bax and the 
mitochondrial pericam. 24 hrs after transfection the cells were treated with Fas/CHX to induce 
apoptosis and mounted for live recording. Four frames: phase (grey), RFP-Bax (red), pericam 
excited at 410nm (green), pericam excited at 510nm (blue) were sequentially recorded every 20 
seconds throughout the duration of the experiment. The radiometric image was calculated as 
510 nm / 410 nm; (B) Still frames extracted from the total recording showing the changes in 
RFP-Bax distribution. Bax activation, as detected by the formation of clusters, is first detectable 
in frame 585 (195.2mins after the addition of Fas/CHX); (C) Integrated mean intensities for Bax 
(red/pink) and the ratiometric pericam (blue/blue) are plotted over time for two small regions of 
interest shown in parts (A) and (B) and containing mitochondria.
Supplementary material added In support: Additional parts 1.14.D and 1.14.E can be found 
in Appendix 1 and represent two further cells recorded in replicate experiments. Experimental 
details are therefore as parts (A-C) and in both cases there is an increase in mitochondrial 
calcium in the period prior to RFP-Bax clustering (green trend line).
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Chapter 4 -  Viral pro-survival proteins
4.1 Introduction:
Data presented in the previous chapter indicates that Bax activation is a rapid event that can 
initiate in a discrete sub-cellular region and then spread rapidly across the cell. These 
observations suggest the existence of a feed-forward mechanism to ensure the rapid and co­
ordinated recruitment of all mitochondria in a cell following commitment to apoptosis. 
Preliminary evidence also suggests that an increase in mitochondrial calcium levels occurs prior 
to the onset of Bax activation. There is evidence from the published literature of a calcium 
wave, propagated by mitochondria, existing around the time of the onset of apoptosis and this is 
therefore a candidate for such a feed-forward mechanism.
The rapid nature of Bax activation meant that further characterisation, using live cell 
microscopy was technically challenging and would require much faster rates of image 
acquisition rates than the 1 frame/minute used in the previous examples. The stochastic nature 
of the process also means that imaging for several hours is required to guarantee that cell deaths 
are observed in any given field of cells. In order to address this problem, and in an attempt to 
learn more about the Bax activation process by perturbing it, the effect of over-expressing pro- 
survival proteins was investigated.
Historically viral proteins have proved indispensable in aiding our understanding of diverse 
cellular process. Viruses have co-evolved with their host organisms over millions of years. 
During this time their relatively small genomes have become highly specialised to contain 
proteins that target and subvert key cellular processes for the virus’s advantage. Understanding 
which cellular proteins are targeted by viruses has often led to the identification of key steps in 
the host cell physiology and understanding how the viral proteins function often gives important 
insights into normal regulation of critical cellular processes. For example, the finding that E1A 
targets the tumour suppressor, Rb, has led to the paradigm whereby viral oncogenes target 
tumour suppressor pathways to induce uncontrolled cell proliferation and transformation (Frisch 
and Mymryk, 2002).
- 1 17 -
A number of viruses contain proteins that directly target Bax and Bak (Figure 1.1). Some share 
obvious sequence homology with cellular Bcl-2 proteins, whilst others lack identifiable 
homology in their primary amino acid sequences but have nevertheless been experimentally 
demonstrated to block Bax or Bak activation (for further details see section 1.11). This chapter 
describes experiments using two of these proteins, BHRF1 from Epstein Barr Virus and 
El B 19k from Adenovirus, that provide further insights into Bax activation.
4.2 Characterisation of cell lines expressing pro-survival proteins:
Four pro-survival proteins were chosen for further analysis of their effect upon Bax activation: 
two cellular pro-survival proteins, Bcl-2 and Bcl-XL, and two viral proteins, BHRF1 from 
Epstein Barr Virus, a Bcl-2 sequence homologue, and ElB19k from Adenovirus, which lacks 
significant sequence homology to the cellular Bcl-2 proteins but still protects against apoptosis. 
Constructs encoding each protein, or the empty retroviral vector as a control, were introduced 
into MCF10A cells by retroviral gene transfer. Following infection and drug selection, 
expression, or over-expression in the case of Bcl-2 and Bcl-XL, was confirmed by western 
blotting (Figure 4.1). To assess the level o f protection conferred by these proteins the stable cell 
lines were then subjected to a time course of Fas/CHX treatment to induce apoptosis. Cells were 
harvested every 3 hrs for 15 hrs, fixed and stained for DNA content with propidium iodide. The 
level of apoptosis was assessed by FACS analysis as the percentage of cells with sub-Gl DNA 
content (Figure 4.2 A). During the time course the empty vector control line was efficiently 
killed. Over-expression of the two cellular proteins, Bcl-2 and Bcl-XL, was somewhat able to 
protect the cells, with around a 5% and 10% reduction in the level of apoptosis, respectively. 
However, expression of the two viral proteins, ElB19k and BHRF1, conferred a much stronger 
degree of protection. In both cases the majority of cells remained alive and attached to the 
culture dishes with normal morphology 15 hrs after the addition of the Fas/CHX (Figure 4.2 B). 
The El B 19k and BHRF1 cell lines therefore provided a potential source of cellular material in 
which apoptosis had been strongly triggered for a prolonged period of time but the cells remain 
alive and amenable to further analysis.
It was next important to establish the level at which apoptotic signalling was blocked in these 
cell lines. For these experiments, Fas/CHX was again chosen as the apoptotic trigger since 
events downstream of Fas death receptor activation are well characterised (see section 1.4) and 
includes cleavage of proteins such as pro-caspase-8 and -3, which can be followed by western 
blotting. A further time course was therefore conducted during which cells were harvested every 
3 hrs and lysates prepared and analysed by western blotting for various components of the cell
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death pathway (Figure 4.3). This experiment showed that the processing of proteins located 
downstream of receptor activation, but upstream of the mitochondria, occurred at the same rate 
in all cell lines, regardless of whether or not they subsequently underwent a substantial degree 
of apoptosis. Specifically this was shown to be the case for: the processing of pro-caspase-8, the 
cleavage of full length Bid and the caspase-8 dependent cleavage of full length caspase-3 
(Figure 4.3, labelled pre-mitochondrial events). This contrasted with events known to be 
downstream of mitochondrial dysfunction, which only occurred in those cell lines where 
significant apoptosis was observed, ie. the empty vector control, Bcl-2- and Bcl-XL-expressing 
lines. This was the case for the cleavage of pro-caspase-9, which requires Cyt-c released from 
mitochondria to active the apoptosome complex. It was also the case for cleavage of the DNA 
repair enzyme poly (ADP-ribose) polymerase-1 (PARP), a classical marker for the later stages 
apoptosis. Both of these events were almost completely blocked by expression of El B 19k and 
BHRF1 (Figure 4.3, labelled post-mitochondrial events). It is also noteworthy that whilst the 
caspase-8 dependent cleavage of full length caspase-3 was clearly evident in all cell lines, 
removal of the short pro-domain, converting the caspase-3 from p20 to p i7, occurred only in 
those cell lines where significant cell death was observed and was blocked by expression of 
both El B 19k and BHRF1. This result indicates that caspase-3 is not yet fully active following 
the initial caspase-8 dependent cleavage within the linker region. The processing of p20 to p l7  
is a caspase-9 dependent event and therefore suggests that removal of the short pro-domain 
represents an additional requirement to generate efficient effector caspase activity in vivo. A 
similar observation has been made in another system (Meergans et al., 2000). Together the data 
presented in Figure 4.3 suggests that the strong protection from apoptosis conferred by the 
expression of E lB  19k and BHRF1 is due to their abilities to block apoptosis at a level proximal 
to mitochondria. Under these circumstances events downstream of Fas death receptor 
activation, but upstream of the mitochondria, proceed unopposed whilst events downstream of 
mitochondria are efficiently blocked. These results also demonstrate that MCF10A cells, treated 
with an extrinsic death pathway agonist, appear absolutely dependent on mitochondrial 
dysfunction to initiate apoptosis and the activation of caspases downstream of death receptor 
ligation is insufficient to initiate cell death. Such cells are classically described as Type II cells. 
Since Bax is also critically involved in the regulation of apoptosis at mitochondria, further 
experiments were conducted to determine the effect of these pro-survival proteins on Bax 
activation.
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4.3 The effect of E1B19k and BHRF1 on Bax (and Bak) activation:
In Chapter 3 it was established that upon activation, both Bax and Bak undergo a dramatic 
conformational change and antibodies raised against N-terminal epitopes of these proteins only 
recognise their active conformations. These reagents provide suitable tools with which to assess 
the effect of the pro-survival proteins upon Bax activation. However, for these experiments the 
level of protection offered by Bcl-2 and Bcl-XL in the MCF10A cell system was considered too 
modest to be informative in future analysis and in the subsequent experiments only the El B 19k- 
and BHRF1-expressing cell lines were pursued.
Initially the Bax N20 (11-30) N-terminal antibody was used to immunoprecipitate active Bax 
from the empty vector control, E lB 19k- and BHRF1-expressing MCF10A cell following the 
induction of apoptosis by Fas/CHX treatment (Figure 4.4 A). This experiment showed that in 
the control cells Bax was efficiently activated over the course of 15 hrs of Fas/CHX treatment. 
At later time points, increasing amounts of Bak could also be observed to co-immunoprecipitate 
with Bax, indicative of the hetero-oligomerisation of Bax with Bak (Figure 4.4 A, left panel). In 
contrast Bax activation was almost completely blocked in the BHRF1-expressing cells. In this 
case, since no active Bax was immunoprecipitated, no further inferences can be made regarding 
possible Bax / Bak interactions in these cells (Figure 4.4 A, right panel). The surprising result 
came from the ElB19k-expressing cells. In this case Bax activation was readily detectable, 
becoming active at a similar rate as in the control cells. There was, however, no significant co- 
immunoprecipitation of Bak (Figure 4.4 A, middle panel). This result indicates that Bax still 
undergoes at least the N-terminal conformational change in ElB19k-expressing cells but that 
subsequent hetero-oligomerisation of Bax and Bak is blocked.
An explanation for these results was suggested when MCF10A cells treated with Fas/CHX for 
8 hrs were analysed by confocal microscopy following co-immunostaining with the anti-Bax 
N20 antibody and anti-Cyt-c (Figure 4.4 B). Under these conditions bright foci characteristic of 
active Bax were clearly visible in some of the empty vector control cells and this was always 
correlated with diffuse Cyt-c staining, indicative of its release from mitochondria (Figure 4.4 B, 
upper panels). As expected from the previous result, no Bax activation was detectable in the 
BHRF1-expressing cells and Cyt-c retained a distinctive mitochondrial localisation (Figure 4.4 
B, lower panels). When ElB19k-expressing cells were examined some were indeed strongly 
recognised by the Bax N20 antibody. Strikingly, in these N20 positive cells Bax seemed to be 
evenly distributed over the entire mitochondrial network, co-localising with Cyt-c, which 
retained a mitochondrial localisation (Figure 4.4 B, middle panels). This distribution was never 
observed in either the control or BHRF1-expressing cell lines and therefore suggests that
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ElB  19k is able to block Bax activation at a step subsequent to both its conformational 
activation and recruitment to mitochondria, but prior to the formation of mitochondrially- 
associated foci and Cyt-c release. The failure o f active Bax to co-immunoprecipitate Bak from 
Fas/CHX treated MCF10A El B 19k cells (Figure 4.4 A) is therefore explained by the ability of 
E lB 19k to block Bax at a step prior to the formation of the foci where active Bax and Bak 
would normally co-associate.
The results shown in Figure 4.4 also demonstrate that the rate at which Bax becomes N- 
terminally active in the El B 19k-expressing and control cells is very similar. For example, the 
amount of Bax immunoprecipitated from the El B 19k cells was only slightly less than from the 
control cells (Figure 4.4 A). The failure of Bax to enter oligomers may also explain this small 
difference, since at later time points co-immunoprecipitation of Bax in the form of homo-dimers 
and homo-oligomers would act to inflate the amount of Bax immunoprecipitated in the control 
samples only. In order to confirm this hypothesis MCF10A cells were also fixed and stained 
with ant-Bax N20 and anti-Cyt-c over a similar time course of Fas/CHX treatment and analysed 
by confocal microscopy (Figure 4.5). From this experiment it was clear that El B 19k cells did 
indeed become positive for Bax N20 staining at the same rate as the wild type cells. Also, in 
both cell types this appeared to be a stochastic, all-or-none event. However, once E l B 19k- 
blocked cells gained conformationally active and mitochondrially localised Bax, they persisted 
in the culture dish without releasing Cyt-c. This meant that by the later time points, for example 
the 12 hr time point in Figure 4.5, when many of the control cells had undergone complete 
apoptosis and become detached, the majority of ElB19k-expressing cells had accumulated 
positive staining, mitochondrially localised, active Bax. This contrasted with the MCF10A 
BHRF1 cell line where conformational active Bax and diffuse Cyt-c were only rarely detected 
even 12 hrs after the application of Fas/CHX.
The results presented in this section go some way towards characterising how E l B 19k is able to 
block Bax activation at a step subsequent to its conformational activation and mitochondrial 
translocation. They do not, however, address the Bak activation status in these cells. The failure 
of active Bax to co-immunoprecipitate Bak in E lB 19k-expressing cells (Figure 4.4 A) is likely 
to be explained by a failure of the ElB19k-blocked Bax enter mi tochondri ally-associated 
clusters. However, it could however also be explained if  these cells were absolutely dependent 
on Bak activation and if  it was this protein which El B 19k was specifically targeting. In 
addition, in ElB19k-blocked cells, Bax accumulates at mitochondria where Bak is also 
normally located, so the possibility of an interaction cannot be excluded solely on the grounds 
that they have not yet entered the same location, namely the mitochondrially-associated clusters. 
To address these issues, a similar experiment was conducted in which MCF10A cells, following
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8 hrs of exposure to Fas/CHX, were co-immunostained with an N-terminal Bak antibody, Bak 
NT (23-37), together with anti-Cyt-c (Figure 4.6). Under these conditions it was clear that Bak 
was behaving in an analogous fashion to Bax in all three cell lines. In the control cell line Bak 
was stochastically activated and formed bright foci correlating with Cyt-c release. Activation of 
Bak in MCF10A El B 19k cells was clearly visible by an increase in mitochondrial staining 
intensity by the Bak NT antibody. However, these cells retained mitochondrial Cyt-c staining. 
No significant activation of Bak in MCF10A BHRF1 cells was detectable under these 
conditions. Thus El B 19k appears to be able to efficiently block both Bax and Bak activation at 
a step subsequent to their N-terminal conformational change but before entry into mitochondrial 
clusters and hetero-dimerisation.
Data presented in Figures 4.4, 4.5 and 4.6 correlates the ability of El B 19k to block the co- 
immunoprecipitation of Bax and Bak with the lack of detectable mitochondrially-associated foci 
by immunofluorescence. However, these experiments all rely on the use of N-terminally 
conformationally sensitive antibodies to Bax and Bak. As discussed in Chapter 3, these reagents 
are by definition limited to detection of the proteins after they have undergone conformational 
change. An alternative approach to detecting Bax activation is by gel filtration analysis. This 
approach has the advantage that the entire cellular pool of Bax can be detected, regardless of the 
conformational status of the protein. Lysates were prepared from MCF10A E lB  19k, BHRF1 
and the empty vector cells treated with and without Fas/CHX for 8 hrs to induce apoptosis. 
Proteins were then separated by gel filtration and the resulting fractions analysed by western 
blotting for Bax content (Figure 4.7). This data shows that in the control cells, Bax shifts from 
its monomeric molecular weight of 21 kDa into higher molecular weight fractions following the 
induction of apoptosis (detectable as Bax dimers at ~43 kDa up to molecular weights greater 
than 670 kDa), as has been previously described (Antonsson et al., 2001). In both the ElB19k 
and BHRF1 cells, this change in the Bax elution profile is essentially prevented, with only trace 
amounts of Bax entering the higher molecular weight range. Importantly, this result shows that 
the N-terminally active Bax accumulated at the mitochondria of ElB19k-expressing cells truly 
remains monomeric. Attempts to analyse the gel filtration for Bak were complicated by the 
protein being distributed over a much broader range of molecular weights even in healthy cells 
making results difficult to interpret (data not shown). In addition, evidence collected in these 
experiments suggested that the distribution of El B 19k remained in the low molecular weight 
range in both treated and untreated cells while BHRF1 was sometimes present at much higher 
molecular weights (440 - 670 kDa). However, the nature of this higher molecular range of 
BHRF1 was not investigated although further analysis might provide clues as to the function of 
the protein.
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Finally, two additional pieces of biochemical evidence regarding viral protein blocks are shown 
in Figure 4.8. In the earlier immunoprecipitation experiment using the Bax N20 antibody 
(Figure 4.4), the lack of detectable Bax activation in the BHRF1 -expressing cells meant that no 
inferences could be made about Bak activation status or Bax / Bak interactions. To address this 
issue, a reciprocal co-immunoprecipitation with both anti-Bax N20 and anti-Bak NT was 
performed from MCF10A control and BHRF1-expressing cells (Figure 4.8 A). This shows that 
in empty vector control cells, Bax becomes active and co-immunoprecipitates Bak, and that Bak 
becomes active and co-immunoprecipitates Bax. In the BHRF1 expressing cells activation of 
Bax is almost completely blocked and no Bak co-immunoprecipitates with Bax, whilst 
activation of Bak is absolutely blocked and the small amount of protein recognised in untreated 
cells neither increases, nor co-immunoprecipitates any Bax, following the apoptotic trigger. 
This confirms that BHRF1 acts as a strong block to Bax and Bak activation, preventing even the 
earliest sign of their activation, the N-terminal conformational change, and completely 
preventing co-association of the proteins following an apoptotic trigger.
During the course of this work, several more Bax antibodies characterised in Figure 3.3 where 
used in immuoprecipitation experiments from ElB19k-expressing cells. Three of these: Bax 
N20, Bax al/oS  and Bax 43-61, were used to immunoprecipitate Bax from MCF10A control, 
E l B 19k- and Bcl-2-expressing cells before and after treatment with Fas/CHX (Figure 4.8 B). 
As expected, Bax 43-61 showed no conformational selectivity and immunoprecipitated Bax 
equally in all conditions. Also as expected, Bax N20 was highly conformationally sensitive and 
only immunoprecipitated Bax from the treated cells. In this case no significant protection was 
detectable by Bcl-2 over-expression, and the small reduction in the amount of Bax 
immunoprecipitated from ElB19k-expressing cells may be due to lack of Bax oligomerisaiton 
in these cells, as discussed above. Finally, Bax al/aS , which is normally conformationally 
sensitive as shown in the control and Bcl-2 expressing cells, could not immunoprecipitate Bax 
from treated ElB19k-expressing cells. This result confirms an observation first made following 
infection with recombinant adenovirus (Sundararajan and White, 2001). It suggests that this 
region, which corresponds to the Bax BH2 domain, may interact either directly with El B 19k, 
thereby blocking access to this epitope, or that El B 19k prevents an additional conformational 
change in this region.
In summary, data presented in this section shows that BHRF1 expression potently prevents cell 
death by blocking apoptotic signalling at a step proximal to the mitochondria, but before Bax 
and Bak activation. In contrast to BHRF1, E1B19K appears to block apoptosis by intercepting 
Bax and Bak activation after the initial N-terminal conformational change has occurred and acts
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by preventing only the later stages of their activation, namely the homo- and heter- 
oligomerisation of Bax and Bak.
This characterisation was initiated in order to investigate i f  pro-survival proteins could perturb 
Bax activation in a way making them suitable for use in live cell experiments. The results 
obtained suggest that BHRF1 would be of little help, since it entirely prevents Bax activation. 
However, ElB19k-expressing cells still show evidence of Bax translocation to mitochondria 
and N-terminal conformational activation, and importantly this occurs at the same rate as in 
wild type cells. This result indicates that the apoptotic signalling events that lead to these initial 
steps in Bax activation remain unopposed in the El B 19k cells. Rather, the block to cell death 
acts at a later step, by preventing subsequent oligomerisation of the protein. Since Bax 
activation is a very rapid event, this ability of E l B 19k to separate the initial from the 
subsequent steps in this process and thereby keep the cells alive, would be interesting to 
investigate in real time. However, to use El B 19k to manipulate Bax activation in live cell 
experiments it is first important to determine that over-expressed GFP-Bax can be blocked in an 
analogous manner to the endogenous protein.
4.4 Activation of GFP-Bax can also be blocked by E1B19k:
In order to determine whether ElB19k could also block GFP-Bax activation, MCF10A ElB19k 
cells were transfected with GFP-Bax and treated with Fas/CHX to induce apoptosis. The cells 
were then fixed and stained with anti-Bax N20, to monitor Bax activation status, and anti-Cyt-c, 
to monitor mitochondrial dysfunction. Examination of these cells by confocal microscopy 
showed that the majority of the transfected cells either retained cytoplasmic GFP-Bax, 
indicating the protein was not active, or had already progressed into full apoptosis with cells 
present at various stages of death containing the characteristic bright punctate foci of fully 
active Bax (data not shown). This result was a likely reflection of the total level of Bax in the 
transfected cells simply overwhelming the ability of E lB 19k to provide an efficient block to 
Bax activation. There were, however, a few cells in which over-expressed GFP-Bax appeared to 
become blocked in an analogous fashion to the endogenous protein, representative examples of 
the situations observed are shown in Figure 4.9: following 8 hrs of exposure to Fas/CHX many 
of the untransfected cells stained positively for Bax N20 (Figure 4.9 A, label a), indicating the 
initial N-terminal conformational activation of Bax had taken place. These cells show the 
characteristic even distribution of Bax at mitochondria, without Cyt-c release, characteristic of 
ElB19k-blocked cells, as described in the pervious section. A few cells had yet to initiate Bax 
activation, and did not stain with Bax N20 (Figure 4.9 A, label b). In cases where these cells are
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also transfected with GFP-Bax, the tagged Bax also remains cytoplasmic (Figure 4.9 A, label c). 
In a few cells, GFP-Bax appeared to have become highly enriched at the mitochondria. These 
cells also showed strong mitochondrially localised anti-Bax N20 staining and mitochondrial 
Cyt-c (Figure 4.9 A, label d). In these cells the exogenous GFP-Bax appeared to have been 
blocked in a similar fashion to endogenous Bax was being blocked in the majority of 
surrounding untransfected cells.
In some cells additional distributions could also be observed. Sometimes the E lB 19k block to 
GFP-Bax activation appeared to have formed but subsequently breached, resulting in the release 
of Cyt-c. This is shown in Figure 4.9 B, compare cell a, in which the block is fully formed with 
complete depletion of GFP-Bax from the cytoplasm onto the mitochondria, with cell b, where 
the block appears to have formed and subsequently breached, resulting in the partial release of 
Cyt-c. There were also occasional examples where the block appeared to be partially or 
incompletely formed. This is shown in Figure 4.11 C: compare cell a, in which the block 
appears to be incompletely formed with only partial depletion of cytoplasmic GFP-Bax onto the 
mitochondria, with cell b, where the block appears to have been beached with bright foci of 
GFP-Bax visible and Cyt-c full released.
This experiment confirmed that, following the induction of apoptosis, El B 19k could block 
GFP-Bax at mitochondria in an analogous manner to the endogenous Bax protein. From data 
presented in Figure 4.6 and 4.7, characterising this block using a Bax conformationally sensitive 
antibody, it was not possible to know what fraction of the total cellular pool of Bax had become 
active and translocated to mitochondria. The use of GFP-Bax reports on that entire cellular pool 
and demonstrates that in a cell where the El B 19k block to Bax activation has stably formed 
there is almost complete depletion of the cytoplasmic pool of GFP-Bax to mitochondria. This 
distribution therefore clearly differs from partial mitochondrial enrichment of GFP-Bax seen in 
wild type cells following a UV stress trigger (Figure 3.6). It was next important to characterise 
how this block arose.
4.5 Characterisation of the E1B19k block to GFP-Bax activation in live cells:
The formation of a complete and stable block to GFP-Bax activation is ElB19k-expressing cells 
was not a common event. In Fas/CHX treated cells it occurred in about 1 in 30 transfected cells 
examined. However, this was deemed sufficiently frequent to attempt to record the block 
forming in live cells and thereby determine how the kinetics compared to that of full GFP-Bax 
activation in wild type cells. To this end, live cell microscopy recordings were made of GFP-
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Bax transfected MCF10A El B 19k cells, loaded with TMRE to reveal the location of energised 
mitochondria and treated with Fas/CHX to induce apoptosis. Figure 4.10 and Supplementary 
Movie Figures M4.1 (short record) and M4.2 (full record) show a cell in which the formation of 
the El B 19k block was successfully captured. In this example GFP-Bax is initially cytoplasmic 
as expected. Increased levels of GFP-Bax at mitochondria are first detectable at ~220 mins and 
complete at ~320 mins, giving a total duration of ~100 mins. The ElB19k-expressing cell 
shown in Figure 4.10 remained alive, with intact Aipm, until the end of the recording, more than 
11 hrs after GFP-Bax had become fully loaded onto the mitochondria (Figure 4.10 and Movie 
Figure M4.2). The cell shown in Figure 4.10 was one of six recorded in which GFP-Bax 
became fully blocked by El B 19k. Together they showed a mean duration for the complete 
translocation of GFP-Bax to mitochondria of 64 mins (standard deviation 26 mins). In each of 
these ElB19k-expressing cells the block remained intact for at least 2 hrs or until the end of 
recording. This rate of accumulation is substantially slower than the rate at which GFP-Bax 
enters the bright foci in wild type cells (compare figure 4.10 / M4.1 with Figures 3.7, 3.10 and
3.13 and their accompanying movies). In wild type cells, the bright foci of active GFP-Bax 
rapidly increase in size following their initial appearance, and the majority of cytoplasmic GFP- 
Bax appears to have entered them within 20 mins. However, exact quantitation of this process is 
not possible due to cell shrinkage and shape changes as apoptosis proceeds. Nevertheless, from 
these initial recording, it is apparent that the El B 19k block observed in fixed cells (Figure 4.9 
A) is the result of a gradual enrichment of GFP-Bax at mitochondria over the course of around 
an hour.
As mentioned previously, GFP-Bax activation was only fully blocked at mitochondria in a low 
proportion of ElB19k-expressing cells; in the majority the protein became fully active. This is 
likely to be explained, at least in part, by the change in Bax to E lB 19k stoichiometry caused by 
transfection. It appears that in the MCF10A El B 19k cell line there is sufficient E l B 19k 
expressed to block activation of endogenous Bax in vast the majority of cells (Figure 4.5). It is 
likely that when GFP-Bax is over-expressed this is no longer the case, and the increased amount 
of total Bax in the cell overwhelms the ability of ElB19k to prevent its full activation. A further 
recording, shown in Figure 4.11 B and Supplementary Movie Figure M4.3, goes some way to 
confirm this hypothesis. The experimental set-up was exactly as described for Figure 4.10, 
however the field recorded in Figure 4.11 shows 3 transfected cells. Cell A expresses very low 
levels of GFP-Bax. Early in the recording GFP-Bax translocates to the mitochondria over a 
period of ~55 mins (frames from 230 - 285 mins), where it becomes blocked. GFP-Bax is 
retained in this distribution for the duration of the recording (> 6.5 hrs) with no evidence of full 
GFP-Bax activation or loss of A\|>m. Cell B expresses intermediate levels of GFP-Bax which 
begins to accumulate at mitochondria for ~15 mins (frames from 270 - 285 mins). At this point
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the El B 19k block is becomes breached, resulting in loss of Aipm, GFP-Bax entry into bright foci 
and apoptosis. Additional frames showing these events in more detail are included as 
supplementary part 4.13 C in Appendix 1. Cell C expresses the highest levels of GFP-Bax. In 
this case the protein immediately clusters at -320 mins with an associated loss of Aipm; there is 
no evidence of El B 19k retarding activation of GFP-Bax. This recording therefore supports the 
hypothesis that the level of GFP-Bax expression is a major determinant the ability of El B 19k to 
block complete Bax activation.
Further examples of GFP-Bax becoming transiently blocked in ElB19k-expressing cells, 
followed by the block being breached are included in Figure 4.12 and Supplementary Movie 
Figure M4.4. Cells were prepared and treated exactly as in Figure 4.11. In this recording Cell A 
forms the block for -23 mins (frames from 221 - 244 mins) and Cell B forms the block for -12 
mins (frames from 242 - 254 mins). In each case the breaching of the block can be clearly 
detected by the loss of Ail>m and the appearance of bright foci of GFP-Bax. Interestingly, 
although Cell A continues to shrink until the end of the recording, the intracellular movement of 
GFP-Bax loaded mitochondria freezes at -280 mins, just as the first GFP-Bax foci first become 
clearly visible. This is a further indication that it is Bax oligomerisation that marks the key point 
at which the cell undergoes a bioenergetic death. In total, 8 cells were recorded in which the 
El B 19k block partially formed and was then breached. The period of GFP-Bax accumulation at 
the mitochondria, prior to the formation of bright clusters and loss Ail>m, had a mean duration of 
16 mins (standard deviation 3 mins), substantially less than the -64 mins taken for the complete 
block to form stably.
Examination of fixed cells had previously indicated that El B 19k could occasionally block 
activation of over-expressed GFP-Bax and that this resulted in its complete and stable 
redistribution to mitochondria. Data presented in this section demonstrates that this does indeed 
occur, and the distribution observed in the fixed cells is the result of steady accumulation of 
GFP-Bax at mitochondria over a prolonged period of time, without entry into bright foci or loss 
of A\pm. Images from fixed samples had also suggested that sometimes the El B 19k block may 
partially form and then become breached (Figures 4.9 B and C). The live cell experiments 
presented here also confirm that this is indeed the case. In these cells in which the El B 19k 
block is breached there is a period during which GFP-Bax initially translocates and accumulates 
at mitochondria. However, before complete translocation of the protein has occurred, GFP-Bax 
can be seen to enter bright foci and there is a corresponding loss of A\pm, indicating that the 
block is breached. After observing many of these recordings it became apparent that there were 
additional changes in the Ai|>m of ElB19k-expressing cells induced to undergo apoptosis that 
have not previously been described. These are characterised in the next section.
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4.6 Spreading loss and partial recovery of Aif>m in E1B19k-expressing cells:
After observing many ElB19k-expressing cells in which GFP-Bax activation was only 
transiently blocked, it became apparent that the breaching of this block was often accompanied 
by a progressive loss of A\pm. Representative recordings are shown in Figure 4.13 and 
Supplementary Movie Figures M4.5 to M4.7. These recordings show ElB19k-expressing cells, 
transfected with GFP-Bax and loaded with TMRE to reveal the mitochondria. As before, the 
cells were treated with Fas/CHX to induce apoptosis. Both cells shown in Figure 4.13 B exhibit 
a partial formation of the GFP-Bax block, Cell A for ~6 mins (frames from 198 - 204 mins) and 
Cell B for ~14 mins (frames from 198 - 212 mins). The partially formed block is then breached 
and this correlates with a wave of mitochondrial depolarisation. In both cells this starts at one 
extremity and then progresses across the cell body. Strikingly, this is followed by a partial 
recovery of Alp™, such that as the cells round up and detach they exhibit bright TMRE 
fluorescence. Additional live cell records in Supplementary Movie Figures M4.6 and M4.7 
show further examples of both this spreading loss and partial recovery of A\pm. In total of 52 out 
of 78 (67%) ElB19k-expressing cells observed (both GFP-Bax transfected and untransfected) 
showed evidence of A\pm recovery as described, and retained bright TMRE fluorescence as they 
rounded up and detached. This was never seen in wild type MCF10A cells (n = 30). A graphical 
representation of this phenotype is shown in Figure 4.14 A. In each case the mean integrated 
intensity of TMRE fluorescence was calculated for a region of interest (ROI) defined by the cell 
perimeter exactly at the point when GFP-Bax foci and Aipm loss were first detected (indicated 
by *). Due to the rapid movement of cells into and out of this ROI the traces are only accurate 
for a limited temporal window. Nevertheless, they show that in both wild type MCF10A (Figure
4.14 C panel i) and U20S (Figure 4.14 C panel ii) cells, the loss of Ai|>m was both rapid and 
complete. Five traces from MCF10A El B 19k cells are shown in which the initial decrease in 
A\pm (indicated by *) was followed by a partial recovery phase (Figure 4.14 C panel iii). Finally, 
in some MCF10A ElB19k cells were seen to exhibit dramatically increased rates of A4>m 
flickering, for example see Supplementary movie figures M4.1, M4.5 and M4.8. A particularly 
striking example is shown in M4.8 (panel A), with representative frames shown in Figure 4.14 
B. Although dramatic, this flickering is transient and localised making it clearly distinguishable 
from the cell-wide loss of Aipm that accompanies apoptosis (Figure 4.14 C). As mentioned in 
Chapter 3, flickering of Aipm is a physiologically normal event (O'Reilly et al., 2003), although 
it was rarely seen in recordings made from wild type cells with an image acquisition rate of 1 
frame/minute (Figure 3.12). Although flickering was easily detected in MCF10A ElB19k cells 
it should be noted that it was not predictive of either the initial translocation of GFP-Bax to 
mitochondria or its full activation (see M4.5 for example). Together the data presented in this 
section demonstrates that, when induced to undergo apoptosis, MCF10A El B 19k cells have
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significantly different A\pm characteristics to their wild type counterparts. They show increased 
local A\|)m flickering, a spreading loss of Atpm when cell-wide depolarisation occurs and, in two 
thirds of cells, there is a partial recovery o f Atpm after the initial loss.
4.7 Mitochondrial ultrastructural analysis in protected MCF10A cells:
This study was initiated in order to learn more about Bax regulation by observing its activation 
at high temporal and spatial resolution. Data presented here (Figures 3.5 and 3.6) and elsewhere 
(Annis et al., 2005; Valentijn et al., 2003) demonstrate that Bax can, under certain 
circumstances, partially translocate to mitochondria prior to its full activation. Therefore 
translocation alone cannot explain activation. Data from live cell imaging experiments also 
demonstrated that full Bax activation could initiate in a local subcellular region and then 
propagate across the cell (Figure 3.9 and 3.10). This may be more easily detectable in E lB  19k 
expressing cells when a spreading loss of A\pm was frequently observed (for examples see 
Figure 4.13). In addition, cells protected from apoptosis by the expression of E lB 19k showed 
increased rates of Aipm flickering, relative to wild type controls, indicating that there may be 
perturbations in their mitochondrial physiology prior to Bax activation (Figure 4.14). The 
formation of oligomeric clusters of Bax and Bak is temporally indistinguishable from the 
initiation of mitochondrial dysfunction and the release of inter-membrane space proteins 
(Korsmeyer et al., 2000). However, taken together the observations presented above suggest 
that mitochondria may not function solely as passive bystanders in the apoptotic program up 
until the moment Bax (and Bak) become fully active and oligomerised. Instead, these data raise 
the possibility that Bax activation may, in fact, be influenced by the physiology or local 
environment of the mitochondria at which the protein becomes active.
The precise mechanism of mitochondrial dysfunction and the release of inter-membrane space 
proteins is still a matter of uncertainty. Swelling and rupture of the MOM has sometimes been 
observed in apoptotic and necrotic cell deaths (Lemasters et al., 1998; Vander Heiden et al., 
1997), but the physiological relevance of this as a release mechanism has been questioned 
(Kluck et al., 1999). There are, however, long-standing observations that changes in 
mitochondrial ultrastructure occur during apoptosis (Sheridan et al., 1981). Mitochondria are 
highly organised organelles consisting of an outer membrane and inner membrane. The inner 
membrane can be categorised as either that directly facing the outer membrane, the inner 
boundary membrane, or the membrane that folds inwards to enclose the matrix and form cristae, 
the cristae membranes. A rigid baffle model of cristae structure was held in favour for many 
years, but recently the advent of electron microscope tomography has challenged this view and
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suggests that cristae structure can be more varied (Frey and Mannella, 2000). It has also 
recently been suggested that ultrastructural changes in cristae morphology are required for 
complete and efficient release of Cyt-c (Scorrano et al., 2002). Such a mechanism is thought to 
be necessary since only 15-20% of Cyt-c is estimated to be in the inter-membrane space, 
between the mitochondrial outer and inner boundary membranes (Frey and Mannella, 2000), 
with the remainder sequestered in the cristae folds, which are also the principal site for 
oxidative phosphorylation (Gilkerson et al., 2003). Cristae junctions, where the involuted cristae 
membranes meet the inner boundary membrane, are suggested have a diameter of only ~28nm 
(Frey and Mannella, 2000). This represents a diffusion barrier effectively 
subcompartmentalising the cristae space from the intermembrane space (Mannella et al., 2001). 
High voltage electron microscopic tomography and transmission electron microscopy have been 
used to demonstrate that remodelling of the cristae membranes of purified mitochondria in 
response to recombinant tBid (Scorrano et al., 2002). These experiments were performed in 
mitochondria purified from Bak deficient animals, the implication being that Bax would also be 
absent from the mitochondria as it would been lost, along with other cytosolic proteins, during 
purification, although this was not explicitly demonstrated. The analysis was also performed in 
whole cells from Bax/Bak doubly deficient animals. In both cases this was necessary to separate 
a remodelling function of tBid from its role as a BH3-only protein in promoting Bax and Bak 
activation. The MCF10A cell system characterised in this chapter offers an alternative way to 
address the question of when mitochondrial ultrastructure perturbations occur in response to the 
induction of apoptosis, since the viral proteins El B 19k and BHRF1 potently block apoptotic 
signalling at different steps. Expression of El B 19k allows the initial stages of Bax and Bak 
activation to occur unopposed, namely mitochondrial translocation for Bax and N-terminal 
conformational change for both. Only the later steps involving full activation and 
oligomerisation are prevented. In contrast, BHRF1 expression blocks all detectable signs of Bax 
and Bak activation. In both of the protected cell lines, some upstream apoptotic signalling 
events, including the processing of full length Bid, still occur (Figure 4.3). The advantage of 
using viral proteins to block Bax and Bak at different steps is that the analysis can be performed 
in whole cells in which the Bax and Bak proteins are still present. If ultrastructural changes are 
a result of the Bax/Bak-mediated terminal stages of mitochondrial dysfunction they should only 
occur in the wild type cells. I f  they are related to the first activation of Bax and Bak they may 
also occur in El B 19k cells. However, i f  they are dependent on more upstream responses to the 
induction of apoptosis, which could include the activation of Bid, they will also occur in 
BHRF1-expressing cells.
To test these hypotheses, ElB19k- and BHRF1-expressing MCF10A cells, as well as the empty 
vector control cells, were treated with or without Fas/CHX for 12.5 hrs to induce apoptosis.
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This was sufficient time to cause the initial activation of Bax and Bak in the majority of 
E lB  19k-expressing cells (Figure 4.5), yet there were still sufficient control cells remaining 
adherent to make the analysis feasible (Figure 4.2). The cells were then fixed and prepared for 
transmission electron microscopy. After viewing mitochondria from both treated and untreated 
control cells, a number of structural changes in the cristae were observed following the 
induction of apoptosis (Figure 4.5). Mitochondria from untreated samples displayed wide 
mitochondria with low matrix contrast and cristae membranes forming tight parallel lines. 
(Figure 4.15 A, panel i). In cells treated with Fas/CHX, both moderate (Figure 4.15 A, panel ii) 
and severe (figure 4.15 A, panel ii) changes were observed. These were characterised by 
increased density of the mitochondrial matrix and ballooning of cristae membranes to create 
electron-transparent spaces. Occasionally, a distinctive phenotype was seen in Fas/CHX-treated 
ElB19k cells, which appeared to be disruption of cristae membranes, in some cases resulting in 
their circularisation, but without the increases in matrix contrast or ballooning described above 
(Figure 4.15 A, panel iv). Additionally, in necrotic cell patches, which occasionally form in 
over-confluent MCF10A cell culture, mitochondria were observed with a much more extreme 
ballooning of their cristae (Figure 4.15 A, panel v). These last two phenotypes were not 
investigated further since they occurred very infrequently.
An additional striking feature of the electron micrographs from the treated samples was the 
appearance of electron dense granules in the mitochondrial matrix, referred here as 
mitochondrial spots (Figures 4.15 A, panels ii and iii). It is likely these spots represent 
precipitates of calcium phosphate. In healthy cells, free Ca2+ in the matrix is substantially 
buffered by binding to proteins and phospholipids as in the cytoplasm, resulting in a total/free 
ratio of around 100. However, in the alkaline conditions of the matrix compartment (around pH 
8), an additional buffering system is able to operate whereby calcium can precipitate as 
insoluble calcium phosphate if  the concentration exceeds a few tens of micromolar (Rizzuto et 
al., 2004). Such precipitates have been observed in heavily damaged neuronal cells (David, 
1999) but are also detectable in quickly frozen neuronal samples following brief periods of 
stimulation (Pivovarova et al., 1999). The existence of these precipitates is also consistent with 
long-standing observations that the total concentration of mitochondrial phosphate increases 
with Ca2+ uptake (Greenawalt et al., 1964) and that uptake of Ca2+ by isolated mitochondria is 
greatly increased by the presence of phosphate (Mela and Hess, 1982).
In a previous publication, describing ultrastructural remodelling of mitochondria in response to 
tBid, a series of categories were devised in order to classify the morphological changes 
(Scorrano et al., 2002). These were based on the response of purified mitochondria to 
recombinant tBid as visualised by high voltage electron microscopic tomography. Nevertheless,
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the essential features of these categories were applicable to changes observed in fixed cells 
visualised by transmission electron microscopy. A similar categorisation was therefore devised 
based on the changes observed in Fas/CHX treated MCF10A cells. A schematic of micrographs 
(Figure 4.15 B) and cartoons (figure 4.15 C) illustrating the key features the Type I - Type IV 
categories are shown. Type I represents the distinctive pattern of tight parallel cristae 
membranes observed in healthy cells. The Type II category, as defined by Scorrano et. al, was 
further subdivided into moderate (Type Ila) and more severe (Type lib) cristae remodelling, 
ballooning of crisae membranes and increased matrix density. Type III and Type IV 
mitochondria were those with the most severe morphological alterations, in agreement with the 
previous publication, such mitochondria were rarely observed. These classifications were then 
used to score a minimum of 40 images, each containing a different cell, from MCF10A control, 
E lB 19k and BHRF1 cells, treated with and without Fas/CHX (Figure 4.16 A). This analysis 
shows that Type I cristae predominated in all the untreated samples. As expected, following 
Fas/CHX treatment there was substantial remodelling of the cristae structure of control cells 
with Type I mitochondria being largely replaced with Type Ila and Type lib  morphologies. 
Strikingly, in both the ElB19k and BHRF1 treated samples substantial cristae remodelling was 
also observed, despite the fact these cells are potentially protected from cell death. The 
remodelling was consistently less severe in the E lB 19k cells than in the BHRF1 cells, meaning 
that there was a lower proportion of Type lib  in favour of Type Ila morphologies. Additionally, 
analysis of the median number of electron dense granules, or spots, appearing in the 
mitochondria of these samples was assessed (Figure 4.16 B). This showed that in all untreated 
samples spots were virtually absent from the mitochondrial matrix. However, following 
treatment with Fas/CHX they become common in all samples, with a median frequency of 
around 1.5 spots per mitochondrion. Data from two further replicates of this experiment were 
similarly quantified and showed the same results (Supplementary figures 4.16 C -  E in 
Appendix 1).
Taken together, these results show that El B 19k and BHRF1, which potently protect against Bax 
and Bak activation, albeit at different steps, do not prevent the changes in mitochondrial 
ultrasturcture or the appearance of electron dense granules, presumed to be Ca2+ deposits, 
following the induction of apoptosis with Fas/CHX. The data is consistent with the earlier report 
that tBid is responsible for mitochondrial cristae remodelling since this protein is generated in 
response to the Fas/CHX trigger in all three of the cells lines tested (Figure 4.3). However, the 
additional finding that areas thought to be Ca2+ deposits have also increased in the treated 
samples indicates that the mitochondria have also responded to the induction of apoptosis by 
accumulating substantially increased levels of matrix Ca2+. In light of these findings, it is highly
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unlikely that changes in mitochondrial ultrastructure are the result of Bax and Bak activation, 
and are instead driven by earlier events in the apoptotic pathway.
4.8 Discussion:
The results presented in Chapter 3 indicated that Bax activation might not be a cell-wide 
process but instead initiate in discrete subcellular locations. Live cell recordings suggested the 
existence of a feed-forward mechanism whereby, Bax activation in a single location, could 
rapidly initiate Bax activation in adjacent subcellular regions. Preliminary experiments also 
indicated that there may be a gradual increase in mitochondrial Ca2+ in the period following the 
application of an apoptotic trigger, but before Bax activation. However, the extremely rapid 
nature and unpredictable timing of these events confounded further in-depth investigation of 
these findings. In order to analyse these events in more detail, an alternative approach was 
sought.
Bcl-2 pro-survival homologues are known to block Bax activation (Cory et al., 2003). It was 
therefore possible that imaging cells in which Bax activation had been blocked or perturbed 
might reveal more about the underlying mechanism involved in the normal activation of this 
protein. Four pro-survival proteins were selected for this analysis: Bcl-2, Bcl-XL, El B 19k and 
BHRF1. Over-expression of the two cellular proteins, Bcl-2 and Bcl-XL, offered only modest 
levels of protection to Fas/CHX treated MCF10A cells and were therefore not pursued further. 
Both viral proteins, El B 19k and BHRF1, strongly protected MCF10A cells from Fas/CHX 
induced apoptosis. Fas/CHX was chosen as the apoptotic trigger since it is relatively acutely 
acting, with the majority of control cells undergoing apoptosis within 8 -15 hrs after its addition 
(Figure 4.2). In addition, as it is a trigger for the extrinsic cell death pathway, Fas has 
physiological relevance in respect of the protection conferred by viral pro-survival proteins 
since immune surveillance mechanisms in a host organism include the attack of infected cells 
with secreted death ligands, such as Fas, TNF-a and TRAIL. Viral Bcl-2 homologues are one 
line of defence employed by viruses to block death of the infected cell due to pro-apoptotic 
cytokines released by the host immune system. In other cellular systems, both BHRF1 and 
El B 19k have previously been reported to protect against activation of the extrinsic death 
pathway (Kawanishi, 1997; Sundararajan et al., 2001). In addition, early signalling events 
downstream of Fas death receptor activation are well characterised and include the processing 
of full length forms of caspase-8, caspase-3 and Bid which can be followed by western blotting. 
Strikingly, these events were unperturbed by expression of either El B 19k or BHRF1 (Figure
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4.3), indicating the viral proteins intercept the apoptotic signal further downstream, at a level 
proximal to mitochondrial dysfunction.
Further investigation revealed that expression of BHRF1 almost completely prevented both Bax 
and Bak activation, as assessed by a lack of both N-terminal conformational change and 
oligomerisation of the proteins (Figures 4.4 to 4.8). The nature of protection conferred by 
BHRF1 is not currently understood. As predicted from sequence homology, the structure of 
BHRF1 has the same central helical pair surrounded by several amphipathic helices seen in 
other Bcl-2 proteins (Huang et al., 2003). However, the protein does not contain a prominent 
BH3-binding groove seen in the other family members and, consistent with this, is not able to 
efficiently bind BH3 peptides from Bax, Bak, Bad and Bid (Huang et al., 2003). In this respect 
BHRF1 is more similar to Bid, which also lacks a deep hydrophobic cleft (McDonnell et al., 
1999). It may be that peptide-binding studies do not reflect the interactions formed by BHRF1 
in vivo, or that BHRF1 interacts with cellular Bcl-2 by a different mechanism. For example the 
C-terminal sequence, not included in the published structure, may occupy the hydrophobic 
binding cleft of other family members. Nevertheless, BHRF1 may also have a distinct anti- 
apoptotic function, independent of its binding to other BH3-containing proteins. On the basis of 
mutational studies such a role has also been proposed for Bcl-XL (Minn et al., 1999). In this 
respect, it was interesting that BHRF1 was also seen in high molecular weight fractions of ~670 
kDa by gel filtration (data not shown), as has been observed previously for Bcl-XL (Antonsson 
et al., 2001). Determining the composition of such complexes could provide important insights 
into the pro-survival mechanisms of Bcl-2 family proteins.
Like BHRF1, expression of El B 19k also potently protected MCF10A cells from Fas/CHX 
induced apoptosis. However, further analysis revealed that in these cells the N-terminal 
activation of both Bax and Bak, and the translocation of Bax to mitochondria, still occurred 
(Figures 4.4 to 4.9). Strikingly, at the population level, these events took place at the same rate 
as in the control cells (Figures 4.4 and 4.5), indicating upstream apoptotic signalling events 
were reaching Bax and Bak unopposed. At the single cell level, Bax and Bak N-terminal 
activation still appeared to be an all-or-none event, similar to control cells (Figure 4.5 and 4.6). 
However, in contrast to control cells, the conformational change in Bax and Bak did not result 
in the detectable formation of Bax and Bak foci by immunofluorescence (Figure 4.4 B and 4.6). 
Under these circumstances, N-terminally active Bax and Bak accumulated with an even 
distribution along the mitochondrial network, suggesting that oligomerisation of the proteins 
was blocked by ElB19k. This result was confirmed by the lack of Bax in high molecular weight 
fractions by gel filtration (Figure 4.7) and the failure of Bak to co-immunoprecipitate with Bax 
(Figure 4.4 A). Together these results support earlier data that showed that El B 19k blocked
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Bax-Bak interactions following the infection of HeLa cells with recombinant adenoviruses 
(Sundararajan and White, 2001). It therefore seems likely that E lB  19k has evolved to be a 
highly specialised inhibitor of a key checkpoint in the apoptotic pathway. Oligomerisation is 
likely to be the irreversible step in Bax activation, since enforced dimerisation has been shown 
to result in immediate mitochondrial translocation and mitochondrial dysfunction, which cannot 
be prevented by Bcl-XL (Gross et al., 1998). By preventing the oligomerisation of both Bax and 
Bak, even after their initial conformational activation, it is likely that El B 19k is targeting both 
the key players at the last possible step before mitochondrial dysfunction ensues. This is a 
powerful strategy for a viral protein in order to intercept the widest possible variety of apoptotic 
stimuli.
Direct interaction of Bax and El B 19k has previously been shown by yeast two-hybrid, in vitro 
binding and immunoprecipitation assays (Han et al., 1998; Han et al., 1996) and has been 
shown to be specific for conformationally active Bax (Perez and White, 2000). It is also known 
to involve the Bax BH3 domain (Han et al., 1996). The finding that E lB 19k blocked 
recognition of Bax by an antibody spanning the Bax BH2 domain, following an apoptotic 
trigger, (Figure 4.8) supports an earlier finding made following the infection of HeLa cells with 
recombinant adenoviruses (Sundararajan and White, 2001). It could be that E l B 19k also 
interacts directly with active Bax in this region, thereby blocking access to the antibody. 
Alternatively, this may indicate that the BH2 epitope only becomes exposed upon full 
activation. At present these two possibilities cannot be distinguished.
The finding that over-expressed GFP-Bax could also become blocked at the mitochondria in 
MCF10A cells expressing El B 19k (Figure 4.9) allowed a range of further experiments to be 
attempted. Unlike the conformationally sensitive antibodies, the use of GFP-Bax allows 
visualisation of the entire pool of exogenously expressed Bax, not just the fraction that had 
undergone a conformational change. In fixed cells, the use of GFP-Bax demonstrated that, when 
a stable block formed, it was the result of almost complete relocalisation of cytoplasmic GFP- 
Bax to the mitochondria (Figure 4.9 A). GFP-Bax also allowed the formation of the El B 19k 
block to be followed in live cells. This showed that the block was the result of a gradual 
accumulation of GFP-Bax at the mitochondria, over a substantially longer period than it took to 
enter the bright foci in wild type cells (Figure 4.10). However, the complete and stable 
accumulation of GFP-Bax at mitochondria was rarely observed; usually the block was partially 
formed and then breached, as indicated by a spreading loss of A\pm that was frequently observed 
(Figures 4.11 to 4.13).
- 135 -
The spreading of GFP-Bax activation and A\|>m loss had been observed previously in wild type 
cells (Figures 3.9 and 3.10), and suggested a model by which Bax activation is propagated by a 
feed-forward mechanism. This would consist of the protein first becoming active in a discrete 
subcellular region (local activation). The first pool of active Bax then triggers Bax activation in 
neighbouring sub-cellular regions, thereby resulting in the rapid propagation across the cell 
(cell-wide or global activation). Such a mechanism would have advantages, particularly in large 
cells, by co-ordinating efficient recruitment of all mitochondria into the apoptotic program. 
However, the propagation of Bax activation, and a corresponding loss of Aipm, were only 
observed in particularly highly polarised wild type cells and could not be demonstrated to be 
more generally applicable. Observations made from ElB19k-expressing cells presented above 
suggest that the feed-forward spreading of Bax activation and Aipm loss may, in fact, be a more 
generally applicable phenomenon. It could be that this process it too rapid to be reproducibly 
captured in wild type cells using an image acquisition rate of 1 frame/minute, except in more 
polarised cells where it propagates over larger distances and therefore has a longer duration. 
Since El B 19k is able to block GFP-Bax activation at a step subsequent to mitochondrial 
translocation it must provide a barrier to Bax activation at the mitochondria. I f  Bax becomes 
fully active in a local region, breaching the El B 19k block and initiating feed-forward 
activation, it is likely that there will be additional resistance to further Bax activation created by 
ElB19k at each successive mitochondrion. Whilst this might not prevent the propagation of full 
Bax activation once initiated, it may well act to retard it; bringing the feed-forward propagation 
into a temporal range more easily detected at a 1 frame/minute image acquisition rate. Direct 
visualisation of spreading GFP-Bax activation in E lB 19k cells was complicated by the initial 
formation of the block during which GFP-Bax accumulates at mitochondria. This initial 
enrichment prevented detection of the first crucial bright foci of GFP-Bax, because they were 
superimposed on a background of already elevated GFP-Bax intensity. However, it was 
demonstrated in Chapter 3 that, in MCF10A cells expressing moderate levels of GFP-Bax, the 
loss of A\j)m was synchronous with Bax activation (Figures 3.7 and 3.10). Therefore, detection 
of a spreading loss of A\|>m can be considered as an indirect readout for spreading GFP-Bax 
activation, and thereby provides additional support for the feed-forward model of Bax activation 
and spreading of the apoptotic signal from a local site of initiation.
Mitochondria are known to participate in Ca2+ signalling (Ichas et al., 1997) and apoptotic Ca2+ 
waves have been previously reported in myocardial myotubes (Pacher and Hajnoczky, 2001). 
Therefore, a possible mechanism for the feed-forward propagation of Bax activation is a Ca2+ 
signal that originates from the mitochondria where Bax first becomes active and then triggers 
Bax activation at neighbouring mitochondria. In support of such a model, Ca2+ overload of 
mitochondria is known to promote outer membrane permeabilisation and apoptosis (Bemardi,
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1999). Bax activation has also been shown to result in mitochondrial Ca2+ release in 
permeabilised cells (Carvalho et al., 2004) and, following partial irradiation, Ca2+ release has 
been observed from damaged mitochondria that is then taken up by non-irradiated mitochondria 
(Lum and Nagley, 2003). Although it has not been demonstrated in the present study, the 
MCF10A El B 19k cell system may provide a useful background in which to attempt to 
demonstrate the existence of a Ca2+ wave at the time when loss of Atym and GFP-Bax activation 
propagate across the cell.
Finally, the potent ability of El B 19k and BHRF1 to block Bax and Bak at different steps was 
exploited to examine whether changes in mitochondrial ultrastructure that occur during 
apoptosis (Sheridan et al., 1981) (Figure 4.15 A) were likely to be downstream consequences of 
Bax/Bak mediated mitochondrial dysfunction. Electron microscopy analysis revealed that 
remodelling of mitochondrial ultrastructure occurred in response to treatment of the cells with 
Fas/CHX, independently of both Bax and Bak activation, since it was not prevented by either 
E lB 19k or BHRF1 (Figure 4.16). This places changes in mitochondria ultrastructure in an 
upstream or parallel pathway to Bax and Bak activation. This result was in good agreement with 
a previous study showing that tBid can induce mitochondrial remodelling in a system where 
Bax and Bak were absent (Scorrano et al., 2002) as in the MCF10A ElB19k- and BHRF1- 
expressing cells, used in the present study, tBid was still generated downstream of Fas death 
receptor activation (Figure 4.3).
It has been shown that tBid is able promote Ca2+ uptake by increasing the Ca2+ permeability of 
the MOM, and may therefore accelerate progression towards Ca2+ overload (Csordas et al., 
2002). Strikingly, the electron microscopy analysis also revealed the presence of electron dense 
granules appearing throughout the mitochondrial matrix in cells treated with Fas/CHX, 
indicative of Ca2+ accumulation and precipitation of insoluble Ca2+ phosphate salts (section 4.7). 
The significance of this Ca2+ accumulation w ill be discussed in more detail in Chapter 7, in 
relation to the findings presented in Chapter 6. For now, it is necessary to mention that these 
precipitates are thought to be rapidly reversible (Pivovarova et al., 1999), and therefore a 
prolonged period of Ca2+ accumulation prior to Bax activation suggests mitochondria are 
potentially able to release large amounts of Ca2+, in the form of a propagating apoptotic wave, 
than would normally be the case, as mitochondria contain negligibly low levels of Ca2+ in 
healthy cells (Somlyo et al., 1979).
In summary, the data presented in this chapter supports the model of Bax activation shown in 
Figure 4.17. Following the induction of apoptosis by Fas/CHX, BHRF1, and by extension other 
Bcl-2 sequence homologues, can act to block the earliest detectable signs of Bax activation,
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namely the N-terminal conformational change and mitochondrial translocation of the protein. 
E l B 19k, however, blocks at a later step, allowing these initial changes to proceed unopposed by 
preventing Bax oligomerisation and ensuing mitochondrial dysfunction. Neither protein is able 
to block changes in mitochondrial ultrastructure or the apparent accumulation of mitochondrial 
Ca2+ following exposure to Fas/CHX. This places the mitochondrial changes in either an 
upstream or parallel pathway to Bax activation. Furthermore, when Bax activation does occur, it 
can be seen to initiate locally in a discrete subcellular region. Since Bax activation likely takes 
place in the plane of a membrane (Annis et al., 2005) prior changes in mitochondrial physiology 
are well placed to influence or even explain the initiation of Bax activation. The remainder of 
this thesis describes attempts made to interrogate the mitochondrial stages of Bax activation.
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Figure 4.1 Generation of stable MCF10A cell lines expressing pro-survival proteins.
Pro-survival proteins: Bcl-2, Bcl-XL, E1B19k and BHRF1, or an empty vector control, were 
introduced into MCF10A cells by retroviral transduction. Following selection, stable expression 
was confirmed by analysing 1% CHAPS total cell lysates by SDS-PAGE and western blotting 
using antibodies to the proteins indicated. Relative levels of over-expression of the two cellular 
proteins, Bcl-2 and Bcl-XL, can be seen relative to their endogenous levels. Bax, Bak, Bid and 
Actin are shown as controls.
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Figure 4.2 E1B19k and BHRF1 strongly protect against Fas/CHX induced apoptosis.
MCF10A cells over-expressing the cellular proteins Bcl-2 and Bcl-XL have modest protection 
against Fas/CHX induced apoptosis, but expression of the viral proteins E1B19k and BHRF1 
provides a much greater level of protection. (A) MCF10A cells were grown in 6 cm dishes and 
treated in triplicate with Fas/CHX for the indicated times. To quantify the amount of apoptosis 
both adherent and floating cells were harvested, fixed, stained for DNA content with propidium 
iodide and analysed by FACS. The proportion of cells containing sub-G1 DNA content is shown. 
Error bars represent ± 1 standard deviation from the mean, calculated from triplicate samples; 
(B) Phase contrast images taken showing representative fields containing the cells harvested 
and used for the FACS analysis described in part (A).
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Figure 4.3 Pre-mitochondrial events occur in all cell lines whereas post-mitochondrial 
events are effectively blocked in the most strongly protected lines.
Western blotting analysis of well characterised signalling events in the extrinsic pathway shows
E1B19k and BHRF1 effectively block events downstream of mitochondria. MCF10A cells were
grown in 6 cm dishes and treated with Fas/CHX for the indicated times (0-15 hrs). Whole cell
lysates were then prepared in 1% CHAPS buffer. For each time point 15 yg of total protein was
analysed by SDS-PAGE followed by western blotting for the proteins indicated.
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Figure 4.4 E1B19k and BHRF1 differ in their ability to block Bax and Bak activation.
BHRF1 effectively blocks Bax conformational change whilst E1B19k allows Bax the N-terminal 
change to take place but prevents oligomerisation. (A) The remainder of the MCF10A whole cell 
lysates prepared from the experiment shown in Figure 1.5 were used in immunoprecipitation 
assays with agarose-coupled anti-Bax N20 (11-30) antibody. Equal fractions of the final elutate 
were analysed by western blotting with anti-Bax (2D2) and anti-Bak (NT); (B) In a parallel 
experiment MCF10A were grown on glass coversliips and treated with Fas/CHX for 8 hrs. Cells 
were then fixed and co-immunostained with anti-Bax N20 (11-30) and FITC-coupled anti-rabbit 
IgG (green) together with anti-Cyt-c and Cy3-coupled anti-mouse IgG (red). Cells were then 
imaged by confocal microscopy and representative frames are shown. Scale bars represent 
10 jvm.
- 145 -
E.V. E1B19k BHRF1
Time (h rs )  o 3 6 9 1 2 1 5  0 3 6 9 12 15 0 3 6 9 12 15
Bak
Bax
B
>
UJ
JX.
O)
£
£
cc
1
CD
Bax N20 Merge
Figure 4.5 The Bax conformational change takes place at the same rate in E1 B19k and 
E.V. control cells.
E1B19k-expressing and empty vector control MCF10A cells become positive for Bax N20 (11- 
30) staining at the same rate, while this change is prevented in BHRF1-expressing cells. 
MCF10A cells were grown on coverslips and treated with Fas/CHX over a 15 hr time course. At 
the indicated times cells were fixed and co-immunostained with anti-Bax N20 (11-30) and FITC- 
coupled anti-rabbit IgG (green) together with anti-Cyt-c and Cy3-coupled anti-mouse IgG (red) 
before imaging by confocal microscopy. Representative frames from the 6, 9 and 12 hr time 
points are shown with a 3X enlargement of the indicated area from the 9 hr time point. Scale 
bars represent 20 /^m.
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Figure 4.6 Bak conformational change is also blocked in BHRF1-, but not in E1B19k- 
expressing cells.
MCF10A E1B19k cells also became positive for N-terminal Bak antibody staining but showed 
no evidence of bright foci formation or release of Cyt-c whilst the Bak conformation change was 
prevented in MCF10A BHRF1 cells. MCF10A cells were grown on coverslips and treated with 
Fas/CHX for 8 hrs. Cells were then fixed and co-immunostained with anti-Bak NT (23-37) and 
FITC-coupled anti-rabbit IgG (green) together with anti-Cyt-c and Cy3-coupled anti-mouse IgG 
(red) and imaged by confocal microscopy. The final panel shows a 3X enlargement of the area 
indicated in the merged panels. Scale bars represent 20 pm.
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Figure 4.7 Gel filtration confirms E1B19k and BHRF1 block Bax oligomerisation.
Both E1B19k and BHRF1 block the shift of Bax into higher molecular weight fractions following 
the addition of an apoptotic trigger. MCF10A cells (empty vector control (E.V.), E1B19k- and 
BHRF1-expressing) were treated +/- Fas/CHX for 8 hrs and then lysed in an equal volume of 
2% CHAPS lysis buffer. Samples were analysed by gel filtration followed by SDS PAGE and 
western blotting with anti-Bax (2D2).
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Figure 4.8 Additional biochemical characterisation of the action of BHRF1 and E1B19k.
(A) Co-immunoprecipitations using N-terminal anti-Bax and -Bak antibodies confirms neither 
protein is significantly activated in MCF10A BHRF1 cells following Fas/CHX treatment. MCF10A 
cells (BHRF1-expressing and empty vector controls) were grown in 10 cm dishes and treated 
+ / -  Fas/CHX for 9 hrs. Cells were then lysed in 1% CHAPS buffer and used in 
immunoprecipitation assays with anti-Bax N20 and anti-Bak NT antibodies. Equal fractions of 
the final eluate were analysed by western blotting with anti-Bax (2D2) and anti-Bak (NT); (B) 
MCF10A E1 B19k, Bcl-2 and empty vector control cells were treated as described in part (A) and 
lysates used for immunoprecipitation assays with the indicated anti-Bax antibodies (N20, a7/a8 
and 43-61). Equal fractions of the final eluate were analysed by western blotting with anti-Bax 
(2D2) and anti-ElB19k (for the N20 IP only). Lanes in the upper panel were digitally re-ordered 
for ease of understanding only and without further manipulation.
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Figure 4.9 GFP-Bax is also blocked at mitochondria in E1B19k-expressing cells.
ElB19k can block GFP-Bax at mitochondria in the same way that endogenous Bax becomes 
blocked in surrounding untransfected cells. MCF10A cells were grown on glass coverslips and 
transfected with GFP-Bax. 24 hrs later cells were treated with Fas/CHX for a further 8 hrs. Cells 
were then fixed and co-immunostained with: anti-Bax N20 (11-30) and Cy3-coupled anti-rabbit 
IgG together with anti-Cyt-c and Cy5-coupled anti-mouse IgG. Cells were imaged by confocal 
microscopy. Scale bars represent 10 /vm. (A) E1B19k can fully block GFP-Bax at mitochondria. 
Labels show: (a) untransfected cell with active enendogenous Bax, (b) untransfected cell 
without active endogenous Bax, (c) GFP-Bax transfected cell without active Bax, (d) GFP-Bax 
transfected cells with active Bax blocked at mitochondria: (B) Some cells show Cyt-c release 
indicating the block afforded by E1B19k has been breached. Labels show: (a) GFP-Bax 
transfected cell with active Bax blocked at mitochondria; (b) cell with active Bax and complete 
depletion of GFP-Bax from the cytoplasm to mitochondria, but also partial release of Cyt-c; (C) 
In some cells the GFP-Bax block appeared to be partially formed while in others the appearance 
of bright Bax foci correlated with complete Cyt-c release. Labels show: (a) GFP-Bax partially 
localised at mitochondria in a cell with active Bax, (b) cell with bright punctate Bax distribution 
and completely diffuse Cyt-c, (c) untransfected cell with active enendogenous Bax, (d) 
untransfected cell without active endogenous Bax.
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Figure 4.10 GFP-Bax steadily accumulates at mitochondria of E1B19k-expressing cells.
In MCF10A E1B19k cells the block to full GFP-Bax activation results in a steady depletion of 
cytoplasmic GFP-Bax and accumulation onto the mitochondria over a much longer time frame 
than 5min window observed in control cells. (A) Live cell recording of MCF10A E1B19k cells 
grown in glass-bottomed dishes and transfected with GFP-Bax. 24 hrs after transfection cells 
were loaded with TMRE to reveal the location of energised mitochondria and then treated with 
Fas/CHX before being mounted for live cell recording. The image sequence presented shows 
representative frames extracted from the total recording. Times relate to the addition of the 
Fas/CHX at the start of recording. Scale bars represent 10 /ym. (B) Supplementary movie 
figure M4.1: The complete image sequence from which the still frames shown in part (A) were 
extracted -  for full details of recording see the movie figure legend. (C) Supplementary movie 
figure M4.2: An accelerated version of the recording shown in figure M4.1 documenting the 
persistence of the E1B19k block to GFP-Bax activation and loss for Aipm for a further 11.3 hrs 
until recording was ended -  for full details of the recording see movie figure legend.
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Figure 4.11 The ability of E1B19k to block Bax activation is dependent upon expression 
level of GFP-Bax.
The level of GFP-Bax over-expression is a major determinant as to whether the EB19k block 
forms successfully. (A) Supplementary movie figure M4.3: MCF10A E1B19k cells were 
grown in glass bottomed dishes and transfected with GFP-Bax. 24 hrs after transfection cells 
were loaded with TMRE to reveal the location of energised mitochondria and treated with 
Fas/CHX to induce apoptosis. Cells were then mounted for live cell recording -  for full details of 
the recording see movie figure legend. (B) Representative still frames extracted from movie 
figure M4.3. Cell A expresses low levels of GFP-Bax and orange arrows indicate formation of 
the full block. Cell B is expresses intermediate levels of GFP-Bax and blue arrows indicate when 
the partially formed block is breached with loss of Aipm. Cell C expresses the highest levels of 
GFP-Bax and purple arrows indicate GFP-Bax immediately entering bright foci with the 
corresponding loss of Ai|>m. Times shown relate to the addition of the Fas/CHX at the start of 
recording. Scale bars represent 10 pm.
Supplementary material added in support: Part 4.13 C can be found in Appendix 1 and 
contains additional still frames to more clearly document the partial formation and subsequent 
breach of the E1B19k block in cell B.
Supplementary figure 4.13 C: Additional still frames documenting the partial formation of the 
block in cell B from figure 4.13 B. Recruitment of GFP-Bax onto the mitochondria occurs from 
~270 mins at ~285 mins the E1B19k block is breached, resulting in loss of Aipm and apoptosis. 
For full details of the recording see Figure 4.13 main legend. Additional labels in this part: 
Orange arrows: the E1B19k block to GFP-Bax activation beginning to form. Blue arrows: the 
first signs of Aipm loss and breach of the block. Green arrows: soon after bright foci of GFP-Bax 
become visible. Scale bars represent 10pm.
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Figure 4.12 Further characterisation of E1B19k block forming and being breached.
In E1B19k-expressing cells the slow initial recruitment of GFP-Bax onto mitochondria can 
rapidly convert into the formation of bright foci and onset of A\pm loss. (A) Supplementary 
movie figure M4.4: Live cell recording made from MCF10A E1B19k cells grown in glass 
bottomed dishes and transfected with GFP-Bax. 24 hrs after transfection cells were loaded with 
TMRE to reveal the location of energised mitochondria. Cells were then treated with Fas/CHX 
and mounted for live cell imaging -  for full details of the recording see movie figure legend. (B) 
Representative still frames extracted from movie figure M4.4. The E1B19k block to GFP-Bax 
activation first begins to form in cell A ( arrow) but is subsequently breached with loss of 
A\j>m loss from 245 mins (blue arrow). At around 280 mins bright foci of GFP-Bax become clearly 
visible and internal movement of structures within the cell stops (purple arrow). In cell B the first 
loss of Aipm at 255 mins occurs shortly after recruitment of GFP Bax to the mitochondria has 
begun (green arrow), and by 260 mins bright GFP-Bax foci are visible (red arrow). The times 
shown relate to the addition of the Fas/CHX at the start of recording. Scale bars represent 
10 /ym.
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Figure 4.13 E1B19k-expressing cells exhibit a spreading loss followed by partial 
recovery of Atym.
The breaching of the block to GFP-Bax activation in MCF10A E1B19k cells often results in a 
progressive loss of Aipm spreading across the cell; this is sometimes followed by a partial 
recovery. (A) Supplementary movie figure M4.5: Live cell recording made from MCF10A 
E1B19k cells grown in glass bottomed dishes and transfected with GFP-Bax. 24hrs after 
transfection cells were loaded with TMRE to reveal the location of energised mitochondria. Cells 
were then treated with Fas/CHX and mounted for live cell imaging -  for full details of the 
recording see movie figure legend. (B) Representative still frames extracted from movie figure 
M4.5. Cell A: GFP-Bax begins to accumulate at mitochondria (green arrow), but disruption of 
Aipm soon follows at ~206 mins (orange arrow) and then spreads rapidly across the cell. Cell B; 
disruption of Aipm begins at ~214 mins (blue arrow) and also spreads across the cell. In both 
cells there is a subsequent partial recovery of A^m (for example purple arrow at 240 mins in cell 
B); this leads to both cells rounding up and forming corpses that retain strong TMRE staining 
(red arrows). The times shown relate to the addition of the Fas/CHX at the start of recording. 
Scale bars represent 10 pm.
Supplementary material added in support: Movie figures M4.6 and M4.7 contain additional 
examples of the loss and partial recovery of Aipm in MCF10A E1B19k cells. Experimental setup 
was exactly as described in Figure 4.15 A.
Movie figure M4.6: Cell A shows cell-wide flickering (usually associated with complete loss of 
A ipJ followed by a dear recovery which results in the dying corpse retaining bright TMRE 
staining; Cell B clearly shows loss of Atpm spreading across the cell -  in this case there is no 
significant recovery after the initial loss. Parts 4.15 C and D can be found in Appendix 1 and 
contain representative still frames extracted from Movie figure M4.6.
Movie figure M4.7: Four GFP-Bax transfected MCF10A E1B19k cells illustrating several of the 
scenarios commonly observed: Cell A shows immediate loss of Atpm followed by a partial 
recovery; Cell B shows a partial block forming, followed by spreading loss of Aipm with recovery; 
Cell C undergoes a mitosis and then both daughter cells show loss and partial recovery of Aipm; 
Cell D shows a spreading loss of Aipm. This movie figure is not accompanied by still frames.
Supplementary figure 4.13 C and D: Representative still frames extracted from Movie figure 
M4.6. (C) GFP-Bax transfected MCF10A E1B19k cell exhibits whole-cell flickering of Aii>m 
(normally associated with complete loss of TMRE staining) but then goes on to show a partial 
recovery. (D) GFP-Bax transfected MCF10A E1B19k shows a spreading loss of Aipm. Times are 
measured from the start of the recording and do not relate to the time when Fas/CHX was 
added. Scale bars represent 10pm.
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Figure 4.14 E1B19k-expressing cells exhibit rapid flickering and incomplete loss of Atpm.
MCF10A E1B19k cells, treated to induce apoptosis, show increased flickering of Axpm; cell-wide 
loss A ^m is sometimes followed by a recovery phase. (A) Graphical compilation of Axpm 
recordings. Each trace represents the mean integrated TMRE intensity calculated from a ROI 
defined as the cell shape at the time Aij>m loss was first detectable (indicated by *), (i) Atpm 
recordings from MCF10A wild type cells, (ii) A\pm recordings from U20S wild type cells, (iii) four 
examples of Axpm recordings from MCF10A E1B19k cells where the initial loss of Aipm was 
followed by a recovery. If cells have featured in previous figures in this study the figure numbers 
are indicated. The x-axis shows the time in minutes since the start of each recording and is 
scaled equally in all three graphs. (B) MCF10A E1B19k cells were loaded with TMRE to reveal 
the location of energised mitochondria, then treated with Fas/CHX to induce apoptosis and 
mounted for live cell recording. Representative still frames extracted from Movie Figure M4.8 
(panel A) are shown as an example of the localised flickering of Ai|>m observed. Red arrows 
indicate areas where Ai|>m is transiently lost, green arrows indicate partial recovery. The times 
shown relate to the addition of Fas/CHX and start of recording. Scale bar represents 10 /vm. (C) 
The same cell shown in part (B) but at later time points when complete loss of Aipm occurred. 
(D) Supplementary movie figure M4.8: The complete sequence of images from which those 
shown in parts (B) and (C) were extracted. The movie shows a Ai|>m recording from a single 
MCF10A E1 B19k cell treated with Fas/CHX to induce apoptosis -  for full detail of the recordings 
see movie figure legend.
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Figure 4.15 Characterisation of the changes in mitochondrial ultrastructure occurring 
following the induction of apoptosis.
MCF10A cells were grown on plastic coverslips and treated + / - 250 ng/ml anti-Fas IgM and 
2^/g/ml CHX, in minimal media, for 12.5 hrs to induce apoptosis. Cells were then fixed and 
processed for electron microscopy. Representative images documenting the changes observed 
are shown in this figure. (A) Representative micrographs showing mitochondrial and cristae 
morphology in: (i) healthy, untreated cells; (ii) moderate morphological changes in cells induced 
to undergo apoptosis; (iii) more severe morphological changes in some cells induced to undergo 
apoptosis; (iv) an unusual morphology occasionally observed in MCF10A E1B19k cells. The 
mitochondrial outer membrane seems discontinuous in the plane of the image, cristae 
membranes remain tightly associated but become disordered and some are circularised; (v) a 
distinctive cristae morphology seen in patches of necrotic cells if MCF10A cells were allowed to 
become over-confluent; (B) The various morphologies seen in electron micrographs were 
categorised into Type I (healthy) through to Type IV (terminally disrupted). This scheme was 
subsequently used as the basis for the quantification of morphological changes. The scheme is 
based on criteria established in a previous publication (Scorrano et. al., 2002), however the 
Type II category is further sub-divided into lla and lib to reflect minor and more severe 
ultrastructural changes respectively; (C) Cartoon representations of the morphological 
phenotypes observed highlighting of the key features upon which each classification was based. 
In all electron micrographs scale bars represent 0.5 /vm.
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Figure 4.16 Neither E1B19k nor BHRF1 prevent changes in mitochondrial ultrastructure.
Even though MCF10A E1B19k and BHRF1 cells are strongly protected from apoptosis the 
changes in mitochondrial ultrastructure characteristic of apoptotic cells still occur. (A) MCF10A 
cells (empty vector control, E1B19- and BHRF1-expressing) were grown on plastic coverslips 
and treated + / - 250 ng/ml anti-Fas IgM and 2 /vg/ml CHX, in minimal media, for 12.5 hrs to 
induce apoptosis. Cells were then fixed and processed for electron microscopy. For example, 
sample 40 images were collected each representing a different cell. Changes in mitochondrial 
ultrastructure were quantified by classifying the mitochondria in each image according to the 
scheme show in Figure 1.17 B and C. The graph shows the percentage of mitochondria of each 
morphological class expressed as a percentage of the total number of mitochondria scored. (B) 
In addition to changes in mitochondrial morphology electron dense granules or spots appeared 
in the matrix of cells induced to undergo apoptosis. For each of the image sets quantified in part 
(A), the median number of spots per mitochondria was also calculated.
Supplementary material added In support: Two additional data sets from replicate 
experiments were quantified in a similar manner and the results are included as Part 4.14 C-E 
and can be found in Appendix 1.
Supplementary figure 4.14 C-E: MCF10A cells were prepared and treated exactly as 
described in part (A). (C) and (E) show a similar quantification of the changes in mitochondrial 
ultrastructure observed in these additional data sets. (D) shows quantification electron dense 
spots appearing in the images used in (C).
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Chapter 5 -  Bax structure function analysis
5.1 Introduction:
Data presented in the previous chapter identifies El B 19k as a potentially useful tool with which 
to stabilise cells that have undergone the initial stages of Bax activation, as such cells would 
otherwise be rapidly lost by apoptosis. Using E lB 19k to accumulate cells with active Bax may 
provide an entry point into a biochemical analysis of Bax at a critical step in its activation. 
However, before undertaking such an analysis a further problem exists: how to activate Bax 
rapidly and in as many cells as possible? Previous experiments in this study have, for the most 
part, relied upon Fas/CHX as an acutely acting and reproducible cell death stimulus; the 
majority of cells were induced to initiate Bax activation within 8 - 12 hrs of Fas/CHX addition. 
However, this was due to activation of endogenous Bax. A biochemical strategy to purify Bax 
without the use of multiple chromatography columns would require the expression of 
exogenous tagged Bax and would therefore be more analogous to the experiments using over­
expressed GFP-Bax. As described in chapter 4, El B 19k only rarely blocked over-expressed 
GFP-Bax for a sustained period of time. In addition, the use of Fas/CHX was considered 
economically unfeasible for treating the large number of cells required for biochemical 
purifications. A number of other potential apoptotic triggers were investigated, including H20 2 
and UV irradiation, but all proved much less efficient at reproducibly inducing rapid cell death 
in large-scale cultures. An alternative approach was therefore investigated relying on the use of 
constitutively active Bax mutants. I f  such mutants could be developed and placed under control 
of an inducible promoter system this would allow the synchronous expression of activated Bax 
in all cells in the culture. To this end a structure / function analysis of Bax was conducted to 
determine the effect of mutating key regions of the protein.
5.2 Selection of Bax mutations:
Previously systematic deletion and mutational analysis of the Bax C-terminus identified Serine 
184 (SI84) as critical for regulating Bax subcellular localisation (Nechushtan et al., 1999). 
Mutation of this residue to a more hydrophobic residue such as alanine (S184A) or valine
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(SI84V), or deleting it entirely (AS-184), has previously been shown to result in constitutive 
mitochondrial localisation of a GFP-Bax reporter (Nechushtan et al., 1999). This may be partly 
explained by these mutations increasing the overall hydrophobicity, thereby promoting 
membrane insertion. However, elucidation of the Bax structure also revealed that S184 is 
orientated into the BH3-binding cleft o f Bax (Suzuki et al., 2000). This provides the alternative 
explanation that substitution of S184 may disrupt a salt bridge that normally helps to retain the 
C-terminus folded back across the core of the Bax protein (Suzuki et al., 2000), and that this 
causes the C-terminus to disengage from the core of the protein and constitutively insert into 
mitochondrial membranes. Surprisingly however, the mitochondrial localisation of Bax caused 
by the S184V substitution was not associated with a large increase in Bax toxicity, and the N- 
terminal 6A7 epitope was reported to be still hidden (Nechushtan et al., 1999). These results 
further support the hypothesis developed in Chapter 3 that mitochondrial localisation is not 
sufficient to cause Bax activation and a further change is likely to be necessary to cause full 
activation. To this end other residues in the conformationally sensitive N-terminus and the 
a5/a6 helical hairpin were identified for mutation in an attempt to increase Bax toxicity and 
cause constitutive activation of the protein.
The N-terminus of Bax clearly plays an important role its activation (see Figures 3.1 and 3.3). 
The Bax N-terminus consists of an unstructured and flexible region (residues 1 to 15) followed 
by helix a l (ha l; residues 16 to 35) (Suzuki et al., 2000). The conformational change 
associated with Bax activation is likely to include the disengaging of ha l from the core of the 
protein and Bax mutants lacking the N-terminus have increased toxicity (Cartron et al., 2003). 
For a proteomic study it is preferable to keep the complete protein intact so a mutation, rather 
than deletion, which might mimic the effect of loss of the N-terminus was considered. Hence, 
the second mutation considered targeted a central residue in ha l, leucine 25, and replaced it 
with a helically disrupting proline residue (L25P). It was hoped that this mutation would disrupt 
ha l and destabilise the inactive form of the protein, thereby promoting Bax activation.
The central pair of amphipathic alpha helices in Bax, ha5 and ha6, are structurally conserved in 
both the cellular and viral Bcl-2 proteins. They are also key features of the pore forming 
domains of bacterial toxins such as Diphtheria toxin (Lazebnik, 2001). It is well established that 
the equivalent pair of helices from the toxin proteins insert into cellular membranes (Rosconi 
and London, 2002). For the Bcl-2 proteins the a5/a6 region has been shown to be required for 
their function (Matsuyama et al., 1998), and recent evidence reveals that this region also inserts 
into mitochondrial membranes during apoptosis (Annis et al., 2005; Kim et al., 2004a). It is 
possible that membrane insertion of this region represents a key step in Bax activation. 
Therefore, the final two mutations were selected to target this region.
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A long standing observation, and one of the few major differences at the primary amino acid 
sequence level between pro-apoptotic and pro-survival Bcl-2 proteins, concerns the distribution 
of charged resides within the a5/a6 region (Schlesinger et al., 1997). In Bax there is a 
predominance of positively charged residues, whilst in Bcl-2 negatively charged residues occur 
in the equivalent positions (Figure 5.2 A). Based on an alignment of the primary sequence of 
Bcl-2, Bcl-XL, Bax and Bak in this region, three lysine (K) residues near the apex of the Bax 
a5/a6 hairpin were chosen for mutation (Figure 5.2 B). The first of these, Bax K119, is 
positively charged in both Bax and Bak but the equivalent reside in Bcl-2 and Bcl-XL is small 
and hydrophobic. The second position, Bax K123, is positively charged in both Bax and Bak 
but the equivalent position is negatively charged, a glutamic acid, in both Bcl-2 and Bcl-XL. 
Finally, Bax K128 carries a positive in Bax, but not Bak, with the equivalent residue being 
negatively charged in Bcl-2 and Bcl-XL.
To alter the characteristics of this region alanine (A) and aspartic acid (E) residues were 
introduced. The first of two substitution mutations chosen was K119A, K123E, K128E, referred 
to as AEE throughout this study. This mutation was selected to be a ‘charge reversal’ mutation, 
making the apex of the Bax a5/a6 hairpin resemble that of the pro-survival proteins Bcl-2 and 
Bcl-XL. The other mutation was a triple alanine substitution: K119A, K123A, K128A, referred 
to as AAA throughout this study. This mutation was selected to make the a5/a6 more closely 
mirror the hydrophobic nature of this region in the bacterial toxins such as Diphtheria toxin, 
which is known to insert constitutively into the membrane (Rosconi and London, 2002). 
Multiple alanine substitutions of the Bax a5/a6 have been previously reported to confer a gain- 
of-function phenotype, enhancing Bax toxicity, but detailed localisation data has not been 
reported (Nouraini et al., 2000).
This approach resulted in the generation of a series of five Bax constructs: (i) wild type Bax, (ii) 
the previously described SI84V mutant, (iii) the L25P mutation selected to destabilise the 
cytoplasmic form of Bax, (iv) the triple alanine mutant (AAA) selected to enhance membrane 
insertion and (v) the charge reversal mutant (AEE) selected to mimic pro-survival proteins. The 
position of these mutations in relation to the Bax structure is shown in Figures 5.1 C and 5.1 D.
5.3 Analysis of the effect of Bax mutations on protein localisation:
To assess the effect of these mutations on Bax protein localisation they were introduced into 
wild type GFP-Bax and transfected into MCF10A cells. In all cases, some cells, usually those
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expressing the highest levels of the GFP-Bax proteins, could be seen to exhibit the bright 
punctate GFP-Bax pattern characteristic of fu ll activation. Often these cells failed to stain with 
Mitotracker and showed signs of nuclear condensation, indicating progression into apoptosis. 
This indicated that all the GFP-Bax mutants were functional and induced apoptosis when 
expressed at high levels. The basal location of each GFP mutants in moderately expressing cells 
prior to the onset of apoptosis was recorded. MCF10 empty vector control cells together with 
the El B 19k- and BHRF1-expressing lines were included in the analysis (Figure 5.2). The 
presence of El B 19k and BHRF1 had no effect on the localisation of the GFP-Bax mutants, 
although they did appear to increase the level of GFP expression and number of surviving cells 
24 hrs after transfection. This is presumably because higher expressing cells survived for longer 
in the presence of viral pro-survival proteins (data not shown).
As expected, wild type GFP-Bax was cytoplasmic (Figure 5.2 A) and the SI84V mutation 
caused constitutive localisation to the mitochondria (Figure 5.2 B) as reported previously 
(Nechushtan et al., 1999). The stable mitochondrial distribution of the S184V construct 
provides further evidence that mitochondrial localisation of Bax alone is not sufficient to 
guarantee activation, and further changes, which may occur at the mitochondria, are necessary. 
The L25P mutation however did promote activation of the protein: this construct has a reduced 
cytoplasmic distribution, showed enrichment at mitochondria and frequently entered small foci 
characteristic of active Bax (Figure 5.2 C). Mutations in the a5la6 region also changed the 
protein localisation: the AAA mutation appeared to be the most toxic of the mutant constructs, 
fewer transfected cells were visible 24hrs after transfection and those that remained expressed 
low levels of GFP. Small mitochondrial associated clusters were visible in these cells (Figure 
5.2 D). Finally, the AEE mutation expressed at much higher levels and the AA mutant had an 
intermediate distribution: a large proportion of the protein remains in the cytoplasm but a clear 
enrichment at mitochondria could also be seen (Figure 5.2 E).
When this work was begun it was already established that the Bax N-terminus was 
conformationally sensitive. It was therefore a particular concern that adding a large protein tag 
(GFP is 27 kDa, compared with Bax at 21 kDa) to the Bax N-terminus may interfere with its 
regulation. This could be important if  such a construct were then to be used as the basis for a 
proteomic analysis. Work presented in Chapters 3 and 4 clearly validates the use of GFP-Bax as 
a reporter to monitor Bax activation in live cells. This does not however confirm that GFP-Bax 
is truly regulated in the same manner as the endogenous protein. For example, GFP-Bax may 
faithfully report on the location of the endogenous protein, being rapidly recruited into foci 
upon activation along with endogenous Bax molecules, but not actually participate in the initial 
activation event itself. The observation that high level GFP-Bax over-expression can override
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endogenous controls and promotes the induction of apoptosis (Rosse et al., 1998; Xiang et al., 
1996), argues that the N-terminally tagged protein may indeed retain full functionality. 
However, in an attempt to address these concerns, the behaviour of Bax tagged at the carboxy- 
terminus (Bax-GFP) was also investigated.
Figure 5.3 shows that Bax-GFP was cytoplasmic in wild type MCF10A cells, similar to GFP- 
Bax. Strikingly, the C-terminal GFP tag prevented three of the Bax mutants, S184V, L25P and 
AEE, from altering the protein localisation; all three accumulated in the cytoplasm and were 
indistinguishable from wild type Bax-GFP (Figure 5.3). Occasionally cells were still seen in 
which full Bax activation had occurred and the Bax-GFP constructs entered mitochondrial foci, 
but these were extremely rare in comparison with that seen with the GFP-Bax (data not shown). 
The exception was Bax-GFP AAA, which was still able to form small mitochondrially 
associated foci and expressed at noticeably lower levels than the other C-terminally tagged 
constructs. Together, these results indicate that a C-terminal GFP tag significantly impairs the 
function of the Bax protein and prevents its localisation to mitochondria. The ability of the Bax- 
GFP AAA construct to by-pass the inhibition imposed by the C-terminal tag is an indication 
that this protein retains a gain-of-function phenotype originally reported in an N-terminal HA 
tagged version of this mutant (Nouraini et al., 2000), and shown here with an N-terminal GFP 
tag (Figure 5.2 D).
The effect of E lB 19k and BHRF expression on the localisation of the Bax-GFP constructs was 
also investigated. As with the GFP-Bax mutants, the addition of BHRF1 had no effect on the 
localisation of any of the Bax-GFP mutants (data not shown). The N-terminally tagged GFP- 
Bax mutants were also unaffected by expression of E l B 19k. However, localisation of two of the 
C-terminal Bax-GFP mutants, Bax-GFP L25P and Bax-GFP AAA, was dramatically altered by 
the presence of El B 19k (Figure 5.4). Bax-GFP L25P, which was strongly cytoplasmic in 
control cells, could be seen to enter small mitochondrially associated foci in MCF10A E l B 19k 
cells (Figure 5.4, upper panels). Bax-GFP AAA formed small mitochondrial clusters and 
expressed at low levels in control cells. In E lB  19k cells, however, this mutant expressed at 
higher levels and formed a mesh-like network throughout the cytoplasm with strong straining 
around the nucleus; such a distribution is the signature of ER localisation. A potential model to 
explain this shift in distribution is discussed below.
[Data added in support: Supplementary Figure 5.7 in Appendix 1 shows a comparison of the 
ER-like distribution of Bax-GFP AAA in MCF10A El B 19k cells with that of a resident ER 
protein marker and with El B 19k, which predominantly localises to nuclear and ER membranes 
(White et al., 1984).J
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5.4 The toxicity of Bax mutations correlates with their localisation:
To asses the relative toxicity of the GFP Bax mutants a classical Annexin V / PI apoptosis assay 
was used (Koopman et al., 1994). The GFP Bax constructs were transfected into MCF10A 
control and ElB19k-expressing cells, and 24 hrs later the cells were subjected to FACS 
analysis: first to sort the GFP-expressing cells and then to asses the degree of apoptosis by 
measuring their ability to bind Annexin V. Apoptotic cells were considered as those staining 
positively for Annexin V, indicating extemalisation of the membrane lipid phosphatidylserine 
(PS) and a marker for apoptotic cell death (Koopman et al., 1994), but negatively for the cell 
impermeant DNA stain propidium iodide (PI), thereby excluding cells with ruptured plasma 
membranes. The results of this analysis are shown in Figure 5.6 A. As expected from the 
localisation study, the C-terminally tagged Bax-GFP constructs, being predominantly 
cytoplasmic, are considerably less toxic than the N-terminally tagged GFP-Bax variants. 
Untagged constructs, which were co-transfected with a GFP marker, show an intermediate level 
of toxicity. In most cases the presence of E lB  19k had only a marginal effect in reducing the 
overall level of apoptosis, although this effect becomes more obvious the more toxic the 
construct. For example, the level of apoptosis induced by GFP-Bax L25P and GFP-Bax AAA is 
considerably reduced in the presence of El B 19k (Figure 5.6 A).
Considering the individual mutations in the context of GFP-Bax: whilst over-expression of the 
wild type protein causes a modest increase in apoptosis relative to the GFP empty vector 
control, this level is increased by the constitutive localisation of Bax to mitochondria (SI84V) 
and increased further by promoting entry into mitochondrially associated foci (L25P). 
Mutations in the a5/a6 also influence GFP-Bax toxicity with the AAA construct, which 
constitutively enters mitochondrially-associated foci, being more toxic than SI84V and 
approaching levels seen with L25P. This contrasts with the AEE mutation, which only partially 
localises to mitochondria, does not form foci, and shows levels of toxicity similar to S184V. 
This trend described for the GFP-Bax mutants is suppressed, but still present, in the untagged 
Bax mutant series. Interestingly, it is also still present in the C-terminally tagged Bax-GFP set, 
albeit with much decreased overall levels of toxicity (Figure 5.6 A). Together these results show 
that, in general, there is a strong correlation between the ability of Bax mutations to promote 
mitochondrial localisation and their increased levels of toxicity, with those promoting entry into 
mitochondrially-associated foci being the most toxic of all. A notable exception to this rule was 
the Bax-GFP L25P construct, which, in the presence of El B 19k, did enter very small 
mitochondrial foci (Figure 5.4), yet still displayed very low levels of toxicity (Figure 5.6 A). 
This situation is particularly interesting, as it appears to stabilise a distribution of Bas normally
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associated with much higher levels of toxicity. It could therefore be a useful entry point for the 
biochemical analysis of Bax located at mitochondria.
Finally, this assay showed no significant change in the toxicity of GFP-Bax AAA with and 
without the presence of ElB19k. This is surprising since the ElB19k causes a dramatic shift in 
the localisation of this protein away from mitochondria into an ER-like distribution (Figure 5.4), 
and could therefore be expected to lower the protein’s toxicity. It is also surprising that, in the 
absence of El B 19k, Bax-GFP AAA displays lower toxicity than Bax-GFP L25P despite being 
constitutively localised to mitochondrial clusters while Bax-GFP L25P is predominantly 
cytoplasmic (Figure 5.5). A possible explanation for this was gained by analysing the median 
GFP fluorescence intensity for each sample, as an indicator of their relative expression levels 
(Figure 5.6 B). These data reveals that Bax-GFP AAA expresses at much lower levels than the 
other C-terminally tagged mutants. It is possible that cells expressing extremely low levels of 
GFP fluorescence may not have been detectable by FACS, and therefore inappropriately 
excluded from the subsequent Annexin / PI analysis. This interpretation supports the qualitative 
observation that the AAA variant induced apoptosis in the majority of transfected cells even at 
very low levels of expression (Figure 5.5) and implies the toxicity of the AAA mutation may 
have been under-represented in this FACS based assay. In general, the wide variation in 
expression level seen using these GFP-tagged Bax constructs (Figure 5.6 B) highlights the 
inherent difficulties in assessing the relative toxicity of mutant proteins at a single time point. 
Nevertheless the results obtained are in broad agreement with the conclusions gained from the 
localisation studies (Figure 5.5).
5.5 Discussion:
The objective of the work presented in this chapter was to conduct a structure / function analysis 
of key regions in the Bax protein in order to identify mutations which would constitutively 
activate Bax. The four mutations: S184V, L25P, AAA and AEE were examined. In addition, the 
effect of tagging these mutants with GFP at their N- or C- termini, and the effect of co­
expression of El B 19k was also considered.
N-terminally tagged GFP-Bax is cytosolic in the majority of cells (Wolter et al., 1997) and each 
mutation altered this localisation. The SI84V mutation resulted in a constitutive mitochondrial 
localisation with GFP-Bax SI84V accumulating evenly along the mitochondrial network, as has 
been previously described (Nechushtan et al., 1999). In contrast to the previous report this 
mutant did show increased toxicity relative to wild type GFP-Bax (Figure 5.6 A), but
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considering GFP-Bax was entirely loaded into the mitochondria (Figure 5.2 B), the associated 
increase in toxicity was modest. These data further confirms that mitochondrial localisation 
alone is insufficient to trigger GFP-Bax activation and suggests additional steps, such as 
dimerisation or oligomerisation are necessary for its fu ll activation (Gross et al., 1998). Whilst 
these properties make the S184V mutation potentially useful in isolating Bax forced into a 
mitochondrial localisation it does not appear to significantly promote activation of the protein.
The L25P mutation was selected based on the premise that disrupting ha l in conformationally 
sensitive N-terminus of Bax might promote activation of the protein. The results presented show 
the L25P mutation did significantly enhance both toxicity (Figure 5.6 A) and entry into bright 
mitochondrially-associated toxicity foci (Figure 5.2 C). It is possible that constitutive 
localisation into the foci characteristic of fully active Bax may mean this protein completely 
bypasses earlier steps in the protein’s normal activation, and the point at which El B 19k blocks 
this. If true these properties would make the L25P mutation unsuitable for use in biochemical 
purifications designed to interrogate these earlier steps. However, this appears not to be the case 
as, in a few cells, the protein could also be seen to be either partially cytoplasmic or co-localised 
with mitochondria and not in foci (data not shown). Additionally, the toxicity of GFP-Bax L25P 
mutation could be reduced by the presence of El B 19k. Together the data presented supports an 
interpretation that the L25P mutation does indeed act to promote Bax activation by destabilising 
the inactive conformation of the protein. Recently, a similar mutation in Bax h a l, a glycine (G) 
substitution for leucine 26 (L26G) has been reported (Cartron et al., 2003). In this case it was 
shown to have decreased mitochondrial targeting activity in vitro and decreased toxicity in 
transfection assays, although it retained Cyt-c releasing activity when expressed in yeast 
(Cartron et al., 2003). This is surprising since complete deletion of the Bax N-terminus has been 
reported to enhance Bax toxicity (Goping et al., 1998). At present the reasons for discrepancies 
in these data cannot be explained.
It is likely that the insertion of charged residues within the a5/a6 region into the mitochondrial 
membrane represents a significant energetic barrier to Bax activation. Membrane insertion of 
the Bax a5/a6 region during apoptosis has recently been explicitly demonstrated using a 
chemical labelling technique (Annis et al., 2005). The insertion of the equivalent region of Bcl- 
2 into both mitochondrial and ER membranes upon receipt of an apoptotic trigger has also been 
demonstrated (Kim et al., 2004a). Localisation data obtained using the charge neutralisation 
mutation, AAA, and the substitution mutant, AEE, within the Bax a5/a6 helical hairpin region 
supports the hypothesis that this region has important roles in regulating both the membrane 
targeting and bioactivity of Bax. The AAA mutation in Bax was selected to mimic 
hydrophobicity observed in the analogous region of structurally similar bacterial toxins such as
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Diphtheria toxin. In the toxin protein, this has been shown to insert constitutively into cellular 
membranes (Rosconi and London, 2002). It was hypothesised that increasing a5/a6 
hyrdophobicity may also increase Bax insertion into mitochondria and thereby enhance Bax 
toxicity. In support of this hypothesis a range of alanine substitution mutations into this region 
of Bax have been reported to confer a gain-of-function phenotype in both yeast and mammalian 
cells (Nouraini et al., 2000). In the context of GFP-tagged proteins transfected into MCF10A 
cells the AAA mutation showed enhanced toxicity, even at low-level expression (Figure 5.6), 
and was constitutively localised to small mitochondrially-associated foci in wild type cells 
(Figure 5.5). Interestingly, this change in localisation was unique amongst the mutations 
investigated in that it also occurred when the GFP tag was placed at the C-terminus of Bax 
(Figure 5.5). A possible explanation for these results is that by increasing the hydrophobic 
nature of the a5/a6 region the energetic barrier of insertion of the charged residues in this 
region into the mitochondrial membrane is removed, resulting in constitutive insertion. I f  true, it 
would be interesting to know why it is still mitochondrial membranes that are the preferred 
target for Bax AAA as this may reflect additional protein or lipid requirements necessary for 
Bax action unique to that environment.
A striking feature of the Bcl-2 family proteins is that members with significant sequence 
homology can have opposing cellular function. One of the few clear differences between pro- 
and anti-apoptotic family members is a predominance of positively charged residues within the 
a5/a6 region of pro-apoptotic members, while negative charged residues predominate in the 
pro-survival members (Nouraini et al., 2000). The AEE mutation was selected to change the 
characteristics of the Bax a5/a6 region to more closely resemble that of Bcl-2 and Bcl-XL. 
Whilst the AEE mutation did not turn Bax into a pro-survival protein, it did alter the localisation 
of the protein, resulting in a partial mitochondrial enrichment (Figure 5.2 E), further supporting 
the hypothesis that characteristics of the a5/a6 region contribute to determining the location of 
Bcl-2 family proteins. It is interesting to note that the partial cytoplasmic and mitochondrial 
distribution observed with GFP-Bax AEE closely mimics that described for Bcl-XL (Jeong et 
al., 2004).
Finally, the presence of El B 19k on the localisation of Bax mutants was also investigated. In 
general this had little effect, beyond a modest reduction in their toxicity (Figure 5.6). It is likely 
this reflects the ability of El B 19k to stall Bax activation described in detail in the previous 
chapter. However, the localisation of two of the C-terminally tagged mutants was dramatically 
altered: Bax-GFP L25P moved from being a cytoplasmic protein into small mitochondrially- 
associated foci, and Bax-GFP AAA moved from small mitochondrial foci to an ER-like 
distribution. In healthy cells, E l B 19k predominantly localises to the nuclear lamina,
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endoplasmic reticulum and nuclear membranes (White et al., 1984). Although the protein can 
partially redistribute to mitochondria in the presence of over-expressed Bax (Han et al., 1998) 
and upon the activation of Bax by the expression of tBid (Perez and White, 2000), in which 
cases El B 19k is thought to directly bind the N-terminally active conformation of Bax 
(Sundararajan and White, 2001). The ability of El B 19k to interact with conformationally 
altered Bax with high affinity may explain the shift in localisation of the Bax-GFP constructs. In 
the presence of N-terminal GFP, the L25P mutation promoted Bax activation as discussed 
above, it is therefore likely the same mutation would also destabilise the inactive conformation 
of Bax when the GFP tag is placed at the C-terminus. In the absence of El B 19k this effect may 
not be detected due to the inhibition on mitochondrial localisation generally conferred by the C- 
terminal tag (Figure 5.3). However, when El B 19k is co-expressed the combined effect of a high 
affinity of the destabilised protein for El B 19k may override this effect, causing Bax, and bound 
El B 19k, to enter a mitochondrial distribution where the interaction between these proteins 
normally occurs. A similar argument can be used to explain the change in localisation of the 
Bax-GFP AAA protein. In this case, it can be imagined that the protein is so destabilised and 
prone to activation that rather than El B 19k translocating to bind it at the mitochondria, it is 
recruited to the normal location of El B 19k, namely the ER. I f  correct, one prediction from this 
model would be that Bax-GFP L25P and AAA would both bind avidly to El B 19k. This is 
shown to be the case in data presented in Chapter 6 (Figure 6.7).
The work presented in this chapter was initiated in order to identify mutations in the Bax protein 
that might promote constitutive activation of the molecule to be exploited in biochemical 
purifications. From the data presented both disruption of the conformationally sensitive N- 
terminal ha l by the L25P mutation and charge neutralisation within the a5/a6 region can act to 
promote activation of the protein. It was also discovered that whilst a C-terminal tag is generally 
inhibitory to Bax function, in combination with the L25P mutation and co-expression of 
ElB 19k, Bax appears to become ‘frozen’ in multiple small mitochondrially-associated foci but 
without the associated increase in toxicity usually observed. This combination may be 
particularly interesting to pursue for a biochemical analysis since this distribution is highly 
reminiscent of that of Bax just at the point of its activation in wild type cells treated with an 
apoptotic stimulus.
- 183 -
Figure 5.1 Schematics showing the positions of Bax mutations characterised in this 
study.
(A) Comparison of charged amino acids in the membrane-penetrating a5 and a6 helices of Bax 
and Bcl-2. This region has a net positive charge (blue) in Bax, while the corresponding region 
carries a net negative charge (red) in Bcl-2. Figure adapted from Nouraini et. al., 1997; (B) 
Alignment of the a5/a6 region from four cellular Bcl-2 proteins. The position of the Bax lysine 
residues K119, K123 and K128 targeted for mutation are highlighted. Positively charged 
residues are in , negatively charged residues in blue, and the hydrophobic resides in pro­
survival proteins in place of Bax K119 in ; (C) Cartoon of the Bax protein structure 
indicating the positions of hal (green) and the a6/a6 region (blue). The position of the L25P 
mutation is shown (red); (D) An alternative view of Bax showing the location of ha9 (i ) and 
the S184V mutation ( ). The position of the three lysines targeted in the a5/a6 region
(orange). Images were produced using the Protein Structural Database (PDB) record for Bax 
and RasMol software.
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Figure 5.2 Analysis of the effect of mutations on N-terminal GFP-Bax localisation.
MCF10A empty vector control, E1B19k- and BHRF1-expressing cells were grown on glass 
coverslips and transfected with either wild type or the indicated GFP-Bax mutant. 24 hrs after 
transfection cells were loaded with 200 nM Mitotracker Orange for 20 mins to reveal the location 
of energised mitochondria. Cells were then fixed, mounted and imaged by confocal microscopy. 
For each mutant two representative fields are shown to illustrate the basal distribution of the 
transfected protein in the majority of moderately expressing cells. (A) GFP-Bax wild type control 
is predominantly cytoplasmic, (B) GFP-Bax S184V is constitutively localised to mitochondria; 
(C) GFP-Bax L25P enters into small mitochondrially associated foci; (D) GFP-Bax AAA is toxic 
at low levels and shows small mitochondrial foci; (E) GFP-Bax AEE is largely cytoplasmic but 
shows an enrichment at mitochondria. The presence of E1B19k and BHRF1 does not alter the 
behaviour of the N-terminally tagged GFP-Bax mutants. In all images scale bars represent 
10 f j m .
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MCF10A BHRF1 MCF10A E1B19k MCF10A wild type
MCF10A BHRF1 MCF10A E1B19k MCF10A wild type
MCF10A wild typeMCF10A E1B19kMCF10A BHRF1
MCF10A wild typeMCF10A E1B19kMCF10A BHRF1
MCF10A BHRF1 MCF10A E1B19k MCF10A wild type
Figure 5.3 C-terminally tagged GFP-Bax mutants are predominantly cytoplasmic.
MCF10A wild type cells were grown on glass coverslips and transfected with the indicated GFP- 
Bax construct, 24 hrs after transfection cells were loaded with 200 nM Mitotracker Orange for 
20 mins to reveal the location of energised mitochondria. Cells were then fixed, mounted and 
imaged by confocal microscopy. The cells shown are representative of the basal distribution of 
the transfected protein in the majority of moderately expressing cells. In all images scale bars 
represent 10 pm.
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Figure 5.4 Bax-GFP L25P and Bax-GFP AAA show altered distributions in MCF10A 
E1B19k cells.
MCF10A ElB19k cells were grown on glass coverslips and transfected with the indicated GFP- 
Bax construct. 24 hrs after transfection cells were loaded with 200 nM Mitotracker Orange for 
20 mins to reveal the location of energised mitochondria. Cells were then fixed, mounted and 
imaged by confocal microscopy. The cells shown are representative of the basal distribution of 
the transfected protein in the majority of moderately expressing cells. In all images scale bars 
represent 10 j/m.
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Figure 5.5 Summary of the localisation of the GFP Bax constructs analysed in this study.
Images compiled from the experiments described in figures 5.2, 5.3 and 5.4 to summarise the 
effect of Bax localisation of the Bax mutants. Each of the four mutations tested: S184V, L25P, 
AAA and AEE alters the distribution of the N-terminally tagged GFP-Bax. These changes are 
not seen with Bax-GFP, which is constitutively cytoplasmic, except for the Bax-GFP AAA mutant 
which enters small mitochondrially associated foci regardless of the location of the GFP tag. 
The distributions of two of the constructs: Bax-GFP L25P and Bax-GFP AAA were strikingly 
altered in MCF10A E1B19k-expressing cells, Bax-GFP L25P entering mitochondrial clusters 
and Bax-GFP AAA showing a characteristic ER distribution.
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Figure 5.6 Analysis of the toxicity of GFP Bax mutants.
MCF10A empty vector control and E1B19k-expressing cell lines were grown in 6-well dishes 
and transfected with the indicated GFP-Bax (N-terminally tagged) and Bax-GFP (C-terminally 
tagged) proteins. Untagged Bax constructs were also transfected, together with a GFP empty 
vector marker in a ratio of 10:1 (Untagged). 24 hrs after transfection cells were harvested and 
stained with Annexin V / PI and immediately analysed by FACS. For each data set: EV is the 
GFP empty vector transfected as a control and WT is the wild type Bax construct. (A) The 
proportion of apoptotic (Annexin V positive / PI negative) GFP positive cells in each sample, 
expressed as a percentage of the total number of GFP positive cells; (B) The median GFP 
fluorescence intensity for each sample as an indicator of the relative expression levels of the 
GFP constructs. In both samples error bars represent ± 1 standard deviation from the mean 
calculated from triplicate samples.
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Chapter 6 -  Bax interacting proteins
6.1 Introduction:
The pro-apoptotic Bcl-2 family members Bax and Bak are required for the onset of 
mitochondrial dysfunction and cell death following a diverse range of stimuli (Lindsten et al., 
2000; Wei et al., 2001). Yet, despite intensive investigations the nature of the Bax and Bak 
activation mechanism remains an area of uncertainty and great debate. Once active, Bax and 
Bak form oliogomers that are associated with the loss of A\|>m and release of Cyt-c and other 
mitochondrial inter-membrane space proteins. These events are widely accepted to represent the 
commitment point in the apoptotic program from which cells can no longer recover. Thus, 
understanding the nature of the Bax/Bak activating events goes to the heart of our understanding 
of how apoptosis is initiated in mammalian cells.
As demonstrated in Chapter 3, Bax activation is a sudden and rapid event occurring 
stochastically throughout a population of cells, often many hours after they have been exposed 
to a cytotoxic stress to induce cell death. Once initiated the loss of Ai|)m and translocation of a 
large proportion of the cytoplasmic pool of Bax into mitochondrially-associated clusters is 
complete within a five-minute period. Within an hour the cell is a dead.
Further insights into the mechanism and regulation Bax activation could potentially be gained 
from identifying any proteins interacting with Bax at the critical moments when the first 
molecules become active within the cell. However, the stochastic, transient and irreversible 
nature of this process means that only a small proportion of cells within a population are 
undergoing these events at any one time. Furthermore, data presented in Chapters 3 and 4 
suggests Bax activation may initiate within a localised region of the cell, maybe at a single 
mitochondrion, with other mitochondria being recruited into the apoptotic program by a means 
of a rapidly acting feed-forward mechanism. These characteristics have made the question of 
Bax activation in vivo particularly intractable to biochemical analysis, which is optimally 
performed using large numbers of cells behaving synchronously. For this reason, current models 
for Bax activation are based largely on evidence gained from in vitro reconstitution systems 
using purified mitochondria.
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Some candidate proteins and lipids, have been suggested to be involved in Bax activation, 
including: the DNA repair protein Ku70 and as well as two 14-3-3 proteins, theta and sigma, 
have been suggested to function as cytoplasmic anchors for Bax (Nomura et al., 2003; Samuel 
et al., 2001; Sawada et al., 2003). A ‘hit-and-run’ interaction with tBid had been suggested 
(Eskes et al., 2000). Recruitment to the mitochondrial inner membrane Adenine Nucleotide 
Transporter (ANT) was reported to enhance Bax activation (Marzo et al., 1998) whilst 
Humanin, a short peptide of 24 amino acids, has been shown to bind and inhibit Bax activation 
(Guo et al., 2003). Interestingly there is a complete open reading frame for Humanin within the 
mitochondrial genome and it is suggested the sequence present in mammalian nuclear genomes 
arose by transfer from the mitochondrial genome. Humanin has also been recently shown to 
bind Bid and tBid (Zhai et al., 2005). The apoptosis-associated speck-like protein (ASC) has 
been shown to be a p53 target gene that interacts with Bax and has been shown to promote its 
activation (Ohtsuka et al., 2004) as has an interaction between Bax and Bif-1, and Endophilin B 
family protein (Cuddeback et al., 2001; Takahashi et al., 2005) whilst Bax activation has been 
suggested to be suppressed by an interaction with Clusterin (Zhang et al., 2005). Despite the 
size of this ever-growing list none have yet been proved essential in regulating Bax activation 
and in most cases the physiological relevance of the interactions reported remains to be fully 
demonstrated in vivo. Many of these proteins were identified on the basis or yeast two-hybrid 
screens or functional screens in yeast. An unbiased approach to identify proteins interacting 
with Bax during its activation in mammalian cells has not previously been reported. This 
chapter reports the strategy and results of such an approach.
6.2 Design of the purification strategy:
The identification of proteins interacting with Bax at the time when the protein is becoming 
active is predicted to provide important insights the molecule’s regulation. In order to identify 
such candidates an unbiased proteomic approach was pursued. For such an analysis it may be 
advantageous if  cells could be accumulated at the point when Bax molecules are first becoming 
active. Data presented in Chapter 4 suggests that over-expression of Bcl-2 pro-survival proteins 
is unlikely to augment this aim since they act to delay Bax from becoming active. The level of 
protection afforded by these proteins can eventually be breached, resulting in Bax activation, 
but when this occurs it happens just as in wild type cells (data not shown). A number viral 
proteins targeting Bax and Bak have recently been reported, these include vM IA (Amoult et al., 
2004; Poncet et al., 2004), F1L (Postigo et al., 2006; Wasilenko et al., 2005) and M l 1L (Su et 
al., 2006; Wang et al., 2004), but in each case these proteins were shown to act by constitutively 
targeting and sequestering either Bax or Bak and thereby preventing their normal activation. So
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the former category delays Bax and Bak activation, while the later category removes Bax and 
Bak from their normal activation pathways, in neither case are these pro-survival proteins likely 
to aid the accumulation of cells with active Bax for a proteomic analysis. However, data 
presented in Chapter 4 demonstrates the Adenoviral E l B 19k protein blocks Bax and Bak 
activation at a unique and potentially useful step. Following the induction of apoptosis, 
ElB19k-expressing cells still exhibit the initial stages of Bax activation, namely mitochondrial 
translocation and N-terminal conformational change. Importantly, at the population level, these 
events take place at the same rate as in control cells, indicating upstream signalling events are 
intact and reach Bax unopposed. El B 19k then blocks cell death by preventing only the later 
steps in Bax/Bak activation, namely the homo- and hetero-oligomerisation of Bax and Bak, loss 
of A\pm and Cyt-c release. Over time the initial activation of Bax takes place in an increasing 
proportion of cells, but these cells remain alive and accumulate with mitochondrially 
translocated and N-terminally activated Bax. This mitochondrial pool of Bax protein, stabilised 
by ElB 19k, may be directly comparable to, or at least provide useful insights into, a step in Bax 
regulation that exists only transiently and in a small subset of wild type cells.
The rationale above explains why ElB19k-expressing cells may provide a unique entry point 
for a biochemical analysis of mitochondrially localised Bax. However, before such an analysis 
can be undertaken however, a further problem arises, which is how to activate Bax in as many 
cells as possible. Fas/CHX was used frequently used in the present study due of its acute and 
reproducible action; however, the use of anti-Fas IgM is economically unfeasible for treatment 
of large-scale cultures. A number of other potential cell death triggers, including H20 2 and UV 
irradiation were investigated, but all proved less efficient and less reproducible in initiating cell 
death in large-scale cell cultures. An alternative strategy was therefore pursued, relying on the 
use of mutations to constitutively activated Bax. This approach is outlined in Chapter 5 and led 
to the generation of four Bax mutants: SI84V, L25P, AAA and AEE, of which L25P seemed 
the most promising in terms of promoting constitutive Bax activation. It was reasoned that, if  
expressed under the control of a tetracycline inducible promoter these Bax mutants would 
provide a way to generate activated Bax synchronously and in large numbers of cells. In 
combination with El B 19k, to prevent or delay full apoptosis, it was hoped this would provide 
an entry point with which to purify Bax at a critical step in its activation.
6.3 Characterisation of 293 T-REx cells TAP-tagged Bax clonal cell lines:
The proteomic purification strategy chosen was the Tandem Affin ity Purification (TAP) tag 
system (Rigaut et al., 1999). The TAP method allows the purification of protein complexes
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under native conditions, without prior knowledge of their composition or function. To this end 
the GFP-tag (27 kDa) on wild type Bax and the Bax mutants, characterised in the previous 
chapter, was exchanged for the similarly sized TAP tag (20 kDa).
The TAP tag consists of main components. The first element consists of tandem Protein A 
epitopes, which allows efficient recovery of the tagged protein and associated components by 
affinity purification on an IgG-linked bead matrix. This is followed by a cleavage site for the 
Tobacco Etch Virus (TEV) protease, which allows specific elution from the matrix under native 
conditions. The second element in the tag consists of a calmodulin binding protein (CBP) 
epitope, which allows a second round of affinity purification on a calmodulin-coated bead 
matrix, this is necessary to remove both the TEV protease as well as remaining trace 
contaminants. After washing bound material is again eluted under native conditions, this time 
by the chelation of Ca2+ ions with EGTA. The eluted tagged proteins, together with any co- 
purifying proteins, can then be analysed by SDS PAGE followed either by western blotting or 
mass spectrometry.
The cell line chosen for this analysis was Human Embryonic Kidney 293 cell line. 293 cells 
were originally generated by transformation using sheared fragments of Adenovirus DNA 
(Graham et al., 1977). As a consequence of this they acquired the El B 19k open reading frame 
and express high levels of El B 19k. They are also well suited to biochemical purifications being 
fast and densely growing cell line leading to particularly high protein yields relative to other 
commonly used cell lines. For efficient large-scale purifications it was preferable to use cell 
lines stably expressing the TAP tagged Bax fusion proteins. In order to prevent cells adapting to 
the inherent toxicity of constitutive Bax over-expression, which is substantially increased by 
some of the mutations, expression of the tagged proteins was made dependent on a tetracycline 
inducible expression system (T-REx) to enable their regulated expression in 293 cells stably 
expressing the Tetracycline Repressor (293 T-REx cells).
The generation of 293 T-Rex stable cell lines expressing TAP tagged Bax and Bax mutants is 
outlined in section 2.4.5. Prior to their use in purification experiments the 293 clonal cell lines 
were examined for the localisation by immunofluorescence microscopy to validate the 
distribution of the TAP tagged Bax protein. In all cases the distribution in the TAP-tagged Bax 
proteins in ElB19k-containg 293 clones was analogous to the equivalent GFP-tagged Bax 
protein in MCF10A El B 19k, as characterised in Chapter 5. This is illustrated by the location of 
the Bax-TAP L25P and Bax-TAP AEE, which, in the presence of ElB19k are shifted into 
mitochondrial localised foci or an ER-like distribution respective (Figure 6.1).
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To ensure subsequent TAP purifications would yield meaningful results, two further analyses 
were performed on the 293 T-REx clonal cell lines to validate and characterise TAP-tagged Bax 
activity. Firstly, the effect of Bax induction on their cristae structure was examined by electron 
microscopy. Cells were treated for 12 hrs with 100 ng/ml doxycycline, which was sufficient to 
induce TAP-tagged Bax proteins to a high level. The cells were then harvested, fixed and 
prepared for electron microscopy. Representative images from five clonal lines expressing: 
TAP-Bax, TAP-Bax L25P, TAP-Bax AEE, Bax-TAP and Bax-TAP L25P are shown in Figure 
6.2. This analysis revealed that, relative to a control cell line expressing the TAP tag alone 
(Figure 6.2, panel A), induction of TAP-tagged Bax proteins did not result in disruption of 
mitochondrial morphology or cristae ultrastructure. This result is likely to indicate that, despite 
high level Bax induction, and its presence in mitochondrially associated foci in cells expressing 
the L25P mutation, El B 19k is able prevent mitochondrial dysfunction at this time point. 
Although electron microscopy was not conducted at later times it was observed that between 18 
and 24 hrs after induction of TAP tagged Bax most 293 clonal cell lines showed significant 
levels of death (data not shown). Since expression was maximal after approximately 8-10 hrs of 
induction, the later cell death is likely to reflect the eventual overloading of E lB19k’s ability to 
block cell death. However, this analysis shows that at 12 hrs after induction, when TAP 
purifications were performed, the induced Bax proteins had yet to cause significant 
mitochondrial disruption.
Finally, the TAP-tagged Bax clones were also subjected to gel filtration analysis. The results for 
three cell lines expressing Bax-TAP, Bax-TAP L25P and Bax-TAP AEE are shown (Figure 
6.3). Equal aliquots from fractions spanning the entire column volume were analysed by 
western blotting to visualise the elution profiles of: TAP-tagged Bax (41 kDa), endogenous Bax 
(21 kDa) and the alpha subunit of the FIFO ATP Synthase, which is a 60 kDa protein but as a 
component of much larger macromolecular complexes at mitochondria (up to 670 kDa), and 
thereby provided a marker for the highest molecular weight range separated by the column. This 
analysis reveals that whilst endogenous Bax and wild type Bax-TAP elute at sizes close to their 
monomeric masses, Bax-TAP AEE and, to a greater extent, Bax-TAP L25P shift into higher 
molecular weight ranges. They also cause shifts in the elution profiles of both E l B 19k and a 
small fraction of the endogenous Bax. This data therefore provides preliminary validation of the 
approach, suggesting that TAP-tagged Bax proteins, and in particular Bax-TAP L25P, could 
enter larger protein complexes than are accessible to the wild type Bax-TAP, which appears to 
remain monomeric.
In the literature it has often been assumed that the higher molecular weight fractions of Bax 
from apoptotic cells (Antonsson et al., 2001) are directly comparable to the Bax homo­
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oligomers stabilised by protein cross-linkers (Mikhailov et al., 2003) and the foci observed by 
immunofluorescence analysis (Nechushtan et al., 2001). However, it has been reported that 
these foci are likely to contain around 1,000 to 20,000 Bax molecules (Nechushtan et al., 2001), 
thus making them far larger than either the dimers and tetramers stabilised by cross-linking or 
the 200-600 kDa material seen by gel filtration analysis described above. In addition the very 
large clusters of oligomeric Bax that form in the later stages of apoptosis have been reported to 
be CHAPS insoluble (Annis et al., 2005; Gilmore et al., 2000; Valentijn et al., 2003). It is 
possible that a fraction of the material seen at higher molecular weight ranges on Bax gel 
filtration profiles is a component of larger mitochondrial protein complexes. In support of this 
interpretation, Bcl-XL (Antonsson et al., 2001) and BHRF1 (this study, data not shown) have 
both been seen in high molecular weight fractions (~400-600 kDa) by gel filtration and yet there 
is no evidence that these proteins participate in the formation of Bax oligomers. It was reasoned 
that TAP purifications might assist in characterising the composition of these higher molecular 
weight complexes and these complexes are more accessible to Bax-TAP L25P than the wild 
type Bax-TAP, which appears to remain monomeric.
6.4 Tandem Affinity Purifications with Bax:
Triton X-100, a non-ionic detergent, causes oligomerisation Bax, whilst the zwitterionic 
detergent CHAPS does not perturb Bax conformation (Hsu and Youle, 1997; Hsu and Youle, 
1998). Initial TAP purifications were performed with wild type Bax, tagged at the N-terminus 
and at the C-terminus, in both these detergent conditions (Figure 6.4). Analysis of the final TAP 
eluate by western blotting for Bax revealed an absence of the endogenous protein co-purifying 
with either TAP-Bax or Bax-TAP in CHAPS detergent (Figure 6.4 A). In good agreement with 
the published literature, TAP purifications in the presence of Triton induced co-association of 
Bax and approximately equal amounts of endogenous Bax were co-purified with the TAP- 
tagged proteins (Figure 6.4 B). When the final TAP eluate was analysed by SDS PAGE 
followed by silver staining, a noticeably less complex band pattern was visible in Triton versus 
CHAPS purified material (Figure 6.4 C). The protein content of most of the bands was below 
the level required for identification by mass spectrometry, although the identity of endogenous 
Bax in the Triton-purified material was confirmed. It was also apparent that there were more 
bands co-purifying with Bax-TAP and with TAP-Bax under CHAPS detergent conditions.
The structure / function analysis described in Chapter 5 resulted in the identification of a leucine 
residue within the N-terminally conformationally sensitive ha l of Bax, which, when mutated to 
a helically disrupting proline residue, promoted activation of the N-terminally tagged GFP-Bax.
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It was also determined that placing the GFP-tag at the C-terminus, Bax-GFP L25P, resulted in a 
substantial reduction in Bax activity and a constitutively cytoplasmic localisation. However, 
when expressed in the presence of E l B 19k, the C-terminally tagged L25P mutant was induced 
to enter small mitochondrially associated foci (Figure 5.4), without a large increase in the 
protein’s toxicity (Figure 5.6). In addition, when the GFP-tag was exchanged for the TAP-tag, 
Bax-TAP L25P, and expressed in ElB19k-expressing 293 cells a similar partial localisation into 
mitochondrially-associated foci was observed (Figure 6.1), resulting in a shift to higher 
molecular weight ranges in the protein’s elution profile by gel filtration relative to the wild type 
control (Figure 6.3). When the behaviour of this mutant in TAP purifications was examined 
there was a noticeable increase in both the complexity and intensity in the resulting band 
pattern, relative to that observed with either the N- or C-terminally tagged wild type proteins, 
following analysis by SDS PAGE and silver staining, (Figure 6.5). From this experiment one of 
the co-purifying bands of approximately 19 kDa in size was identified as Adenoviral E lB  19k. 
This provided an initial validation for the hypothesis presented in Chapter 5 that mitochondrial 
localisation of the Bax-GFP L25P in ElB19k-expressing cells was due to destabilisation of the 
protein promoting activation and it enters a mitochondrial localisation due it forming an 
El B 19k to inhibit its complete activation. In support of this, it has been previously 
demonstrated that El B 19k selectively binds the active conformation of Bax, and that this results 
in its translocation to mitochondria (Perez and White, 2000).
Other combinations of Bax mutations and N- and C-terminal tags were investigated, however, 
the Bax-TAP L25P combination consistently resulted in the purification of a more complex and 
more abundant range of co-purifying proteins (see below and data not shown). Therefore this 
variant was chosen for a preparative scale TAP purification experiment. Eluted proteins were 
analysed by SDS PAGE followed by staining with colloidal coomassie (Figure 6.6). Systematic 
identification of co-purifying proteins was achieved by subjecting the entire SDS PAGE 
separation range in 1 mm slices to tandem electrospray mass spectrometry. This resulted in the 
identification of the following protein or protein complexes as major co-purifying species: (i) 
components of the FIFO ATP Synthase from the inner mitochondrial membrane, (ii) 
components of the OST48/Ribophonim complex from the ER and an associated ER-lumenal 
chaperon, Calnexin, (iii) two inner mitochondrial chaperone proteins, the prohibitins (Figure 
6.6).
The prominent representation of mitochondrial inner membrane proteins, namely the FIFO ATP 
Synthase complex and prohibitins, in these initial TAP purification was surprising since Bcl-2 
proteins, including Bax, are thought to be located at the outer mitochondrial membrane. 
However, it is know that in places the mitochondrial inner and outer membranes may come into
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very close proximity and may even fuse in specialised structures known as contact sites 
(Crompton, 2000; Crompton et al., 2002). It is also thought that some Bcl-2 proteins localise to 
these contact sites, including tBid (Kim et al., 2004b; Lutter et al., 2001), and potentially Bax 
(Capano and Crompton, 2002). In addition, the number of mitochondrial contact sites has been 
observed to increase in apoptosis induced by Bax over-expression (He et al., 2003) and 
importantly, the ATP Synthase has been shown to be enriched at contact sites (Hoppel et al., 
2002).
The Bax a5/a6 region is known to insert into membranes, with the apex of this region (residues 
127 - 129 of human Bax), being thought to fully penetrate the lipid bilayer (Annis et al., 2005). 
It is therefore possible that this region of Bax could make contact with inner membrane 
proteins, particularly at contact sites. The AAA (K119A, K123A, K128A) charge neutralisation 
mutant and AEE (K119A, K123E, K128E) charge reversal mutant, introduced in Chapter 5, 
were selected specifically to alter the properties of the a5/a6 region (see section 5.2). It was 
therefore investigated whether, in TAP purification experiments, these Bax mutants were able to 
perturb any of the candidate interactions identified using the Bax-TAP L25P mutant. Based on 
its increased toxicity (see Section 5.5) and similarity to the bacterial toxin proteins, which 
constitutively insert into cellular membranes (Rosconi and London, 2002), it was predicted that 
the AAA mutation is able to bypass some levels of regulation wild type Bax is subjected to. It 
was therefore hypothesised that this mutation may disrupt or weaken interactions with inner 
membrane proteins. The AEE mutation was selected to make the a5/a6 region resemble that of 
the pro-survival proteins Bcl-2 and Bcl-XL. A model has been proposed whereby Bcl-XL and 
Bax compete for a shared, but as yet unidentified, mitochondrial target (Polcic and Forte, 2003). 
On the basis of this data it was hypothesised that i f  such a target protein was among those 
identified in the Bax-TAP L25P purifications, and the a5/a6 region of Bax mediated the 
interaction, then making this region of Bax more closely resemble that of Bcl-XL would 
enhance the interaction.
To test these predictions, parallel TAP purifications were conducted using the using the C- 
terminally tagged Bax mutant panel, S184V, L25P, AAA (two separate clones) and AEE, 
together with the wild type protein. Final TAP eluates were analysed by western blotting for 
some of the major co-purifying species identified by mass spectrometry (Figure 6.7 A). Levels 
of Bax-TAP in the final eluates, as an indication of the protein yield from the experiment, were 
approximately equal. However, assessment of the effect of the mutations on the levels of the 
candidate interacting proteins was not conclusive. In general, the L25P and AEE mutation 
performed consistently better than the other variants, namely WT, SI84V and AAA. However, 
after several attempts at these experiments, it became clear that experimental variation
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introduced by two rounds of affinity purification necessary for TAP purifications also had a 
substantial effect on the levels o f candidate Bax interacting proteins detected. Therefore, whilst 
the trend was that L25P and AEE mutants enhanced the levels of co-purifying proteins, it 
cannot be concluded for certain that this was directly due to the mutations introduced into the 
Bax molecule. These purifications did however confirm the presence of bands, of the correct 
size, recognised by antibodies raised against the FIFO ATP Synthase alpha, beta, d and OSCP 
subunits, Ribophorin I, Calnexin I and E l B 19k in the TAP eluates. In addition, the presence of 
the FIFO ATP Synthase beta subunit, BAP32, BAP37, Ribophorin II was also confirmed (data 
not shown). This data thereby acts as to initially validate the protein identification made by 
mass spectrometry (Figure 6.6). Finally, these experiments did show that the more toxic 
mutations, namely L25P, AAA and AEE, were consistently those co-purifying the highest 
levels of ElB19k, supporting data which suggests ElB19k specifically interacts with the active 
conformation of Bax (Perez and White, 2000).
Purifications with N-terminal tagged constructs were also attempted. In these experiments very 
little ATP Synthase, the major co-purifying complex in the C-terminal TAP data set, was 
detected (Figure 6.7 B). In this case the AAA and AEE mutations both consistently 
outperformed the other mutations, although the reason for this is not known. The low abundance 
of co-purifying proteins obtained with the N-terminal TAP mutant set in these experiments was 
in good agreement with earlier observations using only the wild type proteins (Figure 5.4 and 
5.5). For these reasons the N-terminally TAP tagged Bax mutants were not pursued further.
6.5 Tandem Affinity Purifications with Bcl-XL:
An initial concern regarding the spectrum of proteins identified in Bax TAP purifications was 
their subcellular localisation, with abundant protein complexes from both mitochondrial inner 
membrane and endoplasmic reticulum proteins being highly represented. Whilst both can be 
explained in terms of known localisation of Bcl-2 proteins to mitochondrial contact sites 
(discussed above), and the recently established role for Bax at the ER (Scorrano et al., 2003; 
Zong et al., 2003), it was considered preferable to first try and validate these interactions in a 
heterologous system.
Therefore, in collaboration with Ingram Iaccarino (present location CNR, Naples, Italy), similar 
TAP purifications were undertaken with Bcl-XL fused to an N-terminal TAP tag. Following 
transfection and drug selection, cells were analysed for the ability of the over-expressed Bcl-XL 
to functionally protect from UV induced apoptosis (Figure 6.8 A). Cells were exposed to a
- 208 -
200 J/m2 UV irradiation for 0, 2 or 4 hrs whole cell lysates were then prepared and analysed by 
western blotting for cleavage of the PARP protein, a marker of apoptosis (Figure 6.8 A). This 
result clearly demonstrates that the over-expressed Bcl-XL was functional despite the addition 
of the N-terminal TAP tag, causing a substantial reduction in PARP cleavage 4 hrs after 
irradiation. Following initial TAP purifications it was determined that purification of candidate 
Bcl-XL interacting proteins was significantly enhanced by the addition of a membrane 
fractionation step, prior to detergent solubilisation of the cells (Figure 6.8 B). Systematic 
identification of co-purifying proteins was achieved by subjecting the entire SDS PAGE 
separation range to tandem electrospray mass spectrometry. The complete data set of proteins 
identified in purification with Bax-TAP L25P from 293 T-REx cells and TAP-Bcl-XL from 
HeLa cells is shown in Table 6.1. Proteins highlighted bold are shared between the Bax and 
Bcl-XL data sets. Where possible, proteins of the same complex or subcellular localisation have 
been grouped together. The potential relevance of these proteins to Bax and Bcl-XL function 
and the regulation of apoptosis are discussed in section 6.7 and Chapter 7.
6.6 Preliminary validation of candidate Bax and Bcl-XL interacting proteins:
In order to validate some of the candidate interactions listed in Table 6.1 co- 
immunoprecipitation were performed. The FIFO ATP Synthase was the most abundant co- 
purifying species in Bax-TAP L25P purifications and an antibody that allows the 
immunocapture of FIFO ATP Synthase complex has been reported (Aggeler et al., 2002) and 
was used for the basis of these for co-immunoprecipitation assays from MCF10A cells treated 
with Fas/CHX or STS to induce apoptosis (Figure 6.9). Preliminary result indicates that there is 
an inducible interaction between endogenous FIFO ATP-Synthase and Bax, under conditions 
where subunits of the ATP Synthase complex are immunoprecipitated evenly. In the experiment 
shown, the cells were harvested after 6 hrs of exposure to the apoptotic stimulus, at which time 
STS has induced substantially more death than Fas/CHX (data not shown). In support of this 
result, co-purification of Bcl-XL and the FIFO ATP Synthase to a high degree of purity has 
recently been observed following a sequential biochemical fractionation strategy 
(Marie Hardwick, personal communication). Further characterisation of this interaction is 
ongoing.
From the Bcl-XL data set, further attempts were made to validate the interaction between XL 
and a small transport protein JM4 (see below for discussion). Again, preliminary data is shown 
in figure 6.9, indicates that over-expressed Myc-tagged JM4 co-immunoprecipitates with over­
expressed Bcl-XL following transfection into HeLa cells. Further characterisation of this
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interaction is on-going however, the related protein Rab7 has been seen to interact with Bcl-XL 
by far western (Abigail Hunt and Gerard Evan, personal communication) and there is 
preliminary evidence of a mutually exclusive binding of either JM4 or Rab7 to Bcl-XL (data not 
shown).
6.7 Discussion:
Evidence suggesting that Bcl-2 proteins, and Bax in particular, might interact with additional 
cellular proteins outside of the Bcl-2 family has steadily accumulated. In particular the existence 
of a mitochondrial target for Bax has been predicted both by biochemical fraction models 
(Roucou et al., 2002) and by experiments in yeast suggesting Bcl-XL and Bax may compete for 
a shared target (Polcic and Forte, 2003). Bcl-XL has been suggested to have survival functions 
independent of Bcl-2 family interactions (Minn et al., 1999). In addition, it has yet to be 
definitively shown the higher molecular weight range entered by Bax in gel filtration 
experiments represents only Bax and Bak oligomers and not additional protein complexes. 
Accumulating evidence suggests that Bax oligomerisation is the key event in its irreversible 
activation (Gross et al., 1998), and when this does occur it is likely to happen at mitochondrial 
membranes (Annis et al., 2005). Evidence from the present study suggests that Bax molecules 
may first become activated in a local subcellular region, implicating one or a small subset of 
mitochondria in being intimately involved in the Bax activation event.
In order to isolate candidate proteins interacting with Bax at the critical mitochondrial stages in 
its activation, a strategy was developed which allowed the Bax molecule to be accumulated in 
an active state at mitochondria using a mutation, L25P, while the expression of E lB  19k blocked 
loss of cells due to apoptosis. TAP purifications were performed using a C-terminally tagged 
version of this mutant, Bax-TAP L25P expressed in 293 T-REx cells. Constitutive expression of 
ElB19k in 293 cells, caused Bax-TAP L25P to enter small mitochondrially-associated foci, 
(Figure 6.1), without significant disruption of mitochondrial ultrastructure (Figure 6.2). Bax- 
TAP L25P also displayed a shift to a higher molecular weight range on gel filtration profiles, 
relative to the wild type protein (Figure 6.3). In addition, and for comparison, TAP purifications 
were performed with N-terminally tagged Bcl-XL, which remained functional when over­
expressed in HeLa cells. The combined data Bax and Bcl-XL purification shows a substantial 
degree of overlap, despite the use of different cell lines, different expression systems, and TAP 
tags placed at different ends of the molecules. This section considers the potential significance 
of some of the proteins identified in this screen as co-purifying with Bax and Bcl-XL. A more
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general discussion considering the place o f this data set in the field of apoptosis regulation as a 
whole follows in the final Chapter.
6.7.1 Known interactions - E1B19k and the BH3 only proteins:
The presence of high levels E l B 19k in the Bax data set indicates that the L25P mutant protein 
has gained an active Bax conformation (Perez and White, 2000). It is likely that, following the 
induction of high levels of activated Bax, binding of El B 19k to Bax delays cell death in these 
cells, allowing them to be harvested for purifications. Strikingly within the Bax data set no Bcl- 
2 family members were detected. In contrast the Bcl-XL data set contained Bax and Bak, 
together with BH3-only proteins Bim, Puma, Bid and Bad. Strikingly, these are exclusively 
members of the subset of BH3-only proteins shown to have highest affinity for Bcl-XL in recent 
binding studies (Chen et al., 2005) (Figure 1.4 B). The presence of Bax indicates that perhaps 
mitochondrially localised Bax can be bound by Bcl-2 pro-survival proteins in an analogous 
manner as that now demonstrated conclusively for Bak (Willis et al., 2005) (Figure 1.4 C). 
BH3-only proteins, in particular, are low abundance proteins and of small molecular weight, 
therefore making them difficult to detect by mass spectrometry. The fact that these proteins 
were detected at levels allowing protein sequencing, and in concordance with recently published 
literature, indicates the purifications were working reliably and efficiently.
6.7.2 F1F0 ATP Synthase complex and other inner membrane proteins:
The FIFO ATP Synthase complex is a highly conserved enzyme complex catalysing the 
terminal step in ATP synthesis. The mammalian complex contains at least 17 subunits. The F0 
component acts as a proton channel embedded in the inner mitochondrial membrane. The FI 
component catalyses either the synthesis or hydrolysis of ATP and is attached to the matrix-side 
of the F0. The FIFO ATP Synthase was originally implicated in Bax function when the F0 b 
subunit was identified in a classic yeast genetic screen of mutations conferring Bax resistance, 
although no direct biochemical link was anticipated the time. Although this study was criticised 
for their failure to report the exact genetic defect, it was subsequently demonstrated that 
functional oxidative phorphorylation, in general, is required for Bax killing in yeast (Harris et 
al., 2000). Subunits of the FIFO ATP Synthase complex were major components of both the 
Bax and Bcl-XL data sets. The functional significance of a direct biochemical interaction 
between Bax and the ATP Synthase is at present unclear. However, it is interesting to note that 
changes in Aipm occurring at the time of onset of apoptosis, as yet do not have a defined 
molecular mechanism. In the absence of sufficient flux through the electron transport chain both 
hydrolysis of ATP via reversal of the FIFO ATP Synthase and regulated ATP4'/ATP3' exchange 
through ANT provide alternative mechanisms by which Ai|jm can be maintained. It is possible 
Bax and Bcl-XL have as yet undefined roles in coordinating (Bcl-XL) or disrupting (Bax) the 
metabolic mechanisms by which ATP production and maintenance of A\pm are coordinated.
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6.7.3 The Ribophorin/ OST48/ DAD1 complex:
The Ribophorin / OST complex catalyses the first step in N-linked glycosylation of proteins. 
Calnexin is an associated chaperone. The smallest subunit of this complex, DAD1, was named 
after it was originally identified as Defender Against apoptotic cell Death . Originally 
characterised in CHO cells (Kelleher and Gilmore, 1997). DAD1 has also been reported to 
interact with Mcl-1 in a yeast two hybrid assay (Makishima et al., 2000). Glycosylation defects 
may have as yet unidentified links to the initiation of apoptosis. Inhibition of N-linked 
glycosylation in yeast has been reported to result in a range of phenotypes similar to those seen 
during apoptotic cell death of mammalian cells, such as DNA fragmentation and 
phosphatidylserine exposure, and these could be blocked by Bcl-2(Hauptmann et al., 2006).
6.7.4 VDAC and ANT:
Both mammalian isoforms of VDAC were specifically detected in the Bcl-XL data set, but not 
with Bax. This supports existing data suggesting that VDAC2, a low abundance isoform, can 
specifically interact with the active conformation of Bak to prevent oligomerisation of the 
protein (Cheng et al., 2003). It has also been reported that Bax can regulate with VDAC 
(Shimizu et al., 1999), but more recent evidence argues against this (Rostovtseva et al., 2004). 
Conversely the presence of Adenine Nucleotide Transporter (ANT) was specific to the Bax 
purification data set. ANT has been directly implicated in promoting Bax function (Marzo et al., 
1998), however, its presence could also be explained due to the large amount of FIFO ATP 
Synthase purified, since ANT is known to co-purify with this respiratory complex (Ko et al., 
2003).
6.7.5 Rab7/JM4 and secretory pathway proteins:
The small GTPase Rab7, has recently been implicated in the degradation of nutrient transporters 
in response to growth factor withdrawal (Edinger et al., 2003). Under these conditions, Rab7 
deficiency leads to prolonged cell autonomous survival in the absence of growth factors. 
Another small candidate regulator of the endocytic pathway identified was JM4 which as has 
family of proteins bearing a prenylated Rab acceptor 1 (PRA1) motif. (Schweneker et al., 2005).
6.7.6 Proteins involved in Ca2+ regulation:
Whilst mitochondrial contact sites (discussed above) and the close proximity of the ER to 
mitochondria (Figure 6.2, red arrows) (Collins et al., 2002; Rizzuto et al., 1998) provide a 
possible explanation physiological explanation. In addition to the close physical proximity of 
the organelles, a pool of Bax and Bak molecules have both been reported localise to the ER 
(Scorrano et al., 2003; Zong et al., 2003). Genetic studies have indicated that Bax and Bak can 
promote release of Ca2+ from the ER (Zong et al., 2003), whilst over-expression of Bcl-2 
promotes Ca2+ release by unregulated leak from the ER (Oakes et al., 2005). In this respect it is
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also interesting that a SEC61 complex component (Sec61 beta), as well as the Signal receptor 
delta and signal peptidase proteins were identified in the Bcl-XL data set. The SEC61 complex 
forms the core of the mammalian endoplasmic reticulum (ER) translocon, a transmembrane 
channel for the translocation of proteins across the ER membrane, but has also recently been 
implicated in mediating ER Ca2+ leak (Van Coppenolle et al., 2004). Both Bcl-2 and Bcl-XL 
have been reported to interact with the IP3 receptor (Chen et al., 2004; White et al., 2005), 
which is present in the Bax data set. Also MG29 has been reported to be a small regulator of the 
Ryanodine receptor, a relative of the IP3 receptor, and been reported to promote apoptosis 
through up-regulation of ER Ca2+ leak (Pan et al., 2004).
The proteins identified in these analyses require further validation. However, the presence of 
known Bcl-2 family interacting proteins and proteins previously implicated in the regulation of 
apoptosis provides at least a partial validation of the approach. The substantial overlap between 
the Bax and Bcl-XL data sets despite the use of different cell lines and the proteins being tagged 
at different ends also indicates many o f these proteins may interact with multi-domain Bcl-2 
proteins more generally. Each interaction w ill need to be confirmed by co-immunoprecipitation 
and the relevance to the apoptotic program assessed in function assays. However, the range of 
metabolic and transport proteins identified and not previously implicated in Bcl-2 function 
provides initial evidence that Bax regulation, and that of the Bcl-2 family more generally, may 
be more closely integrated into the control of cell metabolism and physiology than previously 
anticipated.
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Figure 6.1 Distribution of TAP-tagged Bax proteins in 293 T-REx clonal cell lines.
The distributions of TAP-tagged Bax proteins in 293 T-REx clonal cell lines were identical to 
those of the analogous GFP-tagged proteins in MCF10A E1B19k cells. Two of the 293 T-REx 
clonal cell lines generated are shown: Bax-TAP L25P (clone 3.13, top row) and Bax-TAP AAA 
(clone 4.9, bottom row). Cells were plated on glass coverslips and treated with 100 ng/ml 
doxycycline for 12 hrs to induce expression of the tagged Bax protein. Cells were then loaded 
with Mitotracker to reveal the location of energised mitochondria, fixed and stained using a 
FITC-coupled secondary antibody alone. The secondary antibody recognises the TAP tag since 
Protein A epitopes within the TAP tag bind to the constant region of the antibody’s heavy chain. 
Cells were mounted and imaged by confocal microscopy. Scale bars represent 10 //m.
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A  Bax-TAP L25P (clone 3.13) Mitotracker DAPI Merge
B Bax-TAP AAA (clone 4.9) Mitotracker DAPI
Figure 6.2 Expression of TAP-tagged Bax proteins does not change mitochondrial 
morphology in 293 T-REx clonal cell lines.
Analysis of 293 T-Rex clonal cell lines by electron microscopy confirmed that induction of TAP- 
tagged Bax proteins did not cause significant disruption to mitochondria. 293 T-REx cells were 
treated with 100 ng/ml doxycycline for 12 hrs to induce expression of the TAP-tagged Bax 
proteins, then fixed and prepared for electron microscopy. (A) Control cell line expressing the 
TAP tag alone demonstrating normal mitochondrial morphology with tightly aligned cristae 
membranes. This morphology is unchanged following the induction of: (B) wild type (w.t.) TAP- 
Bax (which is mostly cytoplasmic); (C) TAP-Bax L25P (which forms small mitochondrially- 
associated foci); (D) TAP-Bax AEE Bax (which shows a partial enrichment at mitochondria 
without forming foci); (E) wild type (w.t.) Bax-TAP (which is cytoplasmic); (F) Bax-TAP L25P 
(which forms small mitochondrially-associated foci). In all images scale bars represent 0.5 ym. 
Areas where mitochondria are in close proximity to the endoplasmic reticulum are highlighted 
with red arrows (see section 6.5 and Chapter 7 discussion).
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Figure 6.3 The gel filtration profile of TAP-tagged Bax is altered by Bax mutations.
Gel filtration analysis of 293 T-REx clonal cell lines reveals Bax-TAP L25P and Bax-TAP AEE 
mutants have altered elution profiles relative to that of Bax-TAP wild type (w.t.)- 293 T-REx cells 
were treated with 100 ng/ml doxycycline to induce expression of the indicated TAP-tagged Bax 
protein. Cells were then harvested and lysed in an equal volume of 2% CHAPS lysis buffer and 
analysed by gel filtration. 10 y\ aliquots of the indicated fractions were analysed by SDS PAGE 
followed by western blotting with: anti-Bax (2D2), an antibody raised against the alpha subunit 
of the F1F0 ATP Synthase (alpha) and anti-E1B19k. The TAP tagged protein is recognised by 
all antibodies due to Protein A epitopes within the TAP tag. In each case a longer exposure of 
the Bax elution profile is shown to reveal the presence of Bax in higher molecular weight 
fractions. (A) Bax-TAP wild type control, which is predominantly cytoplasmic; (B) Bax-TAP 
L25P, which forms small mitochondrially-associated foci; (C) Bax-TAP AEE, which shows a 
partial enrichment at mitochondria without forming foci.
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Figure 6.4 Effect of detergents on the profile of proteins purified with TAP-tagged Bax.
TAP purifications in the presence of the zwitterionic detergent CHAPS resulted in a distinct 
profile of purified proteins without endogenous Bax whilst the presence of the non-ionic 
detergent Triton X-100 resulted a simpler band pattern and large amounts of endogenous Bax 
are co-purified. 293 T-REx cells (TAP-Bax clone 80, Bax-TAP clone 10f and a TAP control clone 
12c) were grown in 15 x 15 cm tissue culture plates and expression of the TAP tagged protein 
induced with 100 ng/ml doxycycline for 12 hrs. Cells were then harvested and used for TAP 
purifications. Equal fractions were collected at each stage in the TAP purification and used for 
diagnostic western blots with anti-Bax (2D2). (A) purification in CHAPS detergent, there is no 
endogenous Bax in the final eluate (lane 5); (B) purification in Triton X-100 detergent there are 
approximately equal amounts of TAP tagged Bax and endogenous Bax in the final eluate 
(lane 5, compare red boxes to those in part (A)). In both cases the TAP tagged protein and 
endogenous Bax can be seen in Lane 1. The decrease in size of the TAP-tagged Bax from 
Lane 3 onwards is due to loss of the tandem Protein A epitopes due to TEV cleavage. (C) Final 
eluates from the TAP purifications were analysed by SDS PAGE and visualised by silver 
staining. M indicates lanes containing molecular weight markers. Labelled bands: blue arrow is 
TAP-Bax, green arrow is Bax-TAP, pink arrow is endogenous Bax, red arrows are bands 
submitted for mass spectrometry.
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Figure 6.5 The Bax-TAP L25P construct enhances the profile of purified proteins.
C-terminally TAP-tagged Bax consistently resulted in the purification of a more complex band 
pattern and the staining intensity was enhanced by the use of the L25P mutation. 293 T-REx 
cells (Lane 1: TAP-Bax clone 8o, Lane 2: Bax-TAP clone 10f, Lane 3: TAP control clone 12c 
and Lane 4: TAP-Bax L25P clone B12) were grown in 15 x 15 cm tissue culture plates and 
expression of the TAP tagged protein induced with 100 ng/ml doxycycline for 12 hrs. Cells were 
then harvested and used for TAP purifications. Final eluates were analysed by SDS PAGE and 
visualised by silver staining. M indicates lane containing molecular weight markers. Labelled 
bands: blue arrow is TAP-Bax, green arrow is Bax-TAP, red arrows are bands submitted for 
mass spectrometry.
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Figure 6.6 Summary of proteins identified by mass spectrometry in a preparative scale 
TAP purification with Bax-TAP L25P.
Preparative scale TAP purification with Bax-TAP L25P resulted in the identification of E1B19k, 
the FIFO ATP Synthase and the Ribophorin (OST48) complex as major co-purifying species. 
293 T-REx Bax-TAP L25P cells (clone B12) were grown in 60 x 15 cm tissue culture plates and 
expression of the TAP tagged protein induced with 100 ng/ml doxycycline for 12 hrs. Cells were 
then harvested and used for TAP purifications. 20 plates were used in each of 3 parallel 
purifications and the final eluates combined. (A) SDS PAGE analysis of the TAP purified 
proteins visualised by staining with colloidal coomassie. Labelled bands: green arrow is TAP- 
Bax, pink is E1B19k, red arrows are bands submitted for mass spectrometry; (B) Cartoon 
representation showing the subcellular localisation and subunit composition of the major protein 
complexes identified by mass spectrometry: the F1F0 ATP Synthase (F1 subunits in green, F0 
subunits in otango), the ribophorin (Rl, Rll, OST48, Dad1) complex with the associated 
chaperone Calnexin and two mitochondrial chaperones, the prohibitins BAP32 and BAP37.
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Figure 6.7 Western blot confirmation of the presence of proteins identified by mass 
spectrometry.
The presence of proteins identified by mass spectrometry was confirmed by western blotting 
with antibodies raised against: subunits of the FIFO ATP Synthase complex, Ribophorin I, 
Calnexin and E1B19k. 293 T-REx clonal cell lines expressing TAP-tagged Bax proteins 
containing the indicated mutation were grown in 15 x 15 cm tissue culture plates and expression 
of the TAP tagged protein induced with 100 ng/ml doxycycline for 12 hrs. Cells were then 
harvested and used for TAP purifications. Equal fractions of the final eluates were analysed by 
SDS PAGE followed by western blotting using the indicated antibodies. (A) C-terminal TAP tag: 
higher levels of co-purifying proteins were consistently observed using Bax-TAP L25P and AEE 
mutants, although most could be detected using any of the variants. Two separate clones of the 
Bax-TAP AAA mutant are shown (AAA 1 and AAA 2). (B) N-terminal TAP tag: The N-terminally 
tagged Bax variants were much less efficient in TAP purifications with relatively minor amounts 
of the F1F0 ATP Synthase alpha subunit only detectable using the TAP-Bax AAA and AEE 
mutants.
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Figure 6.8 HeLa cells over-expressing TAP-Bcl-XL are protected from apoptosls and can 
be used for TAP purifications.
HeLa cells expressing TAP-Bcl-XL were protected from UV-induced apoptosis and 
subsequently used in TAP purifications to isolate candidate Bcl-XL interacting proteins. (A) 
HeLa cells stably over-expressing either the TAP tag alone or TAP-Bcl-XL were treated with UV 
irradiation (200 J/m2 for 0, 2 or 4 hrs) to induce apoptosis. Whole cell lysates were prepared 
from these cells were analysed by SDS PAGE followed by western blotting for using an anti- 
PARP antibody. (B) HeLa TAP-Bcl-XL cells were grown in 30 x 15 cm and used for TAP 
purifications. 15 plates were used for each of 2 parallel purifications and the final eluates 
combined, analysed by SDS PAGE and visualised by staining with colloidal coomassie. The 
profile of co-purifying proteins was enhanced by the addition of a membrane fractionation step. 
Briefly, cells were first lysed in hypotonic lysis buffer: 20 mM Hepes (pH 7.5), 1 mM EGTA, 
10 mM KCI, 5 mM MgCI2, 1mM DTT with dounce homogenisation and membranes pelleted by 
centrifugation at 9500 x g for 30 mins. The resulting membrane pellet was resuspended in 1% 
CHAPS lysis buffer and TAP purification was performed as described previously (membrane). 
The cytosolic supernatant was also used for TAP purification (cytosol). M indicates lane 
containing molecular weight markers. Bands were cut for identification from by mass 
spectrometry from the membrane purification only. Data produced in collaboration with Ingram 
laccarino, current address: Institute of Genetics and Biophysics - CNR, Naples, Italy.
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Table 6.1 Proteins identified 
in TAP purifications from 
293 T-REx Bax-TAP L25P 
and HeLa TAP-Bcl-XL cells.
Note: proteins listed in bold  
were present in both analyses.
BAX DATA SET IDs: Other names Size
FI: alpha subunit F0F1 ATP synthase 59.7
FI: beta subunit F0F1 ATP synthase 56.5
FI: epsilon FOF1 ATP synthase 5.6
FI: gamma F0F1 ATP synthase 32.9
FI: delta F0F1 ATP synthase 17.5
FO: a subunit F0F1 ATP synthase 24.8
FO: b subunit F0F1 ATP synthase 28.9
FO: c  subunit F0F1 ATP synthase 7.6
FO: OSCP subunit F0F1 ATP synthase 20.9
FO: d subunit F0F1 ATP synthase 18.5
FO: e subunit F0F1 ATP synthase 7.9
FO: g subunit F0F1 ATP synthase 12.8
FO: 1 subunit F0F1 ATP synthase 10.9
FO: A6L subunit F0F1 ATP synthase 8.0
FO: F6 subunit FOF 1 ATP synthase 8.9
ElB19k El B protein, small T-antigen 20.6
Adenine nucleotide translocator ANTI 33.0
BAP32 PHB, prohibitin 1 29.8
BAP37 REA. prohibitin 2 33.4
Nicotinam ide nucleotide transhydrogenase NAD(P) transhydrogenase 113.9
NADH dehydrogenase 1 be ta  subcomplex. 9. 22kDa NDUFB9 21.8
CAD trlfunctlonal protein CSPase/ATCase/DHOase 242.8
Cytochrome c oxidase Subunit II MTC02, COII 25.5
Cytochrome c oxidase Subunit IV MTCOl, COI 19.6
Transterrln receptor p90, CD71 84.8
Ribophorin 1 RPN1 68.5
Ribophorin II RPN2 69.3
Ollgosaccharyltransf erase OST48 50.7
DAD1 Defender against apop to tlc  cell death 12.4
Calnexin Calnexin 67.5
Signal sequence receptor gam m a Translocon-associated protein gam m a 21.1
Signal recogltloin particle SRPR 69.9
IP3 receptor Type 1, II and III -310
SERCA2 SR/ER Ca2+ transporting ATPase 2 114.7
MG29 Mltsugumln 29 30.2
Vesicle transport-related protein Seel family dom ain conta in ing 1 72.3
Vesicle trafficking protein sec22b SEC22L1 24.7
Transmembrane trafficking protein TMP21 25.0
JM4 PRA1 domain family, member 2 19.2
Putative sulfhydryl oxidase (Fe/S proteins) Quiescin Q6-like 1 74.4
ZW10 homolog. centrom ere/ldnetochofe protein ZW10 88.8
Mannosyl-ollgosacchartde glucosldase Glucosldase 1 91.8
Transitional endoplasm ic reticulum ATPase Valosin-containing protein 893
Cytoskeleton-associated protein 4 CKAP4 66.0
Solute carrier family 25. m em ber 13 Cltrin 74.1
Histone H4 11.4
Neutral am ino ac id  transporter
SPFH dom ain family, m em ber 1 SPFH1 38.9
Progesterone receptor m em brane com ponent 1 PGRMC1 21.7
Opioid receptor, sigma 1 OPRS1 25.1
Hypothetical protein MGC5508 Mltsugumln 23 26.2
Alpha tubulin
Beta tubulin
A lpha-1-antitrypsin precursor
lam in  B2
BCL-XL DATA SET IDs: Other names Size
FI: alpha subunit F0F1 ATP synthase 59.7
FI: beta subunit F0F1 ATP synthase 56.5
FI: delta F0F1 ATP synthase 17.5
FI: gamma F0F1 ATP synthase 32.9
FO: a subunit F0F1 ATP synthase 24.8
F0: b subunit F0F1 ATP synthase 28.9
FO: OSCP subunit F0F1 ATP synthase 20.9
FO: d subunit F0F1 ATP synthase 18.5
F0: e subunit F0F1 ATP synthase 7.9
FO: g subunit F0F1 ATP synthase 12.8
FO: 1 subunit F0F1 ATP synthase 10.9
Bak BcQ antagonist killer 1 23.4
Bax Bcl2-assoclated X protein 21.2
Bad Bct2L8. Be 1-2 b inding com ponent 6 18.4
Bid BH3 in teracting dom ain dea th  agonist 22.0
PUMA Bcl2 b inding com ponent 3 20.5
Bim Bcl2-Bke 11, Bcl2Ll 1 22.2
VDAC1 Porin 30.8
VDAC2 38.1
BAP37 REA. prohibitin 2 33.4
Carbam oyl phosphate synthetase 1 CPS1 164.8
Phosphofructoklnase. p latlet PFK-C. PFKF 85.5
Cytochrom e b5 outer m em brane isotorm 16.3
M anose-P-dolchol utilization detect 1 Lec35, SL15 26.7
Solute carrier family 3, m em ber 2 MDUI, 4F2 antigen heavy chain 57.9
Na+/K+ ATPase a lpha  1 subunit Na.K-ATPase 81.7
CAD trltunctlonal protein CSPase/ATCase/DHOase 242.8
Cytochrome c oxidase Subunit II MTC02, COII 25.5
Cytochrome c oxidase Subunit IV MTCOl, COI 19.6
Transferrin receptor Transferrin receptor 84.8
Ribophorin 1 RPN1 68.5
ODgosaccharyttransterase OST48 50.7
Calnexin CNX 67.5
Protein translocatlon com plex beta SEC61 be ta  subunit 9.8
ER lumen protein retaining recepto r 1 KDEL recepto r 1 24.5
Signal sequence recepto r delta SSR4, TRAPD 19.0
Signal peptidase 18kD subunit 18.0
SERCA2 SR/ER Ca2+ transporting ATPase 2 114.7
Small GTP binding protein Rab7 23.5
Ras-related protein Rab7A 23.2
ER-Golgi intermediate com partm ent 32kD protein KIAA1181 36.9
Vesicle associated mem brane protein 3 Synaptobrevin 3 11.3
Transmem. emp24 protein transport domain containing 5 TMED5 19.1
Vesicle trafficking protein sec22b SEC22L1 24.7
Transmembrane trafficking protein TMP21 25.0
JM4 PRA1 domain family, member 2 19.2
Interferon Induced transmembrane protein LEU 13, IFI17 17.0
Delta-2-ISPD
Stomatin like 2 SLP2 45.5
Mesenchymal stem cell protein DSCD75 LOC51337 23.9
E2IG5 Growth and Iransformation-dependent protein 16.7
Tricaboxylate carrier protein SFXN1, Slderoflexin 1 35.6
Hypothetical protein MGC5508 Mltsugumln 23 26.2
Hypothetical protein LOC203547 11.3
Hypothetical protein M G C14697 Upreguiated during skeletol muscle growth 5 6.4
Hypothetical protein LOC493856 LOC493856 15.3
Figure 6.9 Preliminary validation of interactions identified in TAP experiments by co- 
immunoprecipitation.
Preliminary evidence suggests an inducible interaction between endogenous Bax and the F1 FO 
ATP synthase and between over-expressed Myc-tagged JM4 and Bcl-XL. (A) MCF10A cells 
(empty vector control or E1B19k-expressing) were treated STS (250 nM) or Fas (250 ng/ml) 
plus CHX (2 /vg/ml) for 6 hrs to induce apoptosis. Cells were then lysed in 1 % CHAPS buffer 
and used in co-immunoprecipitation assays with an anti-F1 FO ATP Synthase antibody (gift from 
R.Capaldi, University of Orgeon). Equal fractions of inputs and final eluates were analysed by 
SDS PAGE followed by western blotting with the indicated antibodies. (B) HeLa cells were 
transfected with Myc-tagged JM4 and untagged Bcl-XL as indicated. 24 hrs after transfection 
cells were lysed and used in co-immunoprecipitation assays with an anti-Myc antibody (9E10, 
CR-UK research services). Equal fractions of inputs and final eluates were analysed by SDS 
PAGE followed by western blotting with either anti-Bcl-XL or anti-myc antibodies as indicated. 
Data in part (B) supplied by Ingram laccarino, current address: Institute of Genetics and 
Biophysics - CNR, Naples, Italy.
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Chapter 7 -  General discussion
7.1 Progress made in this thesis:
This thesis deals with the regulation of the pro-apoptotic Bcl-2 family member Bax. At the time 
this work was begun the generation of Bax-I-Bak-I- doubly deficient animals had recently 
provided genetic proof that the presence of either Bax, or the related protein Bak, was required 
for apoptotic cell death mediated by mitochondrial dysfunction (Lindsten et al., 2000; Wei et 
al., 2001). Yet, despite a significant body of work in this area, both the mechanism of action of 
these proteins, and the process by which they become active, remained a matter of debate and 
does so to this day. The experiments described here were initiated in order to gain further 
insights into the process of Bax regulation and activation.
The Bcl-2 family of proteins are critically placed at a mitochondrial proximal step in the 
apoptotic signalling pathway to mediate what is widely considered the irreversible step in 
apoptotic cell death, namely the initiation of mitochondrial dysfunction and accompanying 
release of Cyt-c. Recently the roles o f some of the proteins in this family have been 
substantially clarified. It now seems likely that the BH3-only proteins act as ligands, each 
activated by a specific range of cellular stress responses or developmentally programmed cues 
(Cory et al., 2003) (Figure 1.4 A). Once active, the BH3-only proteins selectively target and 
inhibit pro-survival proteins, such as Bcl-XL (Chen et al., 2005) (Figure 1.4 B). This inhibition 
of the pro-survival proteins leads to the activation of Bax and Bak. For Bak, the mechanism of 
activation has been partially clarified. Bak is constitutively localised to mitochondria in healthy 
cells and held in check by direct physical interaction with Bcl-XL and Mcl-1. Upon receipt of 
an apoptotic signal this binding is disrupted by BH3-only proteins, thus releasing Bak to initiate 
mitochondrial dysfunction (W illis et al., 2005) (Figure 1.4 C). However, there is no evidence of 
an analogous mechanism for Bax. When purified in the absence of detergents Bax is monomeric 
(Antonsson et al., 2000; Hsu and Youle, 1997; Hsu and Youle, 1998). Activating interactions 
with some BH3-only proteins, namely Bid and Bim, have been suggested but a stable 
interaction of Bax with these proteins has not been detected (Sundararajan and White, 2001; 
Wei et al., 2000).
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A number of lines of evidence indicate that the regulation and function of Bcl-2 family proteins 
may not be entirely explained by intra-family interactions. For example, there is evidence to 
suggest that Bax and Bcl-XL can compete for a shared cellular target in mammalian cells (Hsu 
et al., 1997b) and when the proteins are expressed in yeast (Polcic and Forte, 2003). The 
existence of a Bax-binding partner at mitochondria has also been inferred from in vitro 
reconstitution data (Roucou et al., 2002). For other family members, Bcl-w fails to localise to 
mitochondria when expressed without the last 10 C-terminal residues. This protein is 
biologically inert even though it binds and sequesters BH3-only proteins avidly (Denisov et al., 
2003; Hinds et al., 2003), suggesting additional pro-survival functions at mitochondria beyond 
its ability to bind BH3-only ligands. In addition, a Bcl-XL mutant that failed to interact with 
Bax retained pro-survival function in both yeast and mammalian cells (Minn et al., 1999). A 
growing number of reports have also suggested that Bcl-2 proteins may be complexed with 
other cellular proteins in healthy cells, for example Bak was found to be bound by VDAC2 
(Cheng et al., 2003), Mcl-1 has been found to interact with an E3 ubiquitin ligase, Mule/ARF- 
BP1, which catalyses its poly-ubiquitylation and degradation following the binding of the BH3- 
only protein Noxa (Warr et al., 2005; Zhong et al., 2005). A novel role is emerging for a 
cytoplasmic pool of p53 that interacts with Bcl-XL (Mihara et al., 2003), and upon release by 
binding of the BH3-only protein Puma, may be able to directly activate Bax (Chipuk et al., 
2005). Notably, this pool of p53 molecules is detectable within 30 mins following irradiation 
and is accompanied by an early wave of caspase-3 activation, contrasting with the p53 
transcriptionally controlled effects which occur at later times: PUMA (2 hrs), Noxa (4 hrs), Bax 
(8 hrs) (Erster et al., 2004).
If regulation of Bax is to be explained, at least in part, by interactions with proteins outside of 
the Bcl-2 family, several lines of evidence indicate such interactions take place at cellular 
membranes. It has recently been shown that Bax inserts into membranes and that 
oligomerisation is likely to be driven by the association of transmembrane monomers in the 
plane of the membrane (Annis et al., 2005). This mechanism differs from that of some bacterial 
toxins which are thought to form pores via the concerted membrane insertion of pre-formed 
oligomers (Heuck et al., 2000). However, the exact mechanism of membrane insertion for more 
structurally related toxin proteins, such as the Diphtheria toxin is not yet known. Bcl-2 has also 
been shown to insert into both ER and mitochondrial membranes upon receipt of a death trigger 
or binding of a BH3 peptide (Kim et al., 2004a), and membrane insertion following the receipt 
of an apoptotic signal has also been shown for Bcl-w (Wilson-Annan et al., 2003).
The data presented in this thesis was generated in order to gain further insights into the 
mechanisms of Bax regulation and activation. Chapter 3 showed the results of a detailed
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microscopy-based analysis Bax activation in U20S and MCF10A cells. The premise of these 
experiments was that observing Bax activation at high temporal and spatial resolution might 
reveal clues about how the protein is regulated. The data collected suggested that, following a 
low dose of UV irradiation, Bax can pre-exist at mitochondria, and is not yet fully active. 
Similar observations have also been made by others in an anoikis model (Valentijn et al., 2003). 
When Bax activation did occur it was a rapid event, correlating with loss of Aipm. Pre­
enrichment of Bax to mitochondria was seen to be neither sufficient nor required for complete 
Bax activation as detected by the formation of bright fluorescence foci and loss of A ijv  Some 
evidence that Bax activation may initiate locally and then become rapidly propagated across the 
cell was also obtained. Further analysis of these data was however complicated by the 
extremely rapid nature of the process, with Bax activation typically initiating > 5 hours after the 
addition apoptotic trigger and yet Aipm loss being complete within 5 mins. Evidence of the local 
initiation and propagation of Bax activation in wild type cells was therefore only obtained in the 
more polarised cells shown in Figures 3.9 and 3.10, although the spreading loss of Axpm was 
commonly observed in ElB19k-expressing cells (see Sections 4.6 and 4.8). It is possible this 
mechanism may be more generally applicable in wild type cells but that it occurs too rapidly to 
be seen at a 1 frame per minute image acquisition rate, except in highly polarised cells where it 
propagates over larger distances and therefore exists for longer. A more sophisticated imaging 
system allowing more rapid acquisition cycles, eg. 20 frames per minute, would potentially 
allow this question to be definitively addressed. Further attempts to quantify the live cell 
recordings generated were confounded by movements of the cells being imaged. The 
experiments were performed with a 63X objective to obtain high resolution images of 
mitochondria, however, at this resolution even small cell movements, occurring either through 
migration or in response to changes in the monolayer as nearby cells underwent apoptosis, 
resulted in significant movement of cells out of a defined region of interest defined by either the 
cell perimeter or to contain a subset of mitochondria. Attempts to quantify the rate of increase in 
Bax intensity at mitochondria, appearance of Bax foci and loss of Atpm using two separate 
analysis software packages were unable to reproducibly measure these changes while taking 
into account cell movements. A limited quantification of Ao|im loss showing complete loss 
within 5 mins in wild type cells, and a partial recovery after initial decrease in some E l B 19k- 
expressing cells is shown in Figure 4.14. Even in these cases there are caveats in interpretation 
of Aijim traces beyond 5-10 minutes after GFP-Bax activation due to movement of the cells (see 
Section 4.6 for further details).
Data presented in Chapter 3 establishes the assay and microscopy system that is used in Chapter 
4, in combination with El B 19k and BHRF1 expression to perturb Bax activation in MCF10A 
cells in response to Fas/CHX-induced apoptosis. Together these data led to the model shown in
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Figure 4.17 in which El B 19k blocks Bax activation at a step subsequent to its N-terminal 
conformational change and mitochondrial translocation. This block is therefore later than the 
block afforded by BHRF1-expression when these events are also prevented. More generally the 
data is supportive of a model in which the crucial event in Bax activation is the dimerisation and 
oligomerisation of Bax molecules. This is in agreement with a previous study in which enforced 
dimerisation of Bax induced apoptosis (Gross et al., 1998). It is possible the potent ability of 
ElB 19k to protect MCF10A cells from Fas/CHX-induced Bax activation is explained by the 
ability of ElB 19k to bind and directly prevent co-association of Bax molecules (Figures 4.7 and 
6.6). Substantial areas of uncertainty and controversy do however remain regarding the 
mechanism of action of ElB19k and BHRF1. For example, BHRF1 does not contain a 
prominent BH3-binding groove seen in the other family members and, consistent with this, is 
not able to efficiently bind BH3 peptides from Bax, Bak, Bad and Bid (Huang et al., 2003). It 
may be that peptide-binding studies do not reflect the interactions formed by BHRF1 in vivo, or 
that BHRF1 interacts with cellular Bcl-2 proteins by a different mechanism not recapitulated 
using BH3 peptides alone. Nevertheless, BHRF1 may also have a distinct anti-apoptotic 
function, independent of its binding to other BH3-containing proteins. In this respect, it was 
interesting that BHRF1 was also seen in high molecular weight fractions of ~670 kDa by gel 
filtration (data not shown). Determining the composition of such complexes may help elucidate 
at exactly which step BHRF1 acts in the pathway downstream of Fas death receptor activation. 
BHRF1 could, for example, play a role in directly inhibiting the activity of initiator caspases 
such as caspase-8, alternatively it could perturb mitochondrial physiology in as yet undefined 
ways. In either case, BHRF1 is likely to exert its effects from the mitochondria since both 
untagged and N-terminally GFP-tagged BHRF1 exhibit an exclusively mitochondrial 
localisation, as determined by confocal microscopy (data not shown). In addition, understanding 
how BHRF1 is able to offer such a greater level of protection than cellular sequence 
homologues Bcl-2 and Bcl-XL (Figure 4.2) may provide important insights into understanding 
the pro-survival functions of the cellular Bcl-2 proteins.
For ElB 19k significant questions regarding its precise biological functions also remain. 
Although the protein predominantly localises to endoplasmic reticulum and nuclear membranes 
(Supplementary Figure 5.7) it can also redistribute to mitochondria following Bax activation 
(Perez and White, 2000 and data not shown). The block conferred by ElB19k-expression on 
both Bax and Bak activation occurs subsequently to their N-terminal conformational change, 
when both proteins are located at the mitochondria. A strong interaction between Bax L25P and 
ElB 19k, in approximately 1:1 stoichiometry, was consistently observed in TAP purifications 
(Figure 6.6) and by co-immunoprecipitation (Figure 4.7 B) and has been previously reported 
between Bak and ElB19k (Sundararajan et al., 2001). The interaction between Bax L25P and
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ElB19k was resistant to 1% SDS (data not shown). Together these data suggest that ElB19k is 
likely to block Bax and Bak activation by directly binding the N-terminally active 
conformations before homo- or hetero-dimerisation can occurs. However, GFP-ElB19k could 
also sometimes be seen to have a partial mitochondrial localisation even in healthy cells and 
redistribution to mitochondria in response to an apoptotic trigger appeared to involve only a 
small fraction of total GFP-ElB19k (data not shown). Viral proteins are often promiscuous in 
the interactions they form with cellular proteins and El B 19k may also have other biological 
activities at the ER and nuclear membranes, as well as at mitochondria. In addition further 
experiments will be needed to determine whether the candidate Bax-interacting proteins 
purified in the presence of El B 19k are present through a direct interaction with Bax. Many 
could be present due to indirect interactions (see below) and some may primarily be E l B 19k- 
interacting proteins.
Mitochondrial ultrastructural analysis was performed in the presence of viral proteins to block 
cell death and this analysis revealed that changes in cristae morphology occurred independently 
of Bax and Bak activation (Figure 4.16). This finding places changes in mitochondrial 
ultrastructure in an upstream or parallel pathway to Bax and Bak activation. In the MCF10A 
cell system used, tBid was also efficiently generated following treatment with Fas/CHX in the 
presence of both E lB 19k and BHRF1 to block cell death (Figure 4.3). Therefore, the 
mitochondrial remodelling observed could be tBid-dependent effect, in agreement with a 
previous report (Scorrano et al., 2002). Although this finding has not been pursued further a 
genetic approach, knocking down the levels of Bid with RNA interference, could provide a way 
to directly test this hypothesis. The ultrastructural analysis performed on ElB19k-expressing 
MCF10A cells also illustrates how this system may be analogous to the murine DKO cells in 
which Bax and Bak have been genetically deleted.
The analysis of mitochondrial ultrastructure also revealed the appearance of prominent electron 
dense granules in the mitochondrial matrix of cells treated with Fas/CHX. These are thought to 
be calcium phosphate deposits and may represent a rapidly reversible mitochondrial Ca2+ 
buffering system (David, 1999; Pivovarova et al., 1999). The reversibility of the precipitates 
was not investigated in the present study, however, these Ca2+ precipitates could provide a large 
source of Ca2+ available for release upon permeabilisation of the mitochondria. Ca2+ signals are 
known to be propagated by mitochondria (Ichas et al., 1997), and Ca2+ overload of mitochondria 
induces permeability transition (Bemardi, 1999). It has also been observed that Ca2+ waves can 
occur at around the time of onset of cell death (Carvalho et al., 2004; Pacher and Hajnoczky, 
2001). There is therefore substantial evidence suggesting that the feed-forward propagation of 
Bax activation observed in the present study, whereby Bax activation can initiate locally and
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then propagate across the cell, may be mediated by a mitochondria Ca2+ wave. The existence of 
such a mechanism would have the advantage of coordinating recruitment of all mitochondria, 
especially in large and polarised cells, into the apoptotic program. It also possible that Ca2+ 
precipitates could have both protective and pro-apoptotic functions. For example under 
physiological conditions they may serve as a fast, reversible Ca2+ buffer system, however, under 
stress conditions of Ca2+ overload, they might continue to increase in size and number until the 
counter ion (ie. phosphate) is exhausted. At this point a rapid and uncontrolled rise in 
mitochondrial Ca2+ could result in the initiation of mitochondrial permeability transition.
If the electron dense granules observed in the present study are truly calcium precipitates the 
question arises as to the origin of the calcium. The ability of mitochondria to uptake large 
amounts Ca2+, driven either by oxidative phosphorylation of respiratory substrates for hydrolysis 
of adenosine 5’-triphosphate (ATP) has been known since the 1950s (Carafoli, 2003). Unlike 
that of other ions and metabolites, Ca2+ uptake by mitochondria is not mediated by pumps or 
exchangers but by a ‘uniporter’ , although its molecular identity remains unknown (Nicholls and 
Crompton, 1980). Ca2+ uptake is driven by Aipm, which is around 150-200 mV negative 
compared to the cytosol. I f  Ca2+ accumulation were governed solely by the Nemst equation, the 
concentration in the matrix would be around 106 times greater than that in the cytosol. This does 
not occur due to the presence of antiporters that allow the slow release of Ca2+ in exchange for 
Na+ or H+ ions (Nicholls and Crompton, 1980). Therefore, mitochondrial Ca2+ levels are 
maintained by a combination of membrane potential driven uptake and concentration dependent 
release. This futile cycle establishes a ‘mitochondrial set-point’ for the Ca2+ level in energised 
healthy mitochondria. In reality the rate of cycling is low, and therefore not energetically 
wasteful, due to both the low Ca2+ affinity of the uniporter and the low extra-mitochondrial Ca2+ 
concentration (around l^M ). However, mitochondria are still able to rapidly accumulate Ca2+ 
under physiological conditions (Rizzuto et al., 1992) and this directly affects their metabolic 
activity (Brini et al., 1999; Hajnoczky et al., 1995). This is due to the proximity of mitochondria 
to regions of Ca2+ release, namely inositol 1,4,5-trisphosphate (IP3) receptor-gated ER Ca2+ 
stores. In these regions, or ‘hotspots’ there is a microenvironment where the Ca2+ concentration 
exceeds that of the bulk cytosol by over an order of magnitude (Rizzuto et al., 1993). In this 
respect, it is interesting that several proteins involved in Ca2+ regulation were co-purified in Bax 
and Bcl-XL TAP experiments (see section 6.7.7 for details).
A model invoking the feed-forward spread of Bax activation leads to the question of how an 
initiation site might be selected. An interesting observation made during the course of this work 
was that the first signs of GFP-Bax activation and loss of Aipm reproducibly occurred in the cell 
periphery (see Figures 3.9, 3.10 and 4.13 for examples). It has recently been demonstrated that
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substantial functional heterogeneity exists between mitochondria in the same cell, with a greater 
proportion of highly energised mitochondria in the cell periphery (Collins et al., 2002). Since 
the mitochondrial Ca2+ uniporter is driven by this has also been shown to translate into a 
functional difference. In response to histamine-induced Ca2+ release peripheral mitochondrial 
were observed to accumulate substantially more Ca2+ than those in the perinuclear region 
(Collins et al., 2002). This difference occurs despite those mitochondria in the perinuclear 
region being embedded in a higher concentration of ER network (Collins et al., 2002). The 
results therefore indicate that, under some circumstances, A\|)m and the nature of the Ca2+ signal 
may play a more prominent role in determining mitochondrial Ca2+ uptake than proximity to the 
Ca2+ source. It is also a possible explanation why peripheral mitochondrial may experience Ca2+ 
overload leading to membrane permeability transition before those in the perinuclear region. 
Accurate Ca2+ imaging requires a rapid rate o f image acquisition than was possible in the 
present study. However, beyond this requirement the validity of these hypotheses could be 
addressed by use of Ca2+-free culture media and the addition of Ca2+ chelators such as EGTA or 
emptying of ER Ca2+ stores with thapsigargin, in combination with a cytoplasmic Ca2+ indicator 
or the mitochondrial pericam. Live cell imaging and electron microscopy analysis under these 
conditions would be able to determine: (a) whether the appearance of the electron dense 
granules is a Ca2+-dependent process, (b) whether rapid and efficient cell-wide wide recruitment 
of mitochondria into the apoptotic program is dependent on prior accumulation mitochondrial 
Ca2+ and (c) whether a wave of mitochondrial Ca2+ release accompanies the initiation of 
apoptosis and Bax activation or loss of Axpm.
The data presented in Chapters 3 and 4 supports the view that monomeric Bax can exist at the 
mitochondrial membrane and is not necessarily fu lly active. However, enforced dimerisation of 
Bax kills cells (Gross et al, 1998) and oligomerisation of Bax always accompanied full 
activation and mitochondrial dysfunction. Therefore, determining how and why the first Bax 
molecules enter into dimers and higher order oligomers is crucial to understanding Bax 
activation. In the present study, Bax activation has been seen to initiate in a discrete area of the 
cell, indicating a possible mitochondrial origin for these events, as opposed to synchronous cell- 
wide Bax activation. In addition, Myc-/- cells have been demonstrated to have increased 
resistance to Bax toxicity and cytosol switching experiments involving mitochondria purified 
from Myc-/- cells indicated that this property was inherent to the mitochondria (Annis et al., 
2005). Together, these observations suggest that events taking place at the membranes of 
individual mitochondria and properties intrinsic to mitochondria may be critical in regulating 
the activity of Bax and other Bcl-2 family proteins. A proteomic approach, the TAP purification 
method, was therefore used in an attempt to isolate candidate Bax interacting proteins. To 
enrich for proteins which may be involved in Bax regulation at mitochondria, the effect of
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mutations which promoted the activation and translocation of Bax to mitochondria was also 
investigated. It was reasoned that such mutant proteins, when placed under an inducible 
promote system, would allow the synchronous activation of Bax in all cells in a culture.
The effect of four mutations on the localisation and toxicity of Bax are reported in Chapter 5. 
When Bax was tagged at the N-terminus these mutations each had the effect o f altering the 
protein localisation. The S184V mutation resulted in a constitutive mitochondrial localisation o f 
a GFP-Bax, as has been previously reported (Nechushtan et al., 1999). A  mutation in which the 
N-terminal helix was disrupted by an L25P mutation appeared to be activating, enhancing Bax 
toxicity and resulting in an the formation of bright mitochondrially-associated foci, although, in 
some cells, GFP-Bax L25P was also seen to be partially cytoplasmic or evenly distributed along 
the mitochondrial network. It therefore seems likely the L25P mutation promotes Bax activation 
and this is in good agreement with the finding that deletion of the entire N-terminus of Bax also 
results in enhanced toxicity (Goping et al., 1998). Mutations in the a5/a6 region o f Bax were 
also found to alter the localisation and toxicity of GFP-Bax. The GFP-Bax A A A  appeared to 
enter mitochondrially-associated foci constitutively whilst the GFP-Bax AEE showed a partial 
mitochondrial enrichment. When GFP was fused to the C-terminus o f Bax all mutants were 
cytoplasmic, with the exception of the AAA mutant, which still formed mitochondrially 
associated foci. Finally, two of the C-terminally tagged mutants, Bax-GFP L25P and Bax-GFP 
AAA were altered by co-expression of E l B 19k, with the L25P mutant forming small 
mitochondrially associated foci and the AAA gaining an ER-like distribution (Figure 5.4). 
Therefore the C-terminal GFP tag proved a barrier to Bax activation and mitochondrial 
localisation. However, when compared with untagged constructs, the N-terminally tagged 
versions showed a modest increase in toxicity (Figure 5.6 A). This could mean that whilst the 
C-terminal tag is inhibitory, the addition of an N-terminal tag may promote Bax activation.
The shift in localisation of the C-terminal L25P and AAA constructs in the presence of ElB 19k 
was an unexpected result. This could indicate that these mutations destabilise the Bax molecule 
sufficiently to induce the formation of aggregates or precipitates at particular sub-cellular 
locations. At least for the L25P mutation this seems unlikely since it formed a stable 
cytoplasmic distribution in the absence of E lB  19k, however it cannot be excluded on the data 
presented for the AAA mutation. An alternative explanation is that these Bax proteins are 
destabilised by their respective mutations sufficiently to have a higher binding affinity for 
ElB 19k, which only binds to Bax after an initial conformational change has occurred. In this 
case the localisations may be explained if  the AAA mutation is recruited to the normal location 
of the majority of E l B 19k, namely the ER, whilst the L25P mutation complexes with El B 19k 
at mitochondria, the normal site of Bax activation and Bax-ElB19k interaction. In support of
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this interpretation both mutations strongly associate with E lB  19k by TAP (Figure 6.7 A) and 
co-immunoprecipitation (data not shown).
At present it remains uncertain whether mitochondrial associated clusters formed by GFP- 
tagged L25P and AAA Bax mutant proteins are analogous to the mitochondrially-associated 
foci formed by the endogenous protein in apoptotic cells. In addition, the FACS based 
Annexin/PI assay used is not ideal for the quantification of relative toxicity of the mutant Bax 
proteins since this can also vary with both expression time and expression level, neither of 
which were constant between the mutant constructs tested. To clarify these issues a number of 
further experiments would be possible. An in vitro assay in which the same amount of each 
mutant protein could be tested for ability to cause Cyt-c release from purified mitochondria 
would be helpful in assessing the relative toxicity of the proteins. It would also be informative 
to complement the confocal localisation study with a sub-cellular fractionation approach to 
determine the distribution of the mutant proteins across subcellular compartments such as the 
mitochondria, ER and cytosol. This assay can also be extended with the use of alkali extraction 
of proteins not fully integrated into cellular membranes. Such an approach could yield 
significant additional information about the nature of the distributions of the mutant Bax 
proteins observed by microscopy. Finally, it may also be useful to investigate the localisations 
and activities of the untagged mutant proteins using the panel of endogenous antibodies 
previously characterised. When used for immunoprecipitation assays this may also reveal the 
extent to which the mutations induce conformational change within Bax molecules.
The behaviour of all mutant Bax proteins, both N- and C-terminally tagged, in TAP purification 
experiments was investigated. This revealed that C-terminally TAP tagged Bax proteins 
consistently produced a more complex profile of co-purifying proteins than the N-terminally 
tagged versions. The reason for this is not entirely clear since the wild type, SI84V and AEE 
mutants were predominantly cytosolic and therefore expected to be monomeric. One possibility 
is that interactions, artificial or biologically relevant, may be formed post-lysis in these cases. 
An alternative explanation is that whilst the bulk of the over-expressed complex remains 
monomeric, these C-terminally tagged mutant proteins are still able enter larger molecular 
weight complexes, albeit at low efficiency. This interpretation is supported by their entry of a 
proportion of the over-expressed mutant proteins into higher molecular weight ranges in gel 
filtration assays when compared to the wild type version (Figure 6.3). There is no ideal place to 
tag Bax: the N-terminus of the protein is conformationally sensitive and may therefore be the 
site of important protein-protein interactions whilst the addition of a tag to the C-terminus of 
Bax impairs the protein’s activity and limits its association with mitochondria, perhaps by 
preventing insertion of the ha9 into the mitochondrial membrane. Of all the tag and mutation
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combinations tested for TAP purifications, experiments performed using the combination of C- 
terminally tagged Bax-TAP and the L25P mutation consistently produced the most complex and 
abundant band pattern. This mutation also entered small mitochondrially associated foci and 
higher molecular weight complexes by gel filtration, both of which were interesting since the 
primary aim of the screen was to isolate proteins involved in Bax activation. For these reasons it 
was this combination which was selected for a preparative scale experiment and systematic 
identification of co-purifying proteins by mass spectrometry. However, based on the data 
collected from TAP purification experiments alone is not possible to know whether the proteins 
identified by mass spectrometry are real Bax interacting proteins. They could also be present 
due to incomplete solubilisation of cellular membranes, precipitation or aggregation of the 
mutant Bax proteins or artificially induced interactions due to the high levels of Bax over­
expression used. Candidate Bax interacting proteins from this initial screen therefore need to 
either be confirmed or eliminated in subsequent experiments using different techniques.
Other Bax mutant and TAP tag combinations were investigated in more detail in smaller scale 
TAP purifications. It was hoped these mutant proteins, due to their differing subcellular 
distributions and apoptotic activities, might either disrupt or enhance specific interactions 
identified from the Bax-TAP L25P data set. In these experiments the L25P and AEE mutations, 
in the context of Bax-TAP, performed consistently better than the other mutations in terms of 
the abundance of the co-purifying species (Figure 6.7 and data not shown), however, this line of 
investigation ultimately proved unsuccessful as no clear effect of a particular mutation on a 
particular subset of bands could be identified. It was concluded that whilst the TAP purification 
method is a powerful approach for initial proteomic screening, the experiments are too complex 
and lack sufficient reproducibility to be useful in asking more subtle questions, such as the 
ability of a mutation to disrupt or enhance a particular protein interaction. However, it remains 
possible that the panel of Bax mutants generated could be useful in screening and validating 
candidate interactors in co-immunoprecipitation assays or pull-down assays using in vitro 
purified Bax proteins. At present this possibility has not been investigated further.
A partial validation of some of the mass spectrometry data presented in Figure 6.6 came from 
an TAP purifications with a second Bcl-2 family protein, Bcl-XL. These experiments used an 
N-terminally tagged TAP-Bcl-XL expressed constitutively expressed in HeLa cells. The data 
from both screens reveals a substantial degree of overlap between proteins co-purifying with 
Bax-TAP L25P in 293 T-REx cells and TAP-Bax-XL in HeLa cells (Table 6.1). In addition, the 
presence of known Bcl-2 family interacting proteins, and in particular the BH3-only proteins 
interacting with Bcl-XL, which are low abundance and small molecular weight proteins, 
indicate the purification strategy was working well.
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The FIFO ATP Synthase represented a major co-purifying species in both Bax and Bcl-XL 
purifications. However, this is also a highly abundant complex at the mitochondrial membrane. 
It was therefore a concern as to whether this result represented a specific interaction with Bcl-2 
family proteins or was the result of artificial over-expression of the tagged proteins or 
incomplete solubilisation of mitochondrial membranes. One approach pursued in order to 
further address this question involved the addition of chemical cross-linkers to Bax TAP 
purifications. It was reasoned that i f  a direct interaction exists between the FIFO ATP Synthase 
and Bax it would most likely be mediated by a single subunit that could be fixed by the addition 
of a cross-linker following the TEV cleavage step in the TAP purifications. These experiments 
were indeed successful in stabilising higher molecular weight protein products containing Bax, 
as assessed by western blotting (data not shown). However, these products then had to be 
separated away from other co-purifying proteins of the same molecular weight. This was 
achieved by the addition of SDS to 1 % in order to dissociate any proteins not covalently linked 
by the cross-linker. The SDS was then diluted to 0.1% and Bax-containing species recovered 
using an anti-Bax N20 linked agarose. However, when higher molecular weight Bax-containing 
species were analysed by mass spectrometry and by western blotting with antibodies raised 
against FIFO ATP Synthase components, no subunits were identified other than Bax and 
ElB 19k which appeared to have been stabilised in higher order dimers and multimers (data not 
shown). Nevertheless, the same approach using other chemical cross-linkers with different 
length spacer arms and reactive groups may yet prove to be useful in isolating proteins directly 
interacting with Bax.
An alternative approach to validate interactions with co-purifying proteins is to use a traditional 
biochemical purification strategy in which multiple chromatography steps are used to separate 
the proteins of interest. Such an approach has been successfully used to shown that Bcl-XL and 
the FIFO ATP Synthase are co-enriched over multiple co the FIFO ATP Synthase (M. 
Hardwick, Johns Hopkins, personal communication). Additionally, experiments with protein 
cross-linkers and SDS dissociation described above also revealed the association between Bax 
and the a subunit of the FO ATP Synthase is resistant to 1% SDS, as is the interaction with 
El B 19k (data not shown). This observation makes it less likely the Bax-FIFO ATP Synthase 
result is simply due to incomplete solubilisation of mitochondrial membranes in CHAPS 
detergent. There are unlikely to be many intermediate components if  the association is resistant 
to 1% SDS. When taken together with earlier observations that Bax toxicity in yeast is 
dependent on functional oxidative phosphorylation (Gross et al., 2000; Harris et al., 2000) it 
remains possible that the co-association of Bcl-2 proteins Bax and Bcl-XL with the FIFO ATP 
Synthase may not be artifactual.
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Unfortunately, experiments to show the presence of the FIFO ATP Synthase in Bax co- 
immunoprecipitations were confounded by the extremely high abundance of FIFO ATP 
Synthase in cells, meaning it was difficult to wash out of control samples and yet retain any 
specific interactions (data not shown). However, preliminary indications indicate that the 
reverse experiment may be possible, showing that Bax co-immunoprecipitates with the 
endogenous FIFO ATP Synthase following an apoptotic trigger (Figure 6.9). Co- 
immunoprecipitation assays with some of the less abundant proteins in the list of candidates 
may prove to be less challenging.
Several other approaches to could be used in order to identify potential direct interactions from 
the TAP data sets. One possibility is to screen the TAP eluates by far western using 
recombinant Bax and Bcl-XL. A similar approach has been used to detect an interaction 
between Bcl-XL and Rab7 (A. Hunt, UCSF, personal communication). Alternatively candidate 
protein interactions could also be tested in a pair wise fashion using either the yeast two hybrid 
or the related split-ubiquitin yeast assay systems, the later also being suitable for analysing 
interactions between membrane proteins.
Ultimately however, full validation of candidate interaction will require the development of 
activity based assay and investigation of the relevance of the interaction within the boarded 
context of mammalian apoptotic pathways and Bcl-2 family function. Such experiments could 
initially be based on RNAi or over-expression of candidate proteins in an attempt to determine 
if  they have an effect on apoptotic responses. For some of the TAP proteins identified this will 
be complicated if  they are known to be subunits within larger complexes. However, some of the 
candidate proteins identified have known enzymatic activities, such as recycling of growth 
factor receptors, protein glycosylation and ATP synthesis and for these proteins assays to 
directly measure their activity could be developed.
7.2 Concluding remarks:
This study was initiated to gain further insights into the regulation of Bax, one of the key 
players in the decision to commit to apoptosis. Previous models invoked to explain Bax and 
Bcl-2 family regulation have predominantly focused on the interplay between Bcl-2 family 
members themselves, with the mitochondria becoming involved solely as the targets of Bcl-2 
family action (Figure 7.1 A). Instead, the data presented in this thesis suggests the mitochondria 
may play a more central role in influencing the decision to initiate the apoptotic program
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(Figure 7.1 B). In this alternative view the pro-survival Bcl-2 proteins may have roles in 
regulating cellular metabolism and in particular mitochondrial physiology prior to the receipt of 
an apoptotic signal. Under the right conditions Bax and Bak may be able to intercept the same 
signals to which Bcl-2 family proteins are normally responsive but then initiate the apoptotic 
program. Such a model is consistent with a view that the apoptotic program in mammalian cells 
may be a late evolutionary addition to ensure rapid and co-ordinated removal o f unwanted and 
damaged cells but is directly coupled to basic cellular stress responses common to all eukaryotic 
cells.
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Figure 7.1 Model for the regulation of Bax activation.
(A) Traditional model for Bax activation. The decision to initiate mitochondrial dysfunction and 
apoptosis is controlled exclusively by Bcl-2 family proteins. (B) Alternative model for Bax 
activation. Data presented in this thesis implicates mitochondrial metabolic proteins, 
mitochondrial Ca2+ accumulation and mitochondrial structural changes as candidate upstream 
triggers for Bax activation and regulation. Bax and Bak are shown inactive (green), following 
their N-terminal conformational activation (orange) and in their oligomerised state (red). The 
position of blocks imposed by E1B19k and BHRF1 are also shown.
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Supplementary Figure 5.7: data added in support.
Bax-GFP AAA shows an ER-like distribution in MCF10A E1B19k cells.
The localisation of Bax-GFP AAA in E1B19k-expressing MCF10A cells is similar to that of an 
ER marker construct and that of YFP-ElB19k, and fails to co-localise with mitochondria. (A) 
MCF10A E1B19k cells were transfected with Bax-GFP AAA. 24 hrs later cells were loaded with 
Mitotracker, fixed and mounted for confocal microscopy. The GFP-Bax AAA construct 
demonstrates a reticular distribution throughout the cytoplasm and enrichment around the 
nucleus, both characteristics of an ER localisation. (B) MCF10A cells were transfected with an 
ER marker construct (pEGFP-ER, Clontech) and then prepared as in (A). The resulting 
distribution of the marker construct is very similar to that shown for Bax-GFP AAA in part (A). 
(C) MCF10A E1B19k cells were loaded with Mitotracker, fixed and immunostained using an 
anti-E1B19k antibody and FITC-coupled secondary antibody. The E1B19k antibody is not 
recommended for immunofluorescence experiments by the manufacturer but nevertheless 
shows an enrichment of E1B19k around the cell nucleus, and some evidence of a reticularised 
cytoplasmic distribution. (D) MCF10A cells were transfected with a YFP-E1B19k fusion 
construct (D.Hancock, CR-UK). 24 hrs later cells were fixed and mounted for confocal 
microscopy. The over-expressed YFP-E1B19k shows a similar nuclear enrichment and 
reticularised cytoplasmic distribution as shown in parts (A) and (B). In all images scale bars 
represent 10pm.
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